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ABSTRACT
Assessment of the functional activities of agonists acting on the human 6-opioid 
receptor (hDOR) which couples to G proteins of the G/GoOc class usually involves the 
measurement of adenylyl cyclase (AC) activity. To assess the relative capacitiy of the 
hDOR to activate closely related G proteins, fusion proteins were constructed in 
which the a  subunits of either Gü or Goi, containing point mutations to render them 
insensitive to the actions of pertussis toxin (PTx), were linked in frame with the C- 
terminus of the receptor. Following transient and stable expression in HEK293 cells 
both constructs bound the antagonist [^H] naltrindole with high affinity. D-ala^, D- 
leu^ enkephalin [DADLE] effectively inhibited forskolin-stimulated AC activity in 
intact cells in a concentration-dependent but PTx-insensitive manner. The high 
affinity GTPase activity of both constructs was also stimulated by DADLE with 
similar potency. However, enzyme kinetic analysis of agonist stimulation of GTPase 
activity demonstrated that the GTP turnover number produced in response to DADLE 
was more than 3 times greater for Gna than for Goia. As the effect of agonist in both 
cases was to increase Vmax without increasing the observed Km for GTP this is 
consistent with receptor promoting greater guanine nucleotide exchange on, and thus 
activation of, Gua compared to Goia. An equivalent fusion protein between the 
human p-opioid receptor -1 and Giia produced a similar DADLE-induced GTP 
turnover number as the hDOR-Gna fusion construct, consistent with agonist 
occupation of these two opioid receptor subtypes being equally efficiently coupled to 
activation of Gna,
In addition, I have investigated the characteristics of the ternary complex of 
agonist-GPCR-G protein using high affinity agonist binding studies with the fusion 
proteins. GDP reduced the binding of the agonist [^H] DADLE but not the antagonist 
[^H] naltrindole to both the receptor alone and all the hDOR-Gua (Xaa^^^) fusion 
proteins. For the fusion proteins the pECgo for GDP was strongly correlated with the 
n-octanol/H20 partition co-efficient of G protein residue^^\ Fusion proteins in which 
this residue was either isoleucine or glycine displayed similar association kinetics for 
[^H] DADLE. However, the rate of dissociation of [^H] DADLE was substantially 
greater for the glycine-containing fusion protein than that containing isoleucine, 
indicating the more hydrophobic residue imbued greater stability to the agonist- 
receptor-G protein ternary complex. This resulted in a higher affinity of binding of 
[^H] DADLE to the fusion protein containing isoleucine^^\ In expectation with the 
binding data, maximal DADLE-stimulated GTP hydrolysis was 2 fold greater with the 
isoleucine^^^ containing fusion protein and the potency of DADLE was 7 fold greater 
with the isoleucine^^^ fusion protein than for the version containing glycine. These 
results demonstrate that the stability of the ternary complex between hDOR, Gjia and 
an agonist (but not antagonist) ligand is dependent upon the nature of residue^^^ of the 
G protein and that this determines the effectiveness of information flow from receptor 
to G protein.
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CHAPTER I
Introduction
1.1. Cellular signalling in the centrai nervous system
A large number of G-protein coupled receptors (GPCRs) allow a wide range of 
ligands to initiate signal transduction across the plasma membranes of eukaryotic cells. 
Ligand binding to many different mammalian cell-surface receptors activates sisnaU 
transducins G proteins, and then the effector enzyme adenylyl cyclase (AC) to generate 
the intracellular second messenger, cAMP. The identification of G proteins and their 
role in activating AC to synthesise cAMP in response to hormonal stimulation in the 
mid-1970s was a great step forward in understanding transmembrane signal transduction 
(Gilman, 1987).
Most neurotransmitter act through cell-surface GPCRs (Martens, 1992), which are 
synthesised in the endoplasmic reticulum, undergo post-translational modifications in 
the Golgi complex and are delivered to the plasma membrane of neurones in cell bodies, 
dendrites and axon terminals (Yung et al., 1995). There is growing evidence that, in 
vivo, in the nervous system, the intracellular trafficking and subcellular localisation of 
these receptors undergo complex and physiologically relevant regulation by the 
neurotransmitter environment.
Opioid receptors are cell surface glycoproteins that provide specific binding sites 
for a variety of opioid alkaloids and peptides. These are used in the treatment of pain. 
The recent cloning of opioid receptors has established that the products of three genes 
form the known subtypes, the 5 (DOR), p (MOR) and k opioid (KOR) receptors which
have distinct pharmacological profiles and discrete but overlapping distributions in 
brain. Ho'wever there are many aspects of opioid receptors that still remain poorly 
understood. The benefits of using a GPCR-G protein fusion protein strategy have been 
widely described (Seifert et al., 1999: Milligan, 2000). Using this fusion protein 
strategy, 1 planned to understand the signalling pathways of 5 opioid receptor (DOR).
1.2. G protein-coupled receptors (GPCRs)
Nearly 2000 GPCRs (Ji et al., 1998) have been reported since bovine opsin was 
cloned in 1983 (Nathans and Hogness, 1983) and the P2AR in 1986 (Dixon et al., 1986). 
The GPCR superfamily can be subdivided into three major subfamilies: the 
rhodopsin/p-adrenergic, vasoactive intestinal polypeptide (VlP)/secretin, and the 
metabotropic glutamate receptor families. They are classified into over 100 subfamilies 
according to their sequence homology, ligand structure, and function. A substantial 
degree of amino acid homology is found among members of a particular subfamily, but 
comparisons between subfamilies show significantly less or no similarity. Although the 
majority of GPCRs mediate signal transduction via G proteins, emerging evidence 
indicates that some of these receptor are also capable of sending signals via alternative 
signal molecules, e.g., Jak2 kinase, phospholipase Cy, or protein kinase C. These 
alternative pathways are an indication of the overall diversity occurring in the GPCR 
superfamily.
L Structural features
Glycosylation, palmitoylation, the formation of disulfide bridges between cysteines 
and the phosphorylation of serine and threonine residues are known types of post- 
translational modifications of GPCRs.
a) General structure: N-terminal segment. Seven TMs. Three exoloops. 
Three/four cvtoloops. and C-terminal segment
As shown in Figure 1.1, all GPCRs have an extracellular N-terminal segment, 
seven transmembranes (TMs), which form the TM core, three exoloops, three 
cytoloops, and a C-terminal segment. A fourth cytoplasmic loop is formed when the C- 
terminal segment is palmitoylated at specific Cys residues. Each of the seven TMs is 
generally composed of 20-27 amino acids. On the other hand, N-terminal segments (7- 
595 amino acids), loops (5-230 amino acids), and C-terminal segments (12-359 amino 
acids) vary in size, indicative of their diverse structures and functions. Interestingly, 
there is a weak positive correlation between N-terminal segment length and ligand size 
(Ji et al., 1995), suggesting a role in ligand binding, in particular for large polypeptides 
and glycoprotein hormones. The ubiquitous seven TM structures allow glycosylation 
and ligand binding at the N-terminal segment and palmitoylation at the C-terminal. 
Phosphorylation also occurs at the C-terminal segments and leads to desensitisation. 
(Lefkowitz et al., 1998).

Figure 1.1. Structural features of a G protein coupled receptor
Amino acid sequence of the wild type 5 opioid receptor in the proposed transmembrane 
topology is shown in the picture.
Figure 1.1
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b) Glycosylation
Glycosylation of plasma membrane proteins is a common post-translational 
modification that is thought to be important for protein folding in internal organelles and 
in some cases for membrane targeting and function. The two common classes of 
glycosylation are those containing N-glycosidically linked oligosaccharide chains 
attached to asparagine residues and O-glycosidically linked oligosaccharide chains 
linked to serine or threonine residues in the polypeptide (Lennarz, 1983).
c) Palmitoylation
Palmitoylation of specific cysteine residues has been demonstrated for several 
GPCRs. Post-translational acylation anchors the N-terminal portion of the cytoplasmic 
tail to the plasma membrane, creating a fourth intracellular loop. The acyl group is 
attached by a labile thioester bond to the cysteine residue, which allows the process to 
be reversed and gives cells the potential to control this modification. For receptors, 
abolition of palmitoylation by site-directed mutagenesis has been shown to either 
decrease coupling to G proteins (Hayashi et ah, 1997: Jensen et al., 1995: Okamoto et 
al., 1997), affect receptor internalisation (Kawate and Menon, 1994: Eason et al., 1994), 
or modulate receptor phosphorylation by regulatory kinases (Moffett et al., 1996). 
Agonist stimulation of the p2 adrenergic receptor (P2AR) has also heen shown to 
increase the amount of covalently attached [^H] palmitate (Mouillac et al., 1992) as a 
result of an increased turnover rate of the receptor-bound palmitate (Loisel et al., 1996).
A similar agonist-promoted increase in the turnover rate of receptor-bound palmitate has 
been observed for the a%A adrenergic receptor (a 2AAR) (Kennedy and Limbird, 1994), 
the D2 -dopamine receptor (Ng et ah, 1994), and the m2 -muscarinic receptor (Hayashi 
and Haga, 1997),
d) Dimérisation
The GPCR family is probably the largest in the human genome. It has been 
demonstrated that members of this family can pair up with their own kind 
(homodimerisation). For example, using differentially (Flag and c-Myc) epitope-tagged 
receptors, Cvejic and Devi, (1997) examined the ability of mouse 5-opioid receptor 
(mDOR) to dimerise and the role of receptor dimérisation in agonist-induced 
internalisation. Agonists at the DOR increased the formation of receptor monomer, 
potentially a necessary step in the process of agonist-induced receptor internalisation. It 
has also been shown, however, that p-adrenoceptor agonists stabilise dimer formation 
and enhance receptor activation (Hebert et ah, 1996). Moreover Jordan and Devi, (1999) 
examined the ability of K-opioid receptor (KOR) to heterodimerise with 6-opioid 
receptor (DOR) or p-opioid receptor (MOR). They compared the ligand-binding 
properties of KOR-DOR heterodimers with those of KOR or DOR. The KOR-DOR 
heterodimer synergistically binds highly selective agonists and potentates signal 
transduction, which demonstrated that KOR-DOR heterodimers have been shown to 
have a pharmacology distinct from either DOR or KORs. Thus heterodimerisation of 
these GPCRs represents a novel mechanism that modulates their function. Data from the
opioid receptor study (Jordan and Devi, 1999) it might be interesting to find 
heterodimer-selective compounds.
In addition, several recent studies have provided evidence that GPCRs can pair up 
with even rather distantly related relatives to form larger oligomers (heterodimerisation) 
with distinct properties (Jones et al., 1998: White et al., 1998: Kaupmann et al., 1998: 
Kuner et al., 1999: Ng et al, 1999: Martin et al., 1999). These investigators described 
the identification of a second GABAb receptor, GABAbRi, which must be co-expressed 
with GAB AbRi to provide membrane delivery of the receptor and this was the first clear 
evidence for the existence of heterodimers. Rocheville and co-workers, (2000) showed 
that the dopamine D^ receptor and the somatostatin SST5 receptor can form 
hetero dimers.
e) Phosphorylation
Many GPCRs come to be phosphorylated after agonist binding. One of the most 
intensively studied modification mechanisms involves phosphorylation by a family of 
G protein-coupled receptor kinases (GRKs), which are a family of serine/threonine 
protein kinases that specifically recognise agonist-occupied GPCR proteins as 
substrates. Phosphorylation of an activated GPCR leads to attenuation of receptor-G 
protein coupling. This reflects that binding of an arrestin to a GRK-phosphorylated 
receptor prevents coupling of that receptor to its cognate G protein.
Six distinct mammalian GRKs are known. These differ in tissue distribution and 
in regulatory properties (Premont et ah, 1995). The intracellular localisation of GRKs 
to membrane-bound receptor substrates is the most important known regulatory feature 
of these enzymes. The (3 adrenergic receptor kinases (GRK2 and GRK3) were named as 
activities that phosphorylated the agonist-occupied p2 adrenergic receptor. They are 
targeted to the membrane by associating with heterotrimeric G protein Py subunits 
released upon receptor activation of G proteins, however, their substrate specificity is 
not limited to adrenergic receptors (Benovic et aL, 1989). Within the past few years, a 
novel subfamily of the GRKs has emerged from molecular cloning studies. This 
subfamily includes the mammalian GRK4, GRK5, and GRK6, as well as the 
Drosophila GPRK2 sequence. GRK5 is the most extensively characterised of these new 
kinases and has heen shown to phosphorylate rhodopsin, a 2 and P2 adrenergic receptors, 
and m2-muscarinic receptors. All GRKs appear to play the same general cellular role of 
desensitising activated GPCRs, but utilise distinctly individual means to the same end.
IL Functional regulations
a) Desensitisation
Receptor desensitisation is a rapid and reversible loss of agonist affinity and 
receptor function, which is produced by uncoupling of the receptor from its G protein. 
This process is believed to be dependent upon the phosphorylation of serine/threonine
residues by GRKs (Pei et ah, 1995) and the binding of cytosolic proteins known as p- 
arrestins (Gurevich et aL, 1995). Two types of desensitisation can be distinguished on 
the basis of the underlying mechanism. Homologous desensitisation is mediated by 
agonist-dependent activation of the same receptor, whereas heterologous desensitisation 
is caused by activation of a different receptor. An important component of 
desensitisation, which occurs within seconds to minutes of receptor activation, is 
uncoupling of the activated receptor from its G proteins by receptor phosphorylation. 
Two classes of protein kinases mediate this phosphorylation. A unique class of 
serine/threonine protein kinases, namely G protein receptor kinases (GRKs), mediate 
agonist-dependent phosphorylation of GPCRs and initiate homologous desensitisation, 
which depends on their functional co-factors, the arrestins. Second messenger- 
dependent kinases [protein kinase C (PKC)] and [protein kinase A (PKA)] mediate 
phosphorylation of receptors in response to second messenger production and initiate 
heterologous desensitisation. Associated with desensitisation, many GPCRs becomes 
internalised into intracellular endosomes via the clathrin-coated vesicular pathway in a 
process dependent upon the GTPase dynamin (Chu et aL, 1997). Pei et aL, (1995) 
investigated the role of mDOR phosphorylation in receptor desensitisation. When 
expressed in HEK293 cells and exposed to agonist, the DOR underwent receptor- 
specific desensitisation within 10 min. These investigators concluded that short term 
desensitisation of the DOR involves phosphorylation of the receptor by one or more 
GPCR kinases but not PKC.
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b) Internalisation and sequestration
In recent years, the phosphorylation of serines and threonines has become widely 
accepted as being important for agonist-dependent GPCR internalisation (Lefkowitz et 
aL, 1998). Several GPCRs, including P2AR and neurotensin receptors, and ion channel 
receptors such as the N-methyl-D-aspartate receptor, have been shown to undergo 
agonist-induced tyrosine phosphorylation (Lu et aL, 1999). Kramer et aL, (2000) 
demonstrated that the DOR is phosphorylated at tyrosine residues in response to its 
stimulation by an agonist. The phosphorylation of one or more tyrosine residues appears 
to be important for opioid receptor signalling (MAPK activation) and agonist-dependent 
receptor regulation (internalisation).
c) Down-requlation
Receptor down-regulation is a loss of receptors from a cell that results ftom long­
term (hours to days) continuous exposure of cells to agonists. Here there is an 
irreversible loss from the plasma membrane due to both internalisation and degradation, 
and after also a reduction in mRNA levels (Hausdorff et aL, 1990). Down-regulation 
may occur under pathological circumstances such as when there is continuous secretion 
of hormones and neurotransmitters from tumours. Down-regulation is also important 
during long-term administration of receptor agonists for therapeutic reasons, when it 
may be responsible for tolerance or tachyphylaxis (Lefkowitz, 1993). The requirement 
for downregulation are still not very clear, although there seems to be a requirement for
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functional coupling with Ga, as S49 lymphoma eye cells lacking endogenous GgOi 
exhibit very little agonist-induced downregulation of the P2AR (Mahan et aL, 1985).
IIL Receptor activation models (Figure 1.2) 
a) Two state receptor theory
In the two-state model of agonist action (Leff, 1995: Bond et aL, 1995), receptors 
are proposed to exist in equilibrium between two conformations, an active form (R*) 
and an inactive form (R). It is known that receptors exist in two states, R (receptor 
alone) and RG (receptor coupled to the G protein). The former has a low affinity for 
agonists, while the latter has a high affinity. Agonists act by preferentially binding to 
and enriching the active conformation, thereby increasing effector activity, whereas 
inverse agonists bind preferentially to the inactive (R) conformational state, leading to a 
reduction in ' basal ' effector activity. Neutral antagonists bind equally well to both R 
and R*, thus do not alter either the equilibrium between the two states and do not alter 
effector activity.
b) Ternary complex model and extended ternary complex model
Perhaps the most widely accepted model used to describe agonist activation of 
GPCRs is the ternary complex model, which accounts for the co-operative interactions
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among receptor, G protein and agonist. These models generalised the classical model by 
allowing receptors to interact with ligands as well as G proteins. In its full version the 
ternary complex model assumes that four receptor species, R, AR, RG, and ARG, exist 
at equilibrium.
Work by Cotecchia et aL, (1990) and Kjelsberg et aL, (1992) on the am- 
adrenoceptor suggests that this receptor may exist in active Ra and inactive Ri forms. 
Additional evidence for receptor activation has come from Parma et aL, (1993) who 
found CAM forms of thyrotropin and LH receptors, respectively. Based on such 
experimental results, Samama et aL, (1993) extended the ternary complex model to 
include the possibility of receptor activation. In their model, six receptor species are 
considered to exist at equilibrium, Ri, Ra, AR|, ARa, RaG, and ARgG. In the extended 
ternary complex model, receptor activation is a necessary precondition for G protein 
coupling.
c) Cubic ternary complex (CTO) model
A new equilibrium model of the interactions between receptors, ligands, and G 
proteins - the cubic ternary complex (CTC) model - has been proposed. The CTC model 
is a generalisation of the extended ternary complex model of Samama et al, (1993) by 
permitting G proteins to interact with receptors in both their active and inactive states. 
Thus, in the CTC model eight reeeptor species exist at equilibrium, four native receptor
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species and their four ligand-bound couterparts, Ri, Ra, AR,, ARa, R]G, R&G, ARiG, and 
ARaG. [R;: inactive receptor, R»: active receptor, A: ligand, G: G protein]
14

Figure 1.2. Receptor activation models
a) The ternary complex model
This model takes into account the role of the coupling G protein in receptor activation 
as the presence of guanine nucleotide appears to convert the receptor from a high to 
low affinity state. The scheme shows M as the affinity of R (receptor) for G (G 
protein), a  as the efficacy of the ligand and K the receptor affinity of the ligand. K = 
[HR]/[H][R], M = [RG]/[R][G], a  = [HRG][R]/[HR][RG].
b) The extended ternary complex model
This shows the revised or allosteric ternary complex model. This model introduces an 
explicit isomérisation step regulating the formation of the state of the receptor from R 
to R*, which is capable of binding to the G protein. J represents an equilibrium 
constant in receptor isomérisation. J = [R*]/[R], K = [HR]/[H][R], M = 
[R=*'G]/[R*][G], a  = [HR*G][R*]/[HR'=][R*G], p = [HR*][R]/[HR][R*].
c) The cubic ternary complex (CTC) model
A single receptor can form two distinct activated conformations that selectively 
interact with different G proteins, A = agonist, R = receptor and G = G protein
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d) Inverse agonism of Constitutive Active Mutants (CAM)
Inverse agonists are ligands that preferentially stabilise inactive conformations of 
GPCRs. In a range of systems, sustained treatment with inverse agonist can produce 
substantially greater upregulation of receptor levels than antagonists (Milligan and 
Bond, 1997). The use of constitutively active mutant (CAM) GPCRs allows to display 
enhanced agonist-independent signal transduction compared to the equivalent wild-type 
GPCR when expressed at similar level (Samama et al, 1993). Inverse agonists cause 
upregulation of a CAM aiB receptor, CAM P%AR and wild type pi and Hi receptor. (Pei 
et aL, 1994: MacEwan and Milligan, 1996: Lee et al., 1997: Smit et aL, 1996). Pei et 
aL, (1994) first examined that sustained treatment of CHO cells expressing a CAM form 
of the human PiAR with betaxolol resulted in an approximate doubling of its levels. 
Also MacEwan and Milligan, (1996) demonstrated that following stable transfection of 
the CAM piAR in NG108-15 cells both sotalol and betaxolol produced strong 
upregulation. Wild type rat Hi receptor in transfected CHO cells was also reported that 
the inverse agonist cimetidine, but not the neutral antagonist burimamide, causes an 
increase in the number of constitutively active Hi receptors (Smit et aL, 1996). A rather 
different scenario could be proposed from studies on a Leu*^ "^  to Ala mutation of the Hi 
receptor. This mutation limits both basal and histamine-stimulated cAMP productions, 
and cimetidine failed to cause significant upregulation of this form of the receptor. In 
another study, after upregulation of a CAM am  receptor produced by treatment with 
phentolamine, basal phospholipase D (PLD), basal PLD activity was increased and the
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agonist phenylephrine was then able to stimulate PLD activity to greater levels (Lee et 
a l, 1997).
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1.3. The human 5-opioid receptor (hDOR)
L Opioids for medical use
Opium has been extracted from poppy seeds (Papaver somniferum) for several 
thousand years to treat cough and diarrhoea, to relieve pain, and also because it evokes 
euphoria. The active ingredients of opium are alkaloid compounds, the so-called 
opioids. These molecules display strong analgesic and addictive properties and have 
been the subject of intense investigations. Morphine is the most active component of 
opium and was the first opioid to be isolated. Today, morphine remains the most potent 
pain-killer used clinically, despite a considerable number of adverse side-effects. 
Although the 1980s and 1990s led to the development of many novel potent opioids by 
the pharmaceutical industry, the ideal analgesic is still awaited eagerly. The illegal abuse 
of heroin, a diacetylated morphine derivative, represents a major public health problem, 
but mechanisms underlying opioid addiction are still poorly understood.
IL Cloning
The DOR was the first opioid receptor to be cloned. Two groups independently 
cloned the mouse DOR (mDOR) by preparing an expression library from mouse 
neuroblastoma x rat glioma hybrid NG 108-15 cells and transfecting the library into 
monkey fibroblast (COS) cells (Evans et al., 1992; Kieffer et ah, 1992, 1994). The use
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of the NG108-15 cell line was a critical step because these cells express DOR at a 
greater density than is normally found in brain tissue (Knapp et al., 1995b). Both groups 
used radioligand binding assays to detect mDOR but used different expression screening 
procedures. A cDNA sequence encoding a 372-amino acid protein was identified. The 
rat DOR (rDOR) was cloned by Fukuda et al, (1993) from a rat cerebellum cDNA 
library by a hybridisation screening method using an mDOR DNA as probe. The rDOR 
also had 372 amino acids with 97% homology to the mDOR. Finally, the human DOR 
(hDOR) was cloned using hybridisation-screening methods (Knapp et a l, 1994). cDNA 
fragments obtained from human striatum and temporal cortex libraries showed a highly 
homologous nucleotide sequence to the mDOR. The open reading frame (ORF) encoded 
a 372 residue protein with 93% homology to both the mDOR and rDOR. Later hDOR 
was also cloned by Simonin et al. (1994) from the SH-SY5Y human neuroblastoma cell 
line.
IIL Structural features
The DOR, which belongs to the seven transmembrane GPCR superfamily, 
possesses a common three-dimensional structure that spans the cell membrane seven 
times, forming three extracellular loops and three intracellular loops. This has consensus 
glycosylation sites at Asn^^ and Asn^^ in the N-terminal and there is likely to be a 
disulfide bond between Cys^^  ^and Cys^^ .^ In the C-terminal of the receptor, there are 
sites for palmitoylation at Cys^^  ^and Cys^^ ,^
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IV, Main functions and regulations
The 0-opioid receptor (DOR) is discretely distributed in the central nervous system 
and the highest densities are found in olfactory bulb, neocortex, caudate putamen and 
nucleus accumbens. The thalamus, hypothalamus and brain stem have a moderate 
density of the DOR. The DOR appears to have a role in analgesia, gastrointestinal 
motility, mood and behaviour as well as in cardiovascular regulation. It is well 
established that most DOR-mediated events are dependent on the activity of Pertussis 
toxin (PTx)-sensitive G proteins. It is also well established that DOR-selective ligands 
inhibit intracellular cAMP levels via G/oa proteins and modulate the activity of voltage- 
gated calcium and potassium channels. The Gja subunit interacts with AC, leading to its 
acute inhibition and subsequently to a reduction in cAMP levels in the cell. However, 
chronic activation of inhibitory receptors has been shown to lead to an increase in 
cAMP accumulation upon withdrawal of the inhibitory agonist, in other words, " AC 
superactivation " is observed (Avidor-Reiss et a l, 1995). AC superactivation is believed 
to play a role in the development of tolerance and withdrawal following prolonged 
opiate exposure (Avidor-Reiss et a l, 1995).
Cvejic and Devi, (1997) examined the ability of mDOR to dimerise and the role of 
receptor dimérisation in agonist-induced internalisation. Using differentially (Flag and 
c-Myc) epitope-tagged receptors, these investigators showed that the DOR exist as 
dimers and that agonist treatment modulates the level of dimers. Also Jordan and Devi, 
(1999) examined the ability of the k opioid receptor (KOR) to heterodimerise with DOR
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or p-opioid receptor (MOR) by co-expressing myc-tagged KORs with either Flag-tagged 
DORs or Flag-tagged MORs. They compared the ligand-binding properties of highly 
selective agonists and antagonists to KOR-DOR heterodimers with those of KOR or 
DOR in membranes from cells expressing either KOR or DOR or both KOR and DOR. 
The KOR-DOR heterodimer synergistically bound highly selective agonists and 
potentiated signal transduction. Thus heterodimerisation of these GPCRs may represent 
a novel mechanism to modulate their function.
Knockout strategies involve generating transgenic mice possessing a discrete gene 
deletion that results in failure to express a particular gene product. The absence of a 
particular gene product may 1) disrupt an intricate system of homeostasis and 
development resulting in severe pathology or the death of the mutant or 2) result in a 
deregulated system where alternative systems compensate for the loss of the deleted 
gene product. Recently, mice lacking MORs (MOR-deficient mice) or opioid peptides 
have been produced by gene targeting, providing molecular tools to study opioid 
function in vivo (Sora et al., 1997: Matthes et al., 1996). Sora et al, (1997) generated a 
transgenic MOR loiockout mouse by homologous recombination technology and used 
this to study interactions between DOR and MOR in the central nervous system. 
Although the heterozygous knockout mice exhibit about 54% of wild-type levels of 
MOR expression, the homozygous knockout mice displayed 0% receptor expression. 
These investigators used hot-plate and tail-flick tests and found that DOR-selective 
agonist [D-Pen^, D-Pen^]-enkephalin (DPDPE) induced a weaker than expected 
antinociceptive effect in p-knockout mice compared with control animals. These results
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indicate that the DOR is functional and mediates antinociception in the absence of the 
MOR. Matthes et al., (1996) showed that an analgesic dose of morphine decreased 
respiratory frequency and increased respiration time in wild-type mice. However, no 
change in respiratory parameters could be measured in similarly treated MOR-deficient 
mice. Respiratory depression is the primary factor in the lethal toxicity of morphine.
Zhu et al, (1999) used gene targeting to delete exon 2 of mDOR-1, which encodes the 
DOR. These investigators demonstrated that DOR-1 mutant mice do not develop 
analgesic tolerance to morphine, genetically demonstrating a central role for DOR-1 in 
this process. The use of opioid-receptor-deficient mice in animal models for the study of 
chronic pain, stress and reward mechanisms should provide substantial insights of DOR, 
MOR or KORs.
Human opioid receptors of the DOR, MOR and KOR subtypes have been 
successfully expressed in Escherichia coli (E. coli.) as fusions to the C-terminus of the 
periplasmic maltose-binding protein (MBP) product of the malE gene, a soluble 
periplasmic protein that is part of the maltose import chain in E. coll (Stanasila et a l, 
1999). Binding of [^H] diprenorphine to intact cells or membrane preparations was 
saturable, with a Kj of 2.5 nM, 0.66 nM and 0.75 nM for hDOR, hMOR and hKORs 
respectively. Receptor high-affmity state for agonists was reconstituted in the presence 
of heterotrimeric G proteins. This study demonstrated that opioid receptors can be 
expressed in a functional form in bacteria and pointed out the advantage of E. coli. as an 
expression system for pharmacological studies.
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Constitutively active mutant (CAM) GPCRs display enhanced agonist-independent 
signal transduction compared to the equivalent wild-type GPCR when expressed at 
similar levels (Samama et al, 1993). Ligands which display inverse agonism at GPCRs 
decrease this intrinsic activity. Expression of the DOR in Rat-1 fibroblasts resulted in 
the inverse agonist ICI174864 being able to cause inhibition of basal high affinity 
GTPase activity and of the binding of [^^S] GTPyS in a membranes of a clone of these 
cells which expresses high levels of the receptor (Mullaney et a l, 1996). These effects 
were blocked by co-addition of the neutral antagonist TIPP[ip], demonstrating a 
requirement for the DOR. The inverse agonist properties of ICIl 74864 could also be 
demonstrated in whole cells, where stimulation of forskolin-amplified adenylyl cyclase 
(AC) activity was produced by ICI 174864.
F. Identification of DOR domains mediating receptor function
The DOR regions involved in mediating receptor function have been identified by 
the construction of chimeric receptors containing sequences from KOR and MOR, site- 
directed mutagenesis of specific amino acid residues within the receptor and by the 
construction of truncation or deletion mutants.
•  Identification of liqand-bindinq domains
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Using the idea that opioid ligands are bivalent molecules in which one portion of 
the ligand mediates signal transduction while another ligand site determines selectivity 
toward DOR, KOR or MOR. Metzger and Ferguson, (1995) explained the selectivity of 
drug binding to opioid receptors. When the sixth transmembrane helix (TM) and third 
extracellular loop of the DOR were replaced by the analogous MOR-sequence, the 
chimeric receptor bounds DOR-selective drugs with affinities similar to control MORs. 
These data were interpreted to mean that the third extracellular loop sequence in the 
chimeric receptor adopts a conformation that blocks DOR-selective agonist binding to 
sites in the highly conserved TMs of the receptor.
a). The third extracellular of the DOR is critical for ligand binding.
Ligand selectivity for DOR depends on recognition sites spanning the fifth through 
seventh TMs. Meng et al., (1995) constructed chimeric receptors from cloned rat 5- 
opioid receptor (rDOR) and KOR. DOR-selective peptides showed moderate affinity for 
k (1 -141 )/ô(l 32-372) and k (1-227)/ô (215-372) constructs, which retain the native fifth 
through seventh TMs of the DOR. However these drugs had no affinity for k (1-141) 
/5(132-214)/k (228-380) and 0(1-214)/k (228-380) constructs, which contain the fifth 
through seventh TMs of the KOR. Also, antagonist ligands bound with high affinity to 
an KOR/DOR-chimeric receptor containing DOR sequence carboxyl to the second 
extracellular loop (amino acids 215-372).
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In addition, Wang et ah, (1994) constructed chimaeric receptors in which mDOR 
sequence from the N terminus and mMOR sequence from the C-terminus were ligated 
at each of the seven TMs. Chimeric receptors exhibited a loss of D-Ala^, N-MePhe"^, 
Gly-ol]-enkephalin [DAMGO, MOR agonist]-binding affinity whenever the first 
extracellular loop of the MOR was lacking and a loss of [D-Ser^, Leu^] -enkephalyl-Thr 
[DSLET, DOR agonist]-binding whenever the third extracellular loop of the DOR was 
missing from the chimeric receptor. Also, these investigators found that point mutations 
in the third extracellular loop of the DOR that replaced both Arg^^  ^and Arg^^  ^with Gin 
selectively reduced the binding of DSLET but not of nonselective opioid agonists. 
Binding of the DOR selective antagonist, naltrindole was also unaffected by this double­
point mutation. These results indicates that 1) the third extracellular loop of the DOR 
play an important role in the high-affmity binding of the DOR-selective agonist DSLET 
and 2) the first extracellular loop of the MOR play an important role in high-affinity 
DAMGO binding.
Other work was performed on chimeric receptors combining DOR/KOR or 
DOR/MOR sequences (Meng et al., 1996). They also introduced a number of point 
mutations in the third extracellular loop of the DOR, Some of these mutations reduced 
the affinity of some DOR-selective ligands, whereas none of the mutations were 
sufficient to ablate the binding of DOR-selective ligands. These results also indicated 
that a region composed of the sixth TM and the third extracellular loop is essential in 
determining selectivity of drugs for DORs.
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In another study, with cells expressing wild type DOR or MOR or one of two 
DOR/MOR-chimeric receptors in transfected HEK293 cells, the binding of three DOR 
agonists (SNC80, DPDPE, Del-II) and DOR-selective antagonist naltrindole were 
measured (Valiquette et al., 1996). The third extracellular loop sequence of DOR was 
replaced by that from the MOR. In both chimeric constructs, the binding of all four 
DOR-selective ligands was significantly reduced. Specific key residues in the third 
extracellular loop region was substituted by Ala or Gly for the wild type amino acid at 
20 different positions between 275 and 312 (sixth TM-seventh TM of the DOR). In 
particular, replacement of Ala for Trp^ "^^ , Val^^ ,^ and Val^^  ^consistently reduced the 
binding of the DOR ligands tested, suggesting that these three residues are involved in 
the selectivity of these drugs.
Furthermore, a hDOR mutant in which Trp^ "^^  was replaced by Leu (W^ '^^L) caused 
a 42-fold shift toward higher drug concentrations in the Kj for binding of SNC121 but 
not other DOR ligands (Li et al., 1996). This suggests that SNC121 interacts with Trp^ "^^  
in a unique manner that is not shared by other DOR-selective ligands.
b). First extracellular loop
A chimeric DOR/MOR/DOR receptor was constructed by replacing the first 
extracellular loop of the cloned rat DOR for the same region in the cloned rat MOR. 
This substitution conferred high affinity for [^H] DAMGO to the chimeric receptor 
(Onogi et al., 1995). Because of seven amino acids difference in the first extracellular
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loops of the MOR and DOR, site-directed mutagenesis was used individually to replace 
those seven residues in the DOR with the corresponding amino acids of MOR (Minami 
et al., 1996). Only upon replacement of Lys^ ®^  was high affinity binding of the MOR- 
selective agonist DAMGO produced. To further characterise the structural requirement 
for the residue at position 108, Lys^ ®^  was replaced by 19 other amino acids. These 
revealed that it was not so much substitution by Asn at position 108 as it was 
elimination of the more obstructive Lys at position 108 that allowed high-affinity 
DAMGO binding.
c) Second extracellular loop
Chimeric receptors constructed by Meng et al., (1996) from cloned rat opioid 
receptors which substituted the second extracellular loop of the DOR for that of either 
the KOR or MOR were shown to be insufficient to confer selective binding of DOR- 
selective ligands. Also using a chimera of the 5(1-186)/p(208-234)/ô(213-372), DOR- 
selective ligands bound to the second loop with affinity similar to the wild type DOR (Li 
et al., 1996). This precludes a role for the second extracellular loop in determining DOR 
ligand recognition.
d) TM domains
The role of residues in the TMs of the DOR in ligand binding is under 
investigation. A study conducted soon after the cloning of opioid receptors showed that
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the Asp^^ residue in TM2 of the mDOR was responsible for high affinity agonist 
binding, but not involved in the binding of antagonists and nonselective agonists (Kong 
et al., 1993). When Asp^^ was replaced with Asn, the mutant receptor exhibited a 
selective reduction in the binding of DOR-selective agonist ligands without any 
alteration in the binding of DOR-selective antagonists.
The third putative TM domain of DOR contains a conserved Asp^^  ^residue that is 
typically found in biogenic amine binding GPCRs [for example, human P2AR, human 
Œ2aAR, human mi muscarinic, rat 5HTa serotonin, rat D2 dopamine, human H2 
histamine] and is generally believed to form an ion pair with the cationic 
neurotransmitters. When this residue was mutated to Ala it did not modify the binding 
affinity of a representative set of opioid compounds, including bremazocine, 
diprenorphine, naloxone, Tyr-D-Thr-Gly-Phe-Leu-Thr [DTLET], D-Ala^, D-Leu^- 
enkephalin [DADLE], D-Pen^, D-Pen^-enkephalin [DPDPE], deltorphine II [Del-II], +/- 
-4“(a-R*)-a-(2S*,5R*)-4-allyl-2,5-di-methyl-l-piperazinyl-3-hydroxybenzyl-N,N- 
diethylbenzamide [BW373U86], and naltrindole. It nevertheless decreased receptor 
expression level and affected the binding of three agonists, DADLE, DTLET and 
BW373U86. However, Asp^^  ^to Asn mutation strongly impaired the binding of all of 
the above ligands and highlighted differential modes of interaction for alkaloids and 
peptides. These results indicate that Asp^^  ^is situated in a region of the receptor that is 
important for ligand binding as the Asp to Asn mutation shifted the affinity of all opioid 
ligands tested.
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Three-dimensional computer modelling of the receptor has identified the role of 
TM aromatic residues in ligand recognition of the DOR, which span TMs III to VII and 
consist of tyrosine, phenylalanine, and tryptophan residues (Befort et al., 1996). Based 
on this model, these investigators mutated residues Tyr*^^(TM III), Trp^^  ^ (TM IV), 
Phe^*  ^(TM V), Phe^^  ^(TM V), Trp '^^  ^(TM VI), and Tyr^ ®^  (TM VII) of the DOR. They 
found that mutations of Tyr*^  ^caused the greatest shifts in drug affinity toward higher 
concentrations. Mutations at Phe^^ ,^ Phe^^ ,^ and Tyr^^  ^had modest effects on the affinity 
of all agonists tested. Mutation of Trp^^  ^and Trp^ "^^  caused 40-fold affinity shifts for 
some ligands and had no effect on others. Taken together, these data demonstrate the 
importance of the TMs in ligand binding and suggest that DOR-selective ligands 
interact at different amino acid residues to mediate binding.
e) N-terminus domain
A subsequent study revealed that both DPDPE and naltrindole bind to the N- 
terminus chimeric k (1-78)/0(70-372) receptor but not to the reverse chimeric 0(1- 
69)/k (79-380) receptor; this finding suggests that the N-terminal domain of the DOR is 
not critical for binding of DOR-selective ligands (Kong et al., 1994).
•  DOR domains mediating down-requlation.
In 1996, Cvejic et al, investigated the down-regulation of the mDOR using 
truncation mutants. When the C-terminal 37 amino acids in the intracellular tail of the
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receptor were deleted, receptor down regulation in response to chronic (2-48h) DOR- 
selective agonist, DADLE treatment was blocked. By contrast when the mDOR was 
truncated by 15 amino acids, the receptor did dovm-regulate on chronic DADLE 
treatment. When the cytoplasmic tail residue Thr^^  ^was mutated to an Ala in the 
mDOR, receptor down-regulation was blocked. Even though Cvejic et ah, (1996) 
demonstrated that Thr^^  ^of the mDOR played an important role in down-regulation, this 
mechanism must be different for the human receptor, because Thr^^  ^is already an Ala in 
the hDOR sequence (Knapp et al., 1994) and the human receptor down-regulates on 
chronic agonist exposure (Malatynska et al., 1996).
•  DOR domains mediating signal transduction cascades.
Recently, there were two reports about the creation of constitutively active DOR 
through mutagenesis. One study demonstrated that the replacement of an Asp residue in 
TM3 with Ala, His, or Lys would endow the mutated receptors with constitutive 
activity. Although naltrindole still functioned an antagonist at an Asp to Ala mutant, it 
became an agonist at the receptor with the Ala to Lys mutation (Cavalli et al., 1999). 
Another study mutated the same Asp residue (Asp^^^) in TM3, the Tyr residue 
immediately below Asp in TM3 (Tyr^^^), and a Tyr residue in TM7 (Tyr^^^) (Befort et 
al., 1999). All these receptor mutants exhibited constitutive activity, suggesting that the 
wild type DOR use these residues to maintain an inactive state in the absence of 
agonists.
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Classical opioid antagonists (i.e., naloxone, naltrexone, naltriben, and TIPPi|/) were 
found to behave as agonists on the MOR and DOR with mutations at a conserved Ser 
residue in TM4 (DORS177L and MORS196L). The mutated receptors were not 
constitutively active, suggesting that Ser plays a specific role in the ligand-induced 
receptor process (Claude et al., 1996). A partial agonist to antagonist conversion was 
also observed in the DOR with a TM2 Asp mutation (Bot et al., 1998). These results 
suggest that ligand interactions with residues of TM helices can alter the conformation 
of the DOR to permit signalling of the receptor to second messenger systems.
Merkouris et al., (1996) examined which regions of DOR mediate interactions with 
G proteins through the use of synthetic peptides. They found that peptides homologous 
to the third intracellular loop inhibited both GTPase activity and [^^S] GTPyS binding 
activity. In addition, these investigators also examined the effect of the peptides on 
binding of the agonist [^H] DSLET. Peptides homologous to the third intracellular loop 
reduced [^H] DSLET binding, whereas peptides homologous to the second intracellular 
loop did not. Unexpectedly, a peptide homologous to residues 322 through 333 of the C- 
terminus also reduced [^H] DSLET binding. These findings suggest that the C-terminal 
tail may interact with receptor-associated G proteins but, it is not vital because neither 
GTPase activity or [^^S] GTPyS binding activity was blocked in the presence of this 
peptide.
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1.4. Guanine nucleotide binding proteins (G proteins)
L Structuresf functions and mechanisms
GPCRs transduce a large variety of signals across the cell membrane via 
heterotrimeric G proteins. G proteins transduce ligand binding to these receptors into 
intracellular responses that underlie physiological responses of tissues and organisms. G 
protein heterotrimers consist of three subunits named a, p and y. So far some 20a, 6 p 
and 12y polypeptides have been identified. All a-subunits share biochemical and 
structural properties and these are summarised in Table 1.1. Four main classes of G 
proteins are known: Gs, G i/o/t, Gq and G 12/1 3 . They can be classified into the following 
structurally and functionally related groups:
1) g ^ - g rou p : the members of this group stimulate the isoforms of AC
2) g j /n / f -  grou p : this can be divided into ai / 0 / z and g  t/ g subunits. The gj / 0 / z 
subunits inhibit some isoforms of AC; they also inhibit and stimulate neuronal Ca 
and channels, respectively (an effect that is due to the release of free py-dimers). 
The g  t /g subunits are transducins and gustducin, which stimulate the retinal cGMP- 
phosphodiesterases and presumably a related gustatory effector, respectively.
3) g» -  grou p : these subunits activate the p-isoenzymes of PLC and non-receptor 
tyrosine kinases of the btk-family,
4) a i 2 /m - grou p : regulate low-molecular-weight G proteins of the Rho-family (which 
affect the cytoskeleton) and Na’^ -H^-exchange.
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The cycle of G protein activation can be summarised into a four-step reaction 
(Figure 1.3).
1) The basal state, in which the G protein is a gpY-heterotrimer with GDP, bound 
to the g-subunit; In the absence of activation by a receptor, the rate of GDP release 
(Koff <0.1 min “ )^ is much loAver than the rate of GTP hydrolysis (Kcat ^  0.1 min "^); 
this kinetic feature clamps the system in the ‘o ff position.
2> Receptor-mediated GPP release; The agonist-liganded, activated receptor interacts 
with the cognate G protein(s) and dramatically accelerates the rate of GDP release 
from the g-subunit. In the absence of added GTP (or of its hydrolysis-resistant 
analogues), agonist (A), receptor (R) and G protein (G) form a ternary complex (ARG), 
in which the agonist is bound with considerably higher affinity than if bound to the 
receptor alone. This high affinity state is typically seen in binding experiments that use 
membrane preparations. However, in intact cells, GTP concentrations are high and GTP 
binds instantaneously to the empty guanine-nucleotide-binding pocket.
3) Subunit dissociation and effector regulation; upon binding of GTP in the presence 
of M g^\ the g-subunit undergoes a change in conformation; the activated g-subunit 
(g* -  GTP -  Mg^ "^ ) dissociates from the Py-dimer; both the GTP-bound g-subunit and 
the firee Py-dimer can then interact with appropriate effector proteins and modulate their 
activity.
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41 Deactivation and return to the basal state: the intrinsic GTPase activity of the a- 
subunit cleaves the terminal phosphate group of GTP; the GDP-liganded a-subunit re­
associates with py which results in the deactivation of both components. The system 
then relaxes to the basal state.
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Figure 1.3. The GTPase cycle of trimeric G proteins
The 'turn-on' step begins when the activated receptor (R*) associates with the trimer of 
(a*GDP»Py), causing dissociation of GDP. Then GTP binds to the complex of R* with 
the trimer in its 'empty' state (ae*py), and the resulting GTP-induced conformational 
change causes a*GTP to dissociate from R* and from py. After the 'turn-off' step 
(hydrolysis of bound GTP to GDP and inorganic phosphate, Pi), a*GDP reassociates 
with py.
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Figure 1.3
Turn on
GDP ^  ^  GTP
^GDpPy GCGTP
Table 1.1. Biochemical properties of G protein a-subunits
Feature Property of a-subunits
Structure
Guanine nucleotide 
binding
Conformational switch 
Membrane anchoring
Receptor binding and 
Activation
Effector regulation
Deactivation
Regulation
Bacterial exotoxin 
Cholera toxin
Pertussis toxin
40-46 kDa: RAS-like (-20 kDa) 
and helical domain (-20 kDa)
GDP/GTP-bound in cleft between the two domains; inactive in the 
GDP-bound form; active in the GTP-Mg^’^ -bound form and when 
joined to GDP-Mg^\
Accommodated by changes in three discontiguous regions (switch I-
in)
Via co-translational (aminoterminal myristoylation, e.g. Gia) and post- 
translational modification (palmitoylation on Cys close to the N- 
terminus)
To C-terminus of Ga: strand p6/helix a5 and last -10 amino acids. 
GDP/GTP-exchange reaction catalysed by the appropriate receptor in a 
manner dependent on Py-dimers
Group-specific for a-subunits. Effector binding to three discontiguous 
regions (switch II; the region adjacent to switch III; helix a4 and the 
loop connecting a4 and a6)
By intrinsic GTPase and by reassociation with Py-dimers (which bind 
to the amnioterminus and to switch II of Ga)
GTPase accelerated and effector regulation blocked by RGS proteins 
through binding to switch regions I-III 
Catalyse NAD-dependent ADP-ribosylation of;
Argl87/188, Arg201/202 in splice variants of Gsa, (G^a) persistent 
activation due to impaired GTP-hydrolysis;
A Cys close to C-terminus in G^a, Gja, Gta —>
Blocks receptor binding
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IL G protein a subunits
There are 20 different mammalian Ga subunits to date, classified into 4 
subfamilies according to the similarity of their amino acids (56% to 95%). As seen in 
Table 1.2, there are 17 gene products, with splice variants of Gga and Goa, and their size 
ranges from 39 to 52 kDa (lismaa et ah, 1994). Members of the same subfamily may 
activate the same effector (e.g., AC or PLC) although this is not absolute.
a) G^a subfamily
The Gga subfamily is so named due to the ability of these G proteins to stimulate 
the enzyme AC upon binding of GTP (Cassel and Selinger, 1978: Ross and Gilman,
1977). Gs is ubiquitously expressed in all cells, and thus, in principle, could be purified 
from any source. The initial purification was from rabbit liver. Ross et al., (1979) found 
two protein components, either of which by itself catalyses the formation of cyclic AMP 
with Mg-ATP as substrate, which were found plasma membranes of wild type S49 cells, 
rat or rabbit liver, or avian erythrocytes and also found in an AC-deficient hepatoma cell 
line. Mixture of the two reconstitutes Mg-ATP-dependent, fluoride-and Guanylyl 5 -Py 
imido-diphosphate [Gpp[NH]p]-stimulable activity. Also mixture of AC-S49 
membranes with a crude detergent-solubilised preparation of the regulatory protein 
reconstitutes hormone-stimulable AC activity. The latter findings permitted the 
purification of Gs by Northup et at., (1980). Gsa has 4 splice variants, known as Ggal, 
Gga2 , Gga3, and Gsa4 (Bray et al., 1986). Ggal and Gga3 are identical except that
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Gga3 lacks a single stretch of 15 amino acids (from exon 3). Gga2 and Gga4 are 
identical to Ggal and Gga3 respectively but have 3 additional nucleotides at the 5' end 
of exon 4. The longer forms (Ggal and Gga2) are known as Gga long (Gga(L)) while 
the shorter forms (Gga3 and Gga4) are known as Gga short (Gga(S)). Gga can activate 
all 9 mammalian ACs.
Goifa is grouped under the Gga subfamily due to high homology with Gga. It is 
selectively expressed in the cilia cells of the olfactory bulb and thus in vivo only couples 
to the very large class of olfactory receptors. It has an ability to activate the olfactory 
specific AC type III.
Members of the Gga subfamily are ADP-ribosylated by cholera toxin (CTx) from 
Vibrio cholerae at a crucial arginine residue [arginine 201 in Gga(L)] in the GTPase 
domain. ADP-ribosylation induced by CTx interferes with receptor-stimulated GTP 
hydrolysis.
b) Gja subfamily
First visualised as a 41-kDa substrate for ADP-ribosylation by PTx, oligomeric Gi 
was purified from rabbit liver and human erythrocytes by techniques nearly identical to 
those developed for Gs. Nukada et aL, (1986) purified Gja from bovine brain and the 
eDNA encodes a protein with 354 amino acid residues and a calculated molecular 
weight of 40, 400. Itoh et al., (1986) screened a rat C6  glioma cDNA library with an
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oligonucleotide probe based on amino acid sequence data obtained with purified rat 
brain Gioc and Goa.
Gil a  is one of the largest members of the Gi family with a Mr of 41 kDa and is a 
substrate for ADP-ribosylation by PTx (Figure 1.4), Giza is the smallest of the three Gi 
proteins, is also substrate for ADP-ribosylation by PTx and shares around 8 8 % amino 
acid identity with Gna. Giaa is the third of the Gi family and is thought to stimulate 
various ion channels in the plasma membrane. An amiloride-sensitive Na*^  channel was 
identified in renal epithelial cell line A 6  which could be activated via Gisa (Cantiello et 
al., 1989), apparently via stimulation of phospholipase Az (Cantiello et al., 1990). 
Members of the G ua family have been shown to cause inhibition of cAMP via AC, an 
effect that is blocked by treatment with PTx.
Goa is named for G ' other ', first identified as a 39 kDa PTx substrate purified 
from bovine brain (Neer et al., 1984: Milligan and Klee, 1985) and is distributed mainly 
in neuronal and electrically excitable cells. It was demonstrated that this a  subunit could 
inhibit the opening of a voltage sensitive N-type Ca^ '*' channel as well as K^ channel 
(Heschler et al., 1988). The expression of Go proteins is restricted to neuronal and 
endocrine systems and the heart and it is highly abundant in mammalian brain.
Goa splice variants display differential tissue distribution. Three distinct subforms, i.e., 
Goia, Goz a  and Gos ot have been identified, with Goi and Goz, representing splice 
variants whereas Gos represents a recently characterised post-translational modification 
of Goia which represents about 30% of the total Go in brain (Exner et al., 1999).
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Gta (or transducin), which was purified at about the same time as Gg is a major 
component of the disks of the retinal rod outer segment. It was first identified as the 
transducing entity between activated rhodopsin and the phosphodiesterase responsible 
for lowering levels of cGMP and thus causing influx of Na^ from the outside of the cell, 
depolarisation and initiation of nerve impulses to the brain. Two Gta subunits, Gtia and 
Gtza, have been cloned (Yatsunami and Khorana, 1985: Medinski et al., 1985).
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Figure 1.4. Structure of Gna subunit
The structures of Giia with GTPyS»Mg^^ complex (top) or GDP (bottom).
In the top figure, the a  helical domain (left) and G domain (right) of Giia are shown 
together with the switch segments (switch II) (adapted from Sprang 1997).
A. Structure of Gna with GIPyS^Mq^  ^complex
B. Structure of Giia with GDP
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Figure 1.4
A. Complex with GTPyS. Mg2+ 
helical domain Switch
G domain 
«4
(c) 135 
- g 4____
p2 P3 (n) Switch II 
a2Switch I
B. Complex with GDP
(Adapted from Sprang 1997)
c) Gqg subfamily
The Gqa superfamily consists of five members whose a-subunits show different 
expression patterns. Gqa and G ua, which are 8 8  % identical, seem to be almost 
ubiquitously expressed. By contrast, the expression of G ^a, which is 81 % identical 
with Gqa, is more restricted. The human Giea and its murine counterpart Gisa are only 
expressed in a subset of hematopoietic cells (Wilkie et al., 1991). Gisa and 
Giea, which are 85 % identical, have been placed into the Gq family since their 
sequences show the highest similarity toward Gqa (57%). All five members of the Gqa 
family share functional properties, i.e., they allow communication between Ca^ "^ ' 
mobilizing GPCRs and phosphoinositidases of the phospholipase Cp (PLCp) class in a 
PTx-insensitive manner (Simon et ah, 1991). It was demonstrated that receptors for 
interleukin 8  and C5a interact selectively with Gi6 but not with Gq and Gn (Wu et al.,
1993). Offermanns and Simon, (1995) have showed that a wide variety of structurally 
and functionally different GPCRs can couple to G15 and G16, indicating that G 15 and Gie 
are unique, i.e., they possess the ability to nonselectively couple a large variety of 
receptors to PLC.
d) G ^a  subfamily
Gi2 a  and Gn a  proteins are ubiquitously expressed but their functions are only 
recently beginning to be understood. There is evidence implicating their involvement in 
regulating a range of signalling pathways. For example, both subunits stimulate the
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Na'*‘/H^ exchanger (NHE), via PKC dependent (Gn a), and independent pathways (Gn 
a). The thrombin receptor has been shown to activate both subunits in platelet 
membranes (Offermanns et aL, 1994). As thromboxane A2 , lysophosphatidic acid 
(LPA), and endothelin receptor induce serum response factor via these G proteins in a 
C3 exotoxin-dependent manner (Mao et aL, 1998) a direct role for the Rho GTPase is 
implicated in these events.
Recently G n a  was found to stimulate Brutons tyrosine kinase (Btk) and Gap I'", a 
RasGAP, in vitro and in vivo (Jiang et aL, 1998). G n a  interacts with a conserved 
domain composed of the pleckstrin-homology domain and the adjacent Btk and GaplT 
The Rho guanine nucleotide exchange factor p l l 5  RhoGEF was found to be a direct 
effector of Gn a  (Hart et aL, 1998). Activated Gn a  stimulated its capacity to catalyse 
nucleotide exchange on Rho. By comparison, activated Gn a  inhibited stimulation of 
p i 15 RhoGEF by Gn a. Thus Gapl™ and pi 15 RhoGEF appeared to provide a link 
between signalling by heterotrimeric and monomeric G proteins.
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Table 1.2. Classifîcation of Ga subunits, their distribution and effectors
Subtvue Expression Effectors
G ot Subfamily
GgŒ (4 splice variants) Ubiquitous Î Adenylyl Cyclase 
Î Ca^  ^Channels, Na  ^Channels
GoifOt
Gitt Subfamily
Olfactory t Adenylyl Cyclase
Giia Widespread 1 Adenylyl Cyclase, etc
G^a Ubiquitous 1 Adenylyl Cyclase, etc
Gisa Widespread 1 Adenylyl Cyclase, etc
Gott Neuroendocrine t Channels, Ca^  ^Channels 
1 Adenylyl Cyclase
Ggust^ C Taste Buds Î cGMP Phosphodiesterase
Gtia Retinal Rods Î cGMP Phosphodiesterase
Gt2a Retinal Cones Î cGMP Phosphodiesterase
Gztt Neuroendocrine 1 Adenylyl Cyclase, etc
G^a Subfamily
Gqa Widespread t Phospholipase C
Giia Widespread t  Phospholipase C
Gi4a Widespread Î Phospholipase C
Gisa Circulatory t Phospholipase C
G^a Circulatory t Phospholipase C
Glia Subfamily
Gi2a Ubiquitous RhoGEF & others
Giaa Ubiquitous RIioGEF & others
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IIL G Py subunits
The p and y subunits of heterotrimeric G proteins form a tightly associated dimer 
complexes in the plasma membrane. So far 6  different Gp and 12 different Gy subunits 
have been identified (Clapham et ah, 1997). Gp and Gy subunits are very widely 
expressed with the exception of yl, present only in the photoreceptor cells, and y2  and 
y3 which are restricted to the brain.
Structurally the GPy complex has been described as a " propeller " based on 
crystallography studies (Sondek et ah, 1996). Gp subunit is made up of 2 structurally 
distinct regions, an amino terminal segment and a repeating sequence. This results in a 
7-membered p-propeller structui’e based on 7 WD-40 repeats (Lambright et ah, 1996) 
and Gy subunits interact with p through a N-terminal coiled-coil and via extensive 
contacts all along the base of p.
The Ga*GDP complex released from the effector molecule is bound with Py to 
form a py«Ga*GDP complex that has high affinity towards GPCRs. Equally, the GPCR 
has a higher affinity for agonist when coupled with PyGa*GDP. The interaction of 
agonist with the (R) (Py*Ga*GDP) complex induces the release of GDP bound to Ga 
such that exchange of GDP with external GTP is facilitated. The resulting 
(A)(R)(Py*Ga*GDP) complex dissociates to form Ga*GTP, GPy, agonist and receptor. 
The Ga-GTP complex can now activate the effector molecules. From this scheme, a
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major function of the Py subunit is to recognise the GDP bound form of G a and to 
promote its binding to receptor and agonist, thus facilitating the recycling of Ga»GDP to 
Ga-GTP.
GPy subunits inhibit GDP release from Ga following Ga-catalysed GTP hydrolysis 
thus rendering reactivation dependent upon the interaction of G a with ligand-activated 
GPCRs (Sprang, 1997). The GPy subunits themselves can play active roles in signal 
transduction. For example, through regulation of K+ channels, PLC p and certain 
isoforms of AC in animal cells, and activation of the pheromone response pathway in 
budding yeast. Clearly, GPy subunits enhance receptor interaction with G a subunits.
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Table 1.3. Biochemical properties of G protein Py-dimers
Feature Property of py-dimers
Structure 
P (35 kDa)
y(7-10kDa) 
Membrane anchoring 
Receptor recognition 
Effector regulation
Deactivation
Regulation
Tightly associated, rigid dimer -  no conformational change upon activation 
Seven WD40 repeats (1 repeat = 4 antiparallel p-strands) form a 7-bladed 
propeller core
Extended a-helix forms coiled-coil with GP 
Via carboxyterminal isoprenoid lipid modification on Gy 
py-dimers required for receptor mediated activation of Ga-subunits 
Conditional: type Il-like AC isoforms; py-dependent stimulation requires 
presence of active Gga. Unconditional (direct regulation); PLC-P2; GIRK 
and neuronal Ca^  ^channels; type I-like AC; dynamin I; non-receptor protein 
tyrosine kinases (BTK and TSK)
By GDP-liganded a-subunits
By phosducin (a 33 kDa protein that binds and scavenges free Py-dimers) and 
phosducin-like proteins, py-dimers provide docking sites for some GPCR 
kinases, which phosphorylate the agonist-bound receptor
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IV. Covalent modifications of G proteins
a) ADP-ribosvlation
Modulation by PTx has been used as a useful tool to characterise certain G protein- 
dependent signalling pathways. PTx is also called Islet activating protein (TAP). It is 
produced by Bordetella pertussis and causes ADP-ribosylation of a cysteine side chain 
four amino acids from the C-terminus of the a-subunits of Gj, Go, and Gt. This prevents 
activation of the G protein trimer by its receptor (Katada et ah, 1982: West, 1985). 
Efficient ADP-ribosylation by PTx requires the complete aPy trimer and isolated a- 
subunits are reported to be poor substrates (Casey et aL, 1989). The py-subunits may act 
by promoting favourable contacts of the a-subunits with PTx or by relieving 
unfavourable contacts between the G protein and the toxin (Scheuring et aL, 1998).
Formation of the complex between PTx, NAD^ and G ^a is of interest in 
charactersing the ADP-ribosylation of a G protein. The crystal structures of both 
Gjia (Mixon et aL, 1995) and PTx (Stein et aL, 1994) have been solved. The structures 
permit interpretation of the transition state chemistry in the context o f known protein 
structures. Scheuring et aL, (1998) has described the steady-state kinetics, substrate 
commitment factor, kinetic isotope effects, and the transition-state structure for the 
ADP-ribosylation of recombinant a-subunit of the G protein Gua catalysed by PTx.
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b) Phosphorylation
Phosphorylation of G proteins is the least well characterised of the covalent 
modifications. The first evidence that G proteins may be regulated by phosphorylation 
derived from observations that treatment of platelet membranes with partially purified 
PKC resulted in phosphorylation of a 41 kDa protein (Katada et aL, 1985). Kozasa et 
aL, (1996) have shown that Giza serves as a substrate for phosphoiylation by various 
isoforms of PKC in vitro suggesting PKC regulates an-mediated signalling pathway by 
preventing their association with Py. The a n  was shown to be phosphorylated by PKC 
and the phosphorylated a n  provided a tighter interaction of pyiz with Goa and Giza 
(Morishita er fl/., 1995).
c) Palnnitovlation
Palmitoylation is a post-translational modification that is limited to a subset of 
cellular proteins among which proteins involved in signal transduction are prevalent 
(Casey, 1995). This thioesterification of cysteine residues by palmitate distinguishes 
itself from other lipid modifications such as prénylation and myristoylation by its 
reversibility. Indeed, in contrast to myristoyl and prenyl moieties that are added co- 
translationally and generally remain attached to the proteins until the protein gets 
degraded, the protein-bound palmitate is added post-translationally and turns over more 
rapidly than the protein itself (Omary et aL, 1981 : Bonatti et aL, 1989). Biologically 
regulated changes in the palmitoylation state of either receptors or G proteins may have
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important functional consequences. For example, it has been found that mutations to 
prevent palmitoylation of the GoOC subunit inhibit their association with the plasma 
membrane and thus their signalling function (Grassie et al, 1994). McCallum et al., 
(1995) have shown that the palmitoylation status of the cysteine residues at positions 9 
and 10 in murine G u a  played a central role in defining membrane assoeiation of this G 
protein and indicated that much of the particulate fraction of the expressed 
palmitoylation-resistant mutants represented non-functional rather than correctly folded 
protein. Palmitoylation of Gga has also been reported to increase its affinity for Gpy (liri 
et al., 1996). For example, activation of Gga through receptor stimulation, following 
direct activation with aluminum fluoride and cholera toxin or as a result of site-directed 
mutagenesis has been shown to lead to increased incoi*poration of [^H] palmitate into 
Gga during pulse labelling experiments. Because pulse-chase-labelling experiments 
clearly indicated that stimulation increased the depalmitoylation rate, the enhanced 
incorporation was attributed to an accelerated turnover rate of the Gga -bound palmitate 
(Degtyarev et a l, 1993: Wedegaertner et al., 1994).
Wise and Milligan, (1997) demonstrated the general utility of generating chimeric 
GPCR-G protein fusion proteins to examine receptor regulation of G protein activation 
and that agonist-induced signal transduction to acylation-deficient mutants of Gua can 
be rescued by expressing these polypeptides as fusion constructs with the receptor. 
Moreover these studies indicated that effective agonist-induced signal transduction is 
unaffected by the palmitoylation potential of the receptor. Loisel et ah, (1999) also 
examined the acylation/déacylation cycle of the proteins in relation to their activity
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status, using the advantage of a fusion protein composed of the stimulatory a  subunit of 
Gs covalently attached to the pzAR. When expressed in Sf9 cells, both the receptor and 
the Gga moieties of the fusion protein were found to be palmitoylated via thioester 
linkage. These investigators have reported that stimulation of the PzAR-Gsa fusion 
protein with p-adrenergic agonists promotes rapid depalmitoylation of both the receptor 
and the G a subunit and inhibited their repalmitoylation.
d) Myristoylation
Co-translational myristoylation has been ascribed as one of the key means of 
targeting of specific G protein a  subunits to the plasma membrane. (Casey, 1995; 
Milligan et aL, 1995). Both myristoylation and palmitoylation may also contribute to 
protein-protein interactions between the G protein a  subunit and both receptors and the 
G protein py complex. Addition of myristate occurs only on the a  subunits of the Gi- 
family of G proteins because they contain the consensus sequence (MGXXXS) for the 
enzyme W-myristoyl-CoA transferase. The glycine that is found at codon 2 acts as the 
acceptor when it is exposed following removal of the initiator methionine. The Gga 
subunit is not myristoylated (Buss et al, 1987). It has an N-terminal glycine but no 
serine at position 6 .
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V. Regulators o f G protein signalling (RGS proteins); GTPase Activating 
Proteins (GAPs) for heterotrimeric G proteins
The slow intrinsic rate of GTP hydrolysis by G a proteins is regulated by 
interactions with so-called GTPase activating proteins or GAPs. GAPs were first 
recognised as regulators of protein synthesis factors and low molecular weight GTPases 
such as Ras. It is now clear that certain effectors of G protein-regulated pathways can 
act as GAPs on cognate Ga proteins (Berstein et ah, 1992). Furthermore, there exists a 
large, recently discovered family of GAPs for G a proteins known as regulators of G 
protein signalling or RGS proteins. These were discovered functionally as negative 
regulators of G protein signalling in Saccharomyces cerevisiae (Sst2p) (Dohlman and 
Thomer, 1997) and Caenorhabditis elegans egg-laying behaviour (Egl-10) (Koelle and 
Horvitz, 1996). Sst2p and Egl-10 both contain a conserved RGS domain of 120 amino 
acids. These accelerate the GTPase reaction of the G protein a  subunit. In addition,
RGS proteins inhibit effector regulation. A mammalian RGS protein, GAIP, was 
independently cloned in a two-hybrid screen for Giga-interacting proteins (DeVries et 
aL, 1995). Subsequently, over 15 mammalian genes have been identified that contain 
the conserved RGS domain. In vitro biochemical studies have shown that RGS proteins 
have GAP activity for purified Gia and Gqa and can enhance GTP hydrolysis rates as 
much as 100-fold (Koelle, 1997). RGS4 is capable of accelerating GTP hydrolysis of 
Gi-proteins by constraining the residues involved in catalysis (Tesmer et aL, 1997).
Effects of purified GAIP and RGS4 on purified Giia, Giza, Gisa, Goa, and Gga 
have been examined in vitro (Berman et aL, 1996). These investigators have found that
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two RGS family members, GAIP and RGS4, are GTPase-activating proteins (GAPs), 
accelerating the rate of GTP hydrolysis by Giia at least 40-fold, All Gi subfamily 
members assayed were substrates for these GAPs; Gga was not. The GAP activity of 
RGS proteins is consistent with their proposed role as negative regulators of G protein- 
mediated signalling.
VI. Receptor~Gprotein coupling interactions
The coupling of GPCRs with heterotrimeric G proteins has long been a topic of 
great interest, as this directly affects the activation of secondary downstream effectors, 
and ultimately the final physiological response.
a) G protein domains essential for coupling with receptor
There are at least 3 regions of Ga postulated to contact the receptor, with the 
strongest evidence pointing to the C-terminus.
On the a  subunit, the best-characterised receptor contact region is at the C terminus 
(Bourne, 1997; Sprang, 1997). Data in support of this model include that the une 
mutation of G^a, which results from an Arg-Pro alteration 6  amino acids from the C- 
terminus, prevents productive interactions with GPCRs (Sullivan et aL, 1987). The last 
7 amino acids of the a  subunit are disordered in the heterotrimer crystal structures, and
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analysis of receptor-binding peptides selected from a combinatorial peptide library 
shows that these 7 residues are the most critical (Martin et aL, 1996). Also, studies using 
chimeric G a subunits confirmed that the last 5 residues play an important role in 
specifying receptor-G protein interaction. Conklin et aL, (1993) replaced C-terminal 
amino acids of Gaq with the corresponding residues of Gaiz to create Gaq/aiz chimeras 
that can mediate stimulation of PLC by receptors, otherwise coupled exclusively to Gj.
A minimum of three Gaiz amino acids, including the glycine three residues from the C- 
terminus, sufficed to switch the receptor specificity of the Gaq/ajz chimeras. These 
investigators proposed that a C-terminal turn, centred on this glycine, plays an important 
part in specifying receptor interactions with G  proteins in the Gj/Go/Gz family.
Evidence that the N-terminus of G a was involved in GPCR coupling was shown 
by a study in which a photo-affinity peptide corresponding to the IC3 region of the azA- 
adrenergic receptor can be cross-linked to the amino terminus of G^a (Taylor et al,
1994). This confirmed previous work by Hamm et aL, (1988) on the inhibition of 
interaction of Gta with rhodopsin using a synthetic N-terminal peptide of Gta.
Finally, a third region of Ga that may contact the receptor surface was mapped to 
residues 311 to 328 of Gta (Hamm et aL, 1989: Hamm, 1991). This peptide behaved 
like the last 11 residues of Gta in inhibiting Gta activation by photorhodopsin and at the 
same time induced spectral changes in photorhodopsin. The analogous region in Ras 
was postulated to be the G5 region where the guanine ring interacts with the side chains 
in this region (Conklin et aL, 1993b).
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VIL Suramin: a nonpeptide G protein antagonist
Suramin, a symmetric polysulphonated naphtylamine-benzamide-derivative, has 
been used for more than 70 years in the treatment of African sleeping sickness and river 
blindness. As well as being effective against various Trypanosoma species and the adult 
fdariae of Onchocerca volvulus, suramin also exerts inhibitory effects on an array of 
mammalian targets such as purinergic receptors, DNA polymerase and growth-factor 
receptors (Voogd et aL, 1993). Moreover, among its targets are G protein a-subunits, 
Suramin acts as a G protein inhibitor because it limits the rate-limiting step in activation 
of the G a subunits, i.e., the exchange of GDP for GTP. In the submicromolar to 
micromolar concentration range, suramin and suramin analogues suppress the rate of 
spontaneous GDP-release from purified G protein a-subunits (Hohenegger et aL, 1998). 
The effect of suramin on GDP release can be reversed upon addition of an effector, 
indicating that binding of an effector and of suramin are mutually excusive (Freissmuth 
et aL, 1996).
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1.5. Adenylyl cyclase (AC)
/. General overview
In the late 1950s Sutherland and co-workers discovered 3% 5’-eyclic adenosine 
monophosphate (cAMP), which was the pivotal event that led to the current paradigm of 
hormone signalling via second messengers. The ACs are the family of enzymes that 
synthesise cAMP (Krupinski et ah, 1989). The synthesis of cAMP by AC is modulated 
by hormones and neurotransmitters acting via receptors that aetivate G proteins. To 
date, mRNAs encoding nine distinct isoenzymes of AC have been identified (Houslay 
and Milligan, 1997: Avidor-Reiss et ah, 1997). Sequence and functional similarities 
allow the categorisation of these ACs into six classes.
a) AC type I (AC-h:
Stimulated by Ca^^/calmodulin, possibly independently of Gsa stimulation.
Inhibited by GPy subunits.
b) AC-VIll:
Stimulated by Ca^"^/calmodulin.
c) AC-V and AC-VI;
Inhibited by low levels of Ca^ "*".
Unaffected by GPy subunits.
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d) AC-11, AC-IV, 3nd AC-VI 11
AC-II, AC-IV are highly activated by GPy subunits in the presence of activated 
Gga.
AC-II, AC-VII are stimulated by activation of PKC.
e) AG-Ill:
Stimulated by a high concentration of Ca^Vcalmodulin in the presence of Gga. 
Unaffected by Gpy subunits.
n AG-IX:
Activated by Gga only.
/ / .  Structure
Cloning studies have identified multiple types of AC which are all stimulated by 
Gga. All ACs are associated with the plasma membrane and hydropathy analyses 
suggest that they span the membrane 12 times. The nine cloned isoforms of mammalian 
AC share a primary structure consisting of two TM regions, Mi and Mz, and two 
cytoplasmic regions, Ci and Cz (Krupinski et ah, 1989). The TM regions each contain 
six predicted membrane-spanning helices. The function of Mi and Mz, aside from 
membrane localisation, is unknown despite their topological analogy to transporters. 
The Cl and Cz regions are subdivided into Cia and Cib and Cza and Czb- The Cia and Cza
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domains heterodimerise with each other in solution (Yan et ah, 1996). These domains 
can also form homodimers. The Cib region is large (~15 kDa), variable, and contains 
several regulatory sites. The Czb is very short in some isoforms and lacks identified 
functions; hence Cz and Cza are sometimes referred to interchangeably.
The structure of the type II AC Cz region revealed a homodimer with two Cz 
monomers in a wreath-like arrangement. Two forskolin moleeules bind to this groove in 
the homodimer. The type C C ia region and type II Cz region arrange themselves in a 
heterodimeric wreath that is nearly identical in overall structure to the Cz homodimer, 
with some critical differences in detail (Tesmer et ah, 1997). The activity of mammalian 
AC depends on the heterologous association of Cia and Cz. This is not the case for many 
other related cyclases.
IIL Regulatory mechanisms of AC
a) G protein a  subunits and By subunits
Transmission of signals through G proteins can be achieved by the use of either 
a  or Py subunits. It had been generally believed that a  subunits were the prime signal 
transmitters. Only a few systems sueh as certain types of channels and the effector in 
the yeast pheromone pathway (Dietzel and Kurgan, 1987) were thought to be regulated 
by Py subunits. However, it has been shown that Py subunits can by themselves regulate
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the activity of a number of mammalian effectors such as certain types of AC and 
PLC.Thus it has become increasingly obvious that Py subunits will play a central role in 
many signalling pathways.
Activation by the GTP-bound G protein a  subunit Gga is synergistic, not 
competitive, with respect to forskolin. GTP-Gga binds to a crevice on the outside of the 
wreath formed by a 2 ' and a3 ' of Cz and by the N-terminal portion of Ci (Tesmer et aL, 
1997). Gioc selectively inhibits AC types V and VI and binds to the AC catalytic core on 
a groove pseudosymmetrically related to the Gga binding groove (Tesmer et aL, 1997).
Gpy subunits conditionally regulate several AC. Type II AC is activated by 
GPy when Gga is bound. The Gpy site is adjacent to, but does not overlap, the GgOt site, 
consistent with conditional activation. The a4~p6 region of Gga was predicted to 
interact with AC based on mutagenic analysis, but no such contact with the catalytic 
domain was seen in the crystal structure. Gpy regulation of the soluble AC model has 
not been established, even though the known binding site is located within the type II Cz 
domain. Cib, M%, or Mz might be involved in either of these processes. Tang and 
Gilman, (1991) have shown that Py subunits have been found to have regulatory effects 
on certain types of AC. In the presence of Gg alpha, the a  subunit of the G protein that 
activates AC, one form of AC was inhibited by Py, some forms were activated by 
py, and some forms were not affected by Py. Moreover, Gao and Gilman, (1991) have 
cloned and expressed a cDNA that encodes a widely distributed form of mammalian AC 
(EC 4.6.1.1).
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b) Free metal ions
Mn activates mammalian AC strongly and millimolar concentrations of free Ca  ^
inhibit. These effects are unlikely to have any physiological meaning or to reflect 
distinct binding sites for these ions.
c) P-site inhibitors
P-site inhibitors are a class of nucleoside inhibitors of AC. P-site inhibition is 
potentiated when AC is activated and is hypersensitive to certain mutations that slightly 
reduce enzyme activity.
d) Forskolin
Forskolin is a hydrophobic activator of all the mammalian AC except type IX. It is 
an extremely powerful activator, increasing activity by up to 1000 fold. The forskolin 
binding pocket is a narrow hydrophobic crevice that almost completely buries the 
forskolin molecule once bound.
e) Ca^Vcalmodulin
Ca^Vcalmodulin activates type I AC by binding to a putative helieal region on the 
Cib (Wu et al., 1993). The precise activation mechanism is unknown. If other
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Ca^Vcalmodulin activated enzymes are precedents, it is likely that Ca^’^ /calmodulin 
binding will disrupt an autoinhibitory interaction between the Cia/Cz catalytic core and 
sequences within the Cib.
f) Protein phosphorylation
PKC activates type II AC by phosphorylating it on Thr-1057 (Bol et aL, 1997).
This site is within a region known to be required for PKC activation (Levin and Reed,
1995). CAM kinase II inhibits type III AC by phosphorylating it at Ser-1076 (Wei et aL,
1996). This Ser is at the outer lip of the active site, hence its phosphorylation could 
directly interface with catalysis. PKC phosphorylates Ser-674 in the Cib of type VI 
(Chen et aL, 1997) and appears to regulate a low affinity secondary binding site for Gga. 
CAM kinase IV phosphorylates type I AC in its Cib domain and disables Ca^^/ 
calmodulin activation by interfering with the calmodulin binding site (Wayman et al, 
1996).
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CHAPTER II
Materials and Methods
MATERIALS AND METHODS (CHAPTER 2)
2.1. Materials
2.1.1. General R eagents
ALEXIS CORPORATION LTD.. Bingham, Nottingham, U.K.
Dithiothreitol (DTT)
AMERSHAM INTERNATIONAL PLC.. Buckinghamshire, U.K 
Enhanced chemiluminescence reagent, ECL detection film
BDH
Ammonium persulphate (AmpS0 4 ), glucose, glycine, Na2HP0 4
BECTQN DICKINSON
Plastipak® sterile syringes
CALBIQCHEM-NQVABIQCHEM LTD.. Beeston, Nottingham, U.K. 
Geneticin (G-418)
CAMBIO LTD.. Cambridge, U.K.
Fast-link™ DNA ligation and screening kit
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CRUACHEM LIMITED.. Glasgow, U.K.
Oligonucleotides
FISHER.. Scientific Equipment, Loughborough, U.K.
Acetic acid, Ethylenediaminetetra acetic acid (EDTA), NaCl, MgClz, 4-[2- 
Hydroxy ethyl] -1 -piperazine-N'-2-ethane-Sulphonic acid (HEPES)
FUJI PHOTO FILM LTD.. Tokyo, Japan 
X-ray film
GIBCO BRL LIFE TECHNOLOGIES INC.. Paisley, U.K. 
Lipofectamine^^, Tris
INVITROGEN.. San Diego, CA, U.S.A. 
pcDNA3, pcDNA(3.1)
ICN
Mycoplasma removal agent (MRA)
MERCK LTD.. Poole, Dorset, U.K.
Agar, NaOH
OXOID LTD.. Hampshire, U.K.
Tryptone, yeast extraet
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PACKARD INSTRUMENTS., BY, Netherlands 
Ultima Gold XR liquid scintilation cocktail
PREM IER BEVERAGES., Stafford, U.K.
Marvel
PIERCE.. Rockford, IL.
Enhanced chemilumincsccnce reagent
PHARMACIA.. Piscataway, NJ 
dNTP's (dATP, dCTP, dOTP, dTTp)
PROMEGA LTD.. Southampton, U.K.
Restriction enzymes. Wizard™ Miniprep kit, Wizard™ DNA clean-up kit,
Geneticin (G-418)
QIAGEN LTD.. Southampton, U.K.
Qiagcn® plasmid maxiprep kit
ROCHE MOLECULAR BIOCHEMICALS LTD.. Lewes, East Sussex, U.K. 
App[NH]p*, Aprotinin, creatine phosphate, creatine kinase, GTP, GTPyS, Tris, N~ 
Glycosidase F (NGF), restriction enzymes. Bovine serum albumin faction V,
Shrimp alkaline phosphatase (SAP)/alkaline phosphatase, DNA Molecular Weight 
Marker X (0.07-12.2 kbp), DOTAP Liposomal Transfection Reagent, T4 DNA ligase 
*ApprNH1p: AMP-PNP (Adenvlvl imidodiphosphate)
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SCOTTISH ANTIBODY PRODUCTION UNIT.. Lanarkshire, U.K.
Horseradish peroxidase conjugated donkey anti-rabbit IgG
SIGMA CHEMICAL COMPANY.. Poole, Dorset, U.K.
Alumina, ATP, ampicillin, cholera toxin, DOWEX AG50 W-X4 (200-400 mesh), 
forskolin, imidazole, mineral oil, Ouabain, Pertussis toxin (PTx), N, N, N', N' 
tetramethyethylenediamine (TEMED), thimerosal, TRICINE Acetic acid, DMSO, 
hydrochloric acid, KCl, KH2PO4 , K2 HPO4 , NaCl, NazCO], NaHCOs, NaH2 P0 4 , 
sucrose, sodium dodecyl sulphate (SDS), trichloroacetic acid (TCA), Coomassie Blue 
R-250, Ponscau S, Trypsin
STRATEGENE LTD.. Cambridge, U.K.
Pfu DNA Polymerase
WHATMAN INTERNATIONAL LTD.. Maidstone, U.K.
Brandcll GF/C Glassfibre filters
2.1.2. R adiochem icals
AMERSHAM PHARMACIA BIOTECH PLC.. Buckinghamshire, U.K.
[^H] Adenine (specific activity; 23.0 Ci/mmol)
NEN™ LIFE SCIENCE PRODUCTS LNC.. Stevengc. Hertfordshire, U.K.
[^H] naltrindolc (specific activity: 33.0 Ci/mmol)
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[^H] DADLE (specific activity: 55.3 Ci/mmol)
[^H] diprenorphinc (specific activity: 58.0 Ci/mmol) 
[y-^^P] GTP (specific activity: 30.0 Ci/mmol)
2.1.3. A ntisera
Antl-Gg antisera
These antisera were generated against synthetic peptides described in Goldsmith 
et aL, (1988). Conjugates of these peptides with keyhole-limpet hacmocyanin were 
injected subcutaneously into New Zealand White rabbits. Bleeds were obtained from 
the ear artery. Amino acid sequence of the synthetic peptides derived from the various 
G a are listed below:
Antiserum Peptide Sequence Amino acid 
Sequence
Identification Reference
n c LDRIAQPNYI 159-168 aa of Giia Green et al
Giia (1990)
ONI GCTLSAEERAA 1-16 aa of Goia Goia, Go2 a Gcorgoussi et al
LERSK and Go2 0 t (1993)
Anti-rabbit IgG
Donkey polyclonal antibody conjugated with horseradish peroxidase, produced 
by the Scottish Antibody production unit, Lankarshire, U.K.
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2.1.4. T issue culture
AMERTCAN TISSUE CULTURE COT J.ECTTON.. Rockville, U.S.A.
Human embryonic kidney (HEK293) cells
GIBCQ BRL LIFE TECHNOLOGIES INC.. Paisley, Strathclyde, Scotland, U.K. 
Glutamine (2000 mM), Newborn calf serum (NBCS), Optimem-1 medium, NaHCOa 
(7.5 %
SIGMA CHEMICAL COMPANY.. Poole, Dorset, U.K.
Dulbecco's Modified of Eagle’s Medium (DMEM), Minimum Essential Medium 
(MEM), Trypsin-EDTA solution
IWAKI SCITECH DIV. Asahi Techno Glass..
Dishes 10 cm diameter, Flasks 25 cm^ and 75 cm^. Plates 6 , 12 and 24 wells. 
Disposable cell scraper
STERILIN BIBBY LTD.. Stone, Staffordshire, U.K.
Pipettes 5 ml, 10 ml and 25 ml, centrifuge tube 50 ml
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2,1.5. S tandard  buffers
a) Tris-EDTA-MgCb Buffer (TEM)
Tris 75 mM
EDTA 5 mM
MgCl] 12.5 mM
p H  adjusted to 7.5 at 25 °C
This was made up for [^H] naltrindole/diprenorphine binding and [^H] DADLE 
binding assays.
b) Tris-EDTA Buffer (IE)
Tris 75 mM
EDTA 5 mM
p H  adjusted to 7.5 at 4 °C
This was made up for washing of binding experiments and was usually made up 
as a 5X stock solution and diluted when required.
c) Tris-EDTA Buffer (TE)
Tris 10 mM
EDTA 0.1 mM
pH  adjusted to 7.5 at 4 °C
This was made up for membrane preparation and protein measurement.
68
dl Phosphate-buffered Saline (PBS)
KCl 2.7 mM
KH2PO4 1.5 mM
NaCl 140 mM
Na2HP0 4  8  mM
p H  adjusted to 7.5
This was made up as a 1 OX stock solution and diluted when required.
Usually for 1 litre in PBS (IX) buffer, NaCl (10 g), KCl (0.25 g), Na2HP0 4  (1 . 8  g) 
and KH2PO4 (0.3 g). (sterilised PBS -  autoclaved)
e) Tris Buffered Saline (TBS)
NaCl 150 mM
Tris/HCl 20 mM
p H  adjusted to 7.5
This was usually made up from 30 ml of IM Tris (pH 7.5) and 20 ml of 5M NaCl 
for a 1 litre solution and used for SDS-PAGE.
f) Tris Buffered Saline with Tween (TBST)
NaCl 150 mM
Tris/HCl 20 mM
Tween 20(0.1%) 
p H  adjusted to 7.5
This was made up by adding Tween 20 (0.1% %) to TBS buffer for SDS-PAGE.
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g) Laemmii Buffer (2x)
DTT 0.4 M
SDS 0.17 M
Tris/HCl (pH 8.0) 50 mM
Urea 5 M
Bromophenol Blue 0.01% ^/v
This was stored in aliquots at -20 °C until required.
h) Gel Running Buffer
Glycine 36 g
Tris 7.5 g
10% SDS 25 ml
Total volume dissolved in 2.5 litre H2 O
This was made up for SDS-PAGE gel running buffer.
il Western transfer buffer
Glycine 72 g
Tris 15 g
Total volume dissolved in 4 litre H2 O and 1 litre methanol
This was made up for western transfer buffer and usually kept in 4 ° C without 
methanol.
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2.2. Molecular biology for subcloning
Molecular biological works were performed in an environment where 
contamination of DNA and DNAse were kept to a minimum. I autoclaved all 
materials (e.g., pipette tips (yellow/blue), eppendorfs, buffers, water, PCR tubes, etc), 
cleaned up the bench and pipetters with 70% alcohol, and wore gloves for every 
experiments.
2.2.1. R eagents for M olecular biology
a) Tris-acetate-EDTA Buffer (TAE)
Tris-acetate 40 mM
EDTA 1 mM
pH  adjusted to 8.0
This was made up for DNA agarose gel analysis.
Usually for 300 ml in TAE buffer, 72.6g Tris base, 17.13ml glacial acetic acid and 
30ml 0.5M EDTA (pH 8.0)
b) Luria Bertani (LB) medium
For 1 litre:
Bacto-tryptone 10 g
Bacto-yeast extract 5 g
NaCl 10 g
These were dissolved in deionised water and autoclaved at 126 ° C for 11 min.
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c) Gel Loading Buffer (6X)
for 1 0  ml:
Bromophenol Blue (2%) 1.25 ml
Sucrose 4 g
These were dissolved in autoclaved water to a final volume of 10 ml. The buffer 
was stored in aliquots at -20 ° C.
d) LB Ampicillin Agar Plates
This was made up of the same components as LB and bacto-agar (1.5%  /^y) 
added. After autoclaving, bottle was left to be cool and ampicillin (lOOpl/lOOml) 
added to a final concentration of 50 pg/ml. The liquid LB agar was poured into 100 
mm diameter Petri dishes, allowed to be solid and stored at 4 ° C.
2.2.2. T ransform ations and DNA purifications/preparation 
from bacteria
Transformation, the transfer of DNA into Kcoli, produces multiple copies of the 
DNA from the bacteria replicates, such as DH5a.
a) Preparation of competent bacteria (DH5a)
Solution 1 (for 100 ml)
Potassium acetate (1 M) 3 ml
RbClz (1 M) 10 ml
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CaClz (1 M) 1 ml
M11CI2 (1 M) 5 ml
Glycerol (80% 7v) 18.75 ml
The final volume was made up to 100 ml with deionised water and pH adjusted 
to 5.8 with 100 mM acetic acid. The solution was filter-sterilised and stored at 4 ° C.
Solution 2 (for 40 ml)
MOPS (100 mM; pH 6.5) 4 ml
CaCl2 (1 M) 3 ml
RbCl2 (1 M) 0.4 ml
Glycerol (80% %) 7.5 ml
The final volume was made up to 40 ml with deionised water and pH adjusted to 
6.5 with HCl. The solution was filter-sterilised and stored at 4 ° C.
A conical flask with 250 ml of LB was inoculated with 5 ml of culture of 
DH5a E. coli overnight, allowed to incubate at 37 ° C with shaking for 4-5 h until the 
optical density (at 550 nm) of the culture reached 0.48. Then the culture was chilled 
on ice for 5 min, and the bacteria collected by spinning in a chilled centrifuge at low 
speed (-3000 rpm). The pellet was resuspended in 100 ml of solution 1 for 5 min on 
ice. The bacteria cells were pelleted as before, and then resuspended in 5 ml of 
solution 2 for 15 min on ice. The DH5a bacteria are ready for transformation or can 
be stored at -80 ° C in aliquots until required.
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b) Preparation of " Ultra-Competent " E.coli (Inoue Method)
SOB Medium
Bacto tryptone (2 % ^/y)
Yeast extract (0.5 % % )
NaCl (10 mM)
KCl (2.5 mM)
MgCl2 (10 mM)
MgS0 4  (10 mM)
pH was adjusted to 6 .7-7.0.
TB (Transformation Buffer)
Pipes (10 mM)
MnCb (55 mM)
CaCl2 (15 mM)
KCl (250 mM)
pH was adjusted to 6.7 with 5 N KOH prior to adding the MnC^.
Inoue et al., (1990) introduced " High efficiency transformation of E.coli with 
plasmids ". The E.coli was inoculated in LB overnight, grown in 250 ml " SOB "at 
18C until the optical density (at 600 nm) of the culture reached 0.6. Then the culture 
was chilled on ice for 1 0  min, and the bacteria collected by spinning in a chilled 
centrifuge at low speed (-2500 g) for 1 0  min at 4 ° C. The pellet was resuspended 
gently in 80 ml of ice cold " TB ", left for 10 min and the bacteria collected by 
spinning in a chilled centrifuge at low speed (-2500 g) for 10 min at 4 ° C. The
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bacteria cells were then added DMSO to a final concentration of 7 %, placed on ice 
for 10 min. " Ultra-competent " bacteria are ready for transformation or can be stored 
at liquid nitrogen until required.
c) Transformation of DNA
Each plasmid DNA (5 p i /10-50 ng) was incubated with 50 pi of competent 
bacteria in a sterile 13 ml white top tube for 15 min on ice. Then the DNA/ bacteria 
mixture was heated at 42 ° C for 60-90 sec, and straightly back into ice for 2 min. 450 
pi of LB or SOB was added and the bacteria cells containing LB incubated in a 37 ° C 
for 45 min. LB ampicillin agar plates were pre-waimed at 37 ° C. For normal 
transformation of whole plasmid DNA, -50 pi of this mix was plated out on LB 
ampicillin agar plate with ethanol-washed plater, left at 37 ° C incubator to absorb the 
liquid, and finally incubated at 37 ° C overnight. On next day, colonies was picked 
from the plate and cultured in LB for the further purification of DNA. Moreover, for 
ligation of enzyme-digested DNAs, -100 pi of the mixture was used for plating. Cells 
can be kept as glycerol stocks for up to 2  years.
d) DNA Purification/preparation
The DNA from the inoculated cultures in LB was purified the Promega 
Wizard™ Miniprep/Maxiprep kits, Qiagen Maxiprep kit according to the 
manufacture's intructions, to obtain large copies of DNA.
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2.2.3. Polym erase Chain Reaction (PCR)
Polymerase chain reaction (PCR) was performed by accurate pipetter and all the 
materials (PCR tubes, tips, pipette box, eppendorf tubes etc) were autoclaved and 
sterilised before the use.
A DOR cDNA was obtained from Glaxo-Wellcome Research and Development 
(Stevenage, UK).
a) Construction of the hDOR-G.ia (wild type) fusion protein
♦ The last 157 bps fragment of the human DOR was amplified by PCR using the 
following oligonucleotides primers:
PCR reaction:
Primer 25 pmole/each
5' sense primer 1 =1.1 pi
5' antisense primer 2 =2.3 pi
DNA (template) 10-100 ng (0.1 pg/pl) = 0.7 pi
Deoxvnucleotides tri-phosnhate (dNTP's)
0.2-0.25 mM (0.2 mM each dATP, dCTP, dGTP, dTTP)
= 2 pi from 5 mM stock 
Pfu polvmerase (1 unit) = 1 pi
Pfu nolvmerase buffer G OX) = 5 pi
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KbO (sterilised) = 37.99 pi
Total V = 50 pi 
PCR cycles:
The reaction conditions were as follows;
Preheating 95 ° C 5 min 1 cycle
Adding Pfu polymerase
Dénaturation 95 ° C 50 sec
Annealing 37 ° C 50 sec 30 cycles
Extension 12° C 25 sec
All reactions were performed on a Hybaid OmniGene temperature cycler. 
Primer;
Sense 5 -GACGAGAACTTCAAG- 3 '
Antisense 5 -AGTGTGCAGCCGGATCCCGCGGCAGCGCCA- 3 '
BamHI
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♦ The ORF of a PTx-sensitive rat G ua was amplified by PCR using the following 
primers:
PCR reaction:
Primer 25 pmole/each
5' sense primer 1 = 1 pi
5' antisense primer 2  = 1 pi
DNA (template) 10-100 ng (0.1 pg/pl) = 2 pi 
dNTP's 0.2-0.25 mM (0.2 mM each dATP, dCTP, dGTP, dTTP)
= 2 pi from 5 mM stock 
Pfu polymerase (1 unit) = 1 pi 
Buffer (X 10) = 5 pi
H2 O (sterilised) = 38 pi
Total V = 50 pi 
PCR cycles:
The reaction conditions were as follows:
Preheating 95 °C 5 min 1  cycle
Adding Pfu polymerase
Dénaturation 95 °C 1 min
Annealing 55 °C 1 min 30 cycles
Extension 12° C 3 min
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95° for 1 min
55° for 1 min 1 cycle
72° for 10 min
All reactions were performed on a Hybaid OmniGene temperature cycler.
Primer:
Sense 5 ' -  CTGGGATCCGGCTGCACACTGAGCGCTGAG -  3 '
BamHI
Antisense 5 ' -  GAGAATTCTTAGAAGAGACCACAGTC -  3 '
EcoRI
b) Construction of the hPOR-Gnialwild type) fusion protein
A fragment of 1065 bps from the cDNA encoding G ^ a  was modified by introducing 
the flanking restriction sites 5' 5g ///and  y  X balhy  PCR amplification.
Primer:
Sense 5 ' -GCCTTAGATCTATGGGATGTACTCTGAGCGC- 3 '
Bglll
Antisense 5 ' -  GCTCTAGATCAGTACAAGCCACAGCCCCG- 3 '
Xbal
79
2.2.4. A garose DNA gel e lec trophoresis  and purification from 
ag a ro se  gel
First the DNA required for agarose gel electrophoresis was diluted to the 
appropriate concentration (1 pg) with sterilised water. Gel loading buffer (6 X) was 
added in the ratio 1:5 with the diluted DNA. Agarose gel was prepared in 35 ml TAE 
buffer (2.2.1a) to a final concentration of 0 .8 - 2  % %  agarose, which is dependent 
upon the size of the DNA fragments to be separated. For example, 35 ml TAE buffer 
at 1 % agarose was made up of 700 pi 50 X TAE buffer, 0.35 g agarose and 35 ml 
water. This mixture was heated in the microwave oven for about 1-2 min. 2 pi of 
ethidium bromide (EtBr, 10 mg/mi) were added, mixed well with the liquid agarose 
and poured into the chamber of the electrophoresis kit (Life technologies, Gibco 
Horizon 58 with Model 200 power pack). The appropriate combs were inserted to 
form wells in the gel. The gel was left to be set and 1 X TAE buffer (200 ml) was 
added to cover it. Then the prepared DNA and DNA molecular marker were loaded 
into the wells and the electrophoresis started (75 100 V) for about 30-60 min.
Finally the gel examined under UV light and an electronic image printed. Used gel 
should carefully dispose in a separate waste to avoid contamination.
Purification of DNA fragments from agarose gel was performed using the 
QIAquick Gel Extraction kit (Qiagen, West Sussex, U.K). First the desired DNA 
fragment on the gel was excised with a clean, sharp scalpel and transferred into a 1.5 
ml eppendorf tube. The gel slice was weighed and 3 volumes of Buffer QG to 1 
volume of gel (lOOmg/lOOpl) were added. The tube was incubated at 50-55 ° C for 10
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min until the gel slice has completely dissolved (the color of the mixture is yellow), 
0.7 volume of isopropanol was added to the sample and mixed by inverting. Then the 
sample was transferred to a QIAquick column fitted on tope of a 2 ml collection tube. 
The whole assembly was centrifuged for 1 min at about 13,000 rpm in a micro­
centrifuge and the flow-through discarded. 0.5 ml of Buffer QG was added to the 
QIAquick column, and centrifuged as before to remove all traces of agarose from the 
column. The column was washed with 0.75 ml of Buffer PE by repeating the 
centrifugation and discarding the waste. The column was further centrifuged for an 
additional 1 min, discarding the waste from Buffer PE and placed into a clean and 
sterile 1.5 ml eppendorf tube. 50 pi of sterilised water or Buffer EB was added to the 
centre of the QIAquick column, stand for 1 min, and centrifuged for 1 min at 13,000 
rpm. The eluted DNA fragment can be kept in -20 ° C or used immediately (i.e., 
restriction enzyme digestion etc),
2.2.5. Restriction enzym e treatm ent and m easurem ent DNA 
concentration
Restriction enzyme treatment was used in order to subclone cDNAs to vectors 
(pcDNA 3). In order, sterilised H2O, DNA, Buffer and restriction enzyme were added 
step by step and incubated at the suitable temperatures according to different enzyme 
for at least 2 h or overnight.
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Normally, the concentration of DNA was measured using absorption observation 
of UV spectrophotometer (UV-1201, Shimadzu). 1 A 200 unit of double-stranded DNA 
is corresponding to 50 pg/ml.
2.2.6. DNA S equencing
Sequencing of constructed DNAs was done by the Molecular Biology Support 
Unit located at the Anderson College, Institute of Virology, University of Glasgow.
All fusion constructs were fully sequenced to identify hDOR cDNA and the correct 
amino acid Cys^^^Xaa of Gua before the use.
2.2.7. C onstruction of hDOR-Giia(wild type) and P T x-resis tan t 
hDOR-Giia(Xaa^®^) fusion protein m utants
A DOR cDNA was obtained from Glaxo-Wellcome Research and Development 
(Stevenage, UK). The last 157 bps fragment of the human DOR was amplified by 
PCR using the oligonucleotides primers [see 2.2.3(a)]. Also the ORF of a PTx- 
sensitive rat Giia was amplified by PCR using the primers [see 2.2.3(a)].
The PCR amplified fragments were digested with appropriate enzymes [157 bps 
fragment of hDOR and Giia(wild type)]. All three different fragments were ligated to 
pcDNA3.1 (Invitrogen, Netherlands) thi'ough these restriction sites (see Figures 3.1 A, 
3.2A)
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Cys^^^Xaa PTx-resistant form of rat Gua had been generated previously (Bahia 
et aï., 1998). PTx-resistant hDOR-Gua (Xaa^^^) fusion proteins were constructed by 
recovering the unique restriction sites EcoNI and FcoR/fragment from Giia 
Cys^^^Xaa mutants (He, Leu,Phe,Val, Ser, Arg, Ala or Gly) and replacing the 
equivalent section of hDOR-Gua (wild type) fusion proteins (see Figures 3.1B,
3.2B). All fusion constructs were fully sequenced to identify hDOR cDNA and the 
correct amino acid Cys^^^Xaa of Gua.
2.2.8. C onstruction of h D O R - G o i a ( w i l d  type) and PTx-resistant 
hDOR-Goia(Xaa^®^) fusion protein m utants
5' 120bps of hDOR cDNA was digested with Kpnl and BssHIdind the remaining 
1020bps fragment from the hDOR-Gua (wild type) was digested with BssHI scad 
BamHI.
A fragment of 1065bps from the cDNA encoding Goia was modified by 
introducing the flanking restriction sites 5' BgUI and 3' Xbal hy PCR amplification 
[see 2.2.3(b)]. Three different fragments were ligated into pcDNA 3.1 using the 
compatibility of BamHI scad B glll (see Figures 3.3A, 3.4A).
Using the same approach as for the hDOR-Gua(Xaa^^^) mutants, Cys Xaa 
PTx resistant forms of Goia had been generated previously (Bahia et al., unpublished). 
The PTx resistant hDOR-Goia (Xaa^^^) fusion proteins were constructed by 
recovering the C/a/and fragment from Goia (Xaa^^^) mutants (Ile/Leu/Gly) and
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replacing the equivalent segment of the hDOR-Goia(wild type) fusion protein (see 
Figures 3.3B, 3.4B) All fusion proteins were fully sequenced prior to use.
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2.3. Assays for functional experiments
2.3.1. Radioligand Binding
Membranes of all the hDOR receptor and the PTx-resistant hDOR-Gua (Xaa^^*) 
fusion proteins were prepared for all the radioligand binding experiments.
a) Antagonist l^HI naltrindole binding studies
Binding to membranes expressing the hDOR receptor and the PTx-resistant 
hDOR-Gua (Xaa^^^) fusion proteins were carried out as follows:
Binding assays were initiated by the addition of 5-10 pg of protein to assay buffer (75 
mM Tris, 5 mM EDTA, 12.5 mM MgCb, pH 7.4) containing the antagonist 
radioligand [^H] naltrindole (NEN life sciences products) to membranes expressing 
the hDOR receptor and the PTx-resistant hDOR-Gua (Xaa^^^) fusion proteins. Non 
specific binding was determined in the presence of 100 pM unlabeled naloxone. 
Reaction was incubated for 60 min at 25° C, and bound ligand was separated from 
free ligand by vacuum filtration through GF/C filters. The filters were washed three 
times with ice-cold wash buffer (75 mM Tris, 5 mM EDTA, pH 7.4), and bound 
ligand was determined by liquid scintillation counting. Saturation binding experiments 
were done using radioligand concentrations covering the range of 0.1 -  10 nM ([^H] 
naltrindole). GDP and suramin competition binding experiments were carried out 
using 2 - 2.5 nM of [^H] naltrindole.
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b) Antagonist r^HI diprenorphine binding studies
Binding to membranes expressing the PTx-resistant hMOR-Gua (Ile^^^) fusion 
proteins were carried out as the same as [^H] naltrindole binding experiments:
Binding assays were initiated by the addition of 5-10 pg of protein to assay buffer (75 
mM Tris, 5 mM EDTA, 12.5 mM MgCl2,pH 7.4) containing the antagonist 
radioligand [^H] diprenorphine (NEN life sciences products). Non specific binding 
was determined in the presence of 100 pM unlabeled naloxone. Reaction was 
incubated for 60 min at 25 ° C, and bound ligand was separated from free ligand by 
vacuum filtration through GF/C filters. The filters were washed three times with ice- 
cold wash buffer (75 mM Tris, 5 mM EDTA, pH 7.4), and bound ligand was 
determined by liquid scintillation counting. Saturation binding experiments were done 
using radioligand concentrations covering the range of 0.1 -  10 nM ([^H] 
diprenorphine).
c) Agonist l^Hl DADLE binding studies
Agonist [^H] DADLE binding to membranes expressing the hDOR and the 
hDOR-Gua (Xaa^^^)/-Goia (Xaa^^^) fusion proteins were carried out as same as the 
antagonist binding assays. Binding assays were initiated by the addition of 5-10 pg of 
protein to assay buffer (75 mM Tris, 5 mM EDTA, 12.5 mM MgCl2 , pH 7.4) 
containing the radioligand [^H] DADLE (NEN life sciences products). Non specific 
binding was determined in the presence of 10 pM unlabeled DADLE. Reaction was 
incubated for 60 min at 25° C, and bound ligand was separated from free ligand by 
vacuum filtration through GF/C filters. The filters were washed three times with ice-
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cold wash buffer (75 mM Tris, 5 mM EDTA, pH 7.4), and bound ligand was 
determined by liquid scintillation counting. Saturation binding experiments were done 
using radioligand concentrations covering the range of 0.1 -  20 nM ([^H] DADLE). 
GDP and suramin competition binding experiments were carried out using 1-1.5 nM 
of [^H] DADLE. The association and dissociation binding experiments was carried 
out using 1-2 nM of [^H] DADLE on different time scales at 25° C. After 50-60 min 
incubation of dissociation experiments, 10 pM unlabeled naloxone was added to 
initiate the dissociation of bound [^H] DADLE.
2.3.2. High Affinity GTPase
High affinity GTPase assay was performed as described in Gierschik et ah, 
(1994). Assay mix (for 100 tubes) was prepared as follows:
COMPONENTS VOLUME (uX) Final concentration
Creatine phosphate (0.4 M) 250 20 mM
Creatine kinase (2.5 U/pl) 2 0 0 0.1 U/pl
App[NH]p (0.04 M) 25 0.2 mM
ATP (0.04 M; pH 7.5) 250 2 mM
Ouabain (0.01 M) 1 0 0 0 2 mM
NaCl (4 M) 250 200 mM
MgClz (1 M) 50 10 mM
DTT (0.1 M) 2 0 0 4 mM
EDTA (0.02 M; pH 7.5) 50 0.2 mM
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Tris/HCl (2 M; pH 7.5) 200 80 mM
GTP (10“' M; pH 7.5) 50 1 HM
Deionised H2O to final volume 5000
GTP (50, 000 CPM/Assay) was used for individual experiments and added to 
the above mix.
The assay was carried out at 1.5 ml eppendorf tubes:
Membrane protein (lOpg/assay: 0.5 pg/pl) 20 pi
* Agonist or water or GTP 10 pi
Water 20 pi
Assay mix 50 pi
Total volume: 100 ul
* Assay was set up under 3 different conditions: basal (water), agonist added, and 
non-specific activities (GTP), with a final concentrations of agonist (at various 
concentrations), water, or GTP (lO"'^  M) respectively.
To measure the potency for DADLE (pECso values) to activate the fusion 
proteins was monitored in high affinity GTPase activity assays with a range of 
concentrations of DADLE (10'^^ -  lO'"^  M). Also, when DADLE (100 pM)-stimulated 
GTPase activity was monitored at a wide range of GTP concentrations on membranes, 
the effect of the agonist was predominantly to increase Vmax of the GTPase activity
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with only a minor effect on the estimated for GTP.
The assay was carried in triplicate and incubated at 37 ° C for 30-40 min, 900 pi 
of ice-cold charcoal slurry (5% activated charcoal in 10 mM H3PO4) was added to 
every tube to stop the reaction. Every tubes containing charcoal was spun down at 
13,000 rpm for 20 min in a chilled (4 ° C) centrifuge. 500 pi of the supernant was 
taken out and transferred into vials Cerenkov radiation counting in a Beckman 
radioisotope counter. Radiowastes should be carefully thrown away.
2.3.3. Adenylyl cyclase catalytic activity
Whole intact cell adenylyl cyclase (AC) assays were performed essentially as 
described by Wong, (1994) and Merkouris et al., (1997). This whole cell AC assay is 
based on the use of [^H] adenine whieh labels the intracellular adenine nucleotide pool 
and measurement of subsequent conversion of [^H] ATP to [^H] cAMP on AC 
stimulation.
The [^H] cAMP thus produeed is separated from [^H] adenine and [^H] ATP by a 
two-step column method (Salomon et al, 1979: Taussig et al., 1994). Cells of the two 
clones were split into 1 2  well plates and grow in geneticin containing medium (700 
pg/ml G418 sulphate in DMEM) until about 80% confluence. One day before the 
assay, plates were incubated overnight with [^H] adenine at 1 pCi per well and PTx 
(25ng/ml) was added at the same time. On the day of assay, plates were left at 37 °C, 
removed medium, washed with 2 ml of HEPES buffered DMEM. HEPES buffered
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DMEM medium [IX DMEM, 2 mM L-glutamine, 20 mM HEPES (pH 7.4), 1 mM 3- 
isobutyl-l-methylxanthine, and 1 % penicillin/streptomycine] containing increasing 
concentrations of DADLE was then added and the cells incubated for 30 min at 37 °C. 
Forskolin (50 pM) was also used as a control. The reaction was terminated on ice by 
addition of 1ml of stop solution (5 % %  TCA, 1 mM ATP, 1 mM cAMP: 2.5 g TCA, 
17.6 mg cAMP, 27.5 g ATP per total 50 ml of solution) to extract [^H] adenine 
nucleotides. The TCA-added plates were left for 30 min on ice, scraped into 
eppendorf tubes and spun down for 3-5 min at 13,000 rpm at 4 ° C. The plates can be 
stored at -20 ° C or at 4 ° C for a short time if the columns to separate the nucleotides 
were ready.
Separation of cAMP from the other adenine nucleotides is based essentially on 
the method of Salomon et al., (1974). The Dowex and alumina columns were set up in 
accordance to Farndale et al., (1991). First, a rack of Dowex columns and a rack of 
alumina columns with precise alignment of the column positions were used. Columns 
were made from 5 ml syringes fitted with glass wool at the base to form a retaining 
mesh for the resins. Dowex resins were washed extensively in deionised water, 
followed by 3 washes in 1 M HCl, and again with water. It was finally resuspended 
1 : 1  with deionised water in a beaker and kept in uniform suspension using a magentic 
stirrer. 2  ml of this suspension was pipetted into the columns, giving a 1 ml bed 
volume. Alumina resins were washed once in water and once in 0.1 M Imidazole (pH 
7.3). It was similarly resuspended in deionised water and pipetted into the columns. 
The columns were plugged to prevent the resins from drying when not in use. Before 
using the columns, the Dowex columns were pre-washed through 3 washes of 2 ml of
90
1 M HCl, followed by 5 washes of 2 ml of deionised water; the alumina columns were 
washed 4 times with 2 ml of 0.1 M Imidazole (pH 7.3) and 3 time washes with 
deionised water.
The separation of [^H] cAMP from the rest of the labelled components (e.g., [^H] 
ATP, [^H] ADP, [^H] AMP, [^H] adenine etc) starts with the Dowex columns. Dowex 
50 resins are negatively charged and hence are not expected to bind any of the 
components. However, the passage of cAMP is preferentially retarded in the column, 
probably by a non-specific interaction with the Dowex resin, and allows other labelled 
components to be washed away (Farndale et al, 1991). The alumina resin instead 
binds cAMP less avidly than other adenine nucleotides as the cyclisation leads to the 
loss of vicinal hydroxyls on the ribose ring. Imidazole, which competes for the purine 
binding site, can therefore displace cAMP from alumina columns.
Harvested cell extract was loaded to separate cAMP from other radiolabelled 
nucleotides (adenosine, AMP, ADP etc) by Dowex and then Alumina 
chi'omatography. Firstly the samples (supernants) were added by pipetting into the 
Dowex column placed over scintillation vials and washed by 3 ml of deionised water. 
The eluant was collected in vials containing 5 ml of liquid scintillant. This mixture 
contained [^H] labelled adenine nucleotides except [^H] cAMP. Next the rack of 
Dowex columns was placed on top of the alumina columns, making sure that the 
eluant from the upper Dowex columns go straight into the alumina columns. Then the 
Dowex columns were washed with 5 times of 2 ml of deionised water into the 
alumina columns and removed. This step displaces cAMP from the Dowex to the 
alumina columns. 3 times of 2 ml of 0.1 M Imidazole (pH 7.3) were added to the
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directly alumina columns and the eluant was collected in vials containing 9 ml of 
liquid scintillant, which contained only [^H] cAMP. Finally, [^H] cAMP was eluted 
from the alumina with 0.1 M imidazole (pH 7.3) and quantified. Both sets of vials 
were counted in Beckman scintillation counter. Data was analysed as the ratio of [^H] 
cAMP to total [^H] adenine nucleotides (X I00).
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2.4. Tissue Culture
2.4.1. Routine T issue culture:
growth, m aintenance and harvesting of cells
The cell lines used for the present study ai'e Human embryonic kidney (HEK293) 
cells for stable transfections and Human embryonic kidney T (HEK293T) cells for 
transient transfections. The HEK293T cell line is derivative of HEK293 that gives 
higher levels of expression with transient transfections. Flasks of cells were incubated 
in cell culture incubators (Jencons Nuaire) in an atmosphere of 95% air / 5% CO2 at 
37 °C. Cells were grown in continuous monolayer culture in 75 cm^ /25 cm^ sterile 
tissue culture flasks in growth medium [Dulbecco’s Modified of Eagle’s Medium 
(DMEM) supplemented with 2 mM L-glutamine and 10% NewBorn Calf Serum 
(NBCS)]. Every passages of confluent monolayer cells in the flasks were splited by 
the addition of 1.0 ml trypsin solution (0.1 % trypsin, 0.025% ^/y EDTA, and 10 
mM glucose, pH 7.4) after washing sterilised 1 X PBS (phosphate buffered saline). 
When all the cells were detached, trypsinisation was terminated by the addition of 10- 
20 mis of growth medium (DMEM) containing 5 -  10 % NBCS. Harvested cells were 
centrifuged at about 1000 rpm for about 5 min at room temperature. Finally, supernant 
was taken off and the cell pellet was resuspended in growth medium and plated out as 
1 : 1 0  to 1:15 for routine maintenance of cell line.
When cells in 75 cm^ flasks or dishes reached confluency or the particular 
treatment time had elapsed they were harvested by scraping the monolayer into the
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medium and the cells were collected in a 50ml centrifuge tube or 13 ml polypropylene 
tube on ice. The tubes were centrifuged at 1500-2000 rpm for 5 min at 4 ° C in a 
Beclanan TJ- 6  benchtop centrifuge. The supernant was discarded and the cell pellet 
was resuspended in a 50 ml of ice-cold PBS [NaCl (10 g), KCI (0.25 g), Na2HP0 4  (1.8 
g) and KH2PO4 (0.3 g), pH 7.4] and centrifuged as before. Again the supernant was 
discarded and the pellet was resuspended in 1 X PBS and recentrifuged. The 
supernant was again discarded and the pellet was stored at -80 ° C until required.
2.4.2. T ransient transfec tions
Transient transfection of DNA into HEK293T cells was optimised in 10 cm^ 
dishes using Lipofectamine™ as transfection reagent (Gibco Life Technologies) 
according to the manufacturer's instructions.
First, confluent HEK293T cells of a 75cm^ flask was split into 100mm diameter 
tissue culture dishes the day before transfection. On the day of transfection, the 
confluency of cells should be between 60 to 80%. For each dish, about 10-15 pg of 
DNA was used, diluted in 0.8 ml of serum-free Optimem-1 medium (Gibco Life 
Technologies). Also Lipofectamine™ (25-30 pi) diluted in Optimem-1 medium to 
give a 0.1 mg/ml solution in 0.8 ml of mixture (Lipofectamine™/Optimem-l 
medium). Then both equal volumes of the diluted DNA and Lipofectamine'^^ were 
mixed together by dropping Lipofectamine'^’^  containing Optimem medium to DNA 
suspension mixture (0.8 ml of DNA suspension and 0.8 ml of Lipofectamine™ 
suspension) and incubated at room temperature for 30-40 min. In the meantime, cells,
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which are ready for transfection on the dish, were rinsed twice with 37 ° C pre­
warmed Optimem-1. Finally, 6.4 ml of Optimem-1 medium was added to the DNA/ 
Lipofectamine”^  ^mixture and mixed well (total volume: 8  ml), and then added to the 
cells on the dish.
2.4.3. G eneration and M aintenance of S table cell lines
Appropriately HEK293 cells were grown to 60 - 70% confluency in 100 mm 
diameter tissue culture dishes for transient transfections. cDNAs (10-15 pg) encoding 
either hDOR-Gua (Ile^^^)/-Goia (Ile^^*) fusion proteins were diluted with 0.1 pg/pl 
upto 100-150 pi in sterilised H2 O. These two fusion proteins were added to a sterile 13 
ml polypropylene tube containing serum-free Optimem-1 medium to a final volume of 
800 pi. Lipofectamine™ (25-30 pi per one tube) was added to another sterile tube 
containing serum-free medium to a final volume of 800 pi DNA. Mediums containing 
Lipofectamine^^ were dropped into medium containing DNAs. DNA/liposome 
complexes (1.6 ml) were incubated to form for 30-40 min during which time the cell 
monolayers ready for transfections were washed twice with serum-free medium. Then 
6.4 ml of serum-free medium was added to the DNA/liposome complexes to a final 
volume of 8  ml and the whole mixtures added to one 100mm dish of cells. One 100 
mm dish was for hDOR-Gua (Ile^^^), another for hDOR-Goia (Ile^^^), the third for 
normal HEK293 cells as a control.
After 6-7 h incubation at 37 ° C, medium was replaced with normal DMEM 
containing 5% NBCS. 48 h after DNA transfection, two transfected dishes and one
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untransfected dish were trypsinised and split 1:3 into new 100 mm tissue culture 
dishes. Untransfected cells were also split into 1:3 (as a control) and one was 
maintained with normal medium and the other with medium containing geneticin 
sulphate. Antibiotic (Geneticin G-418 in the case of pcDNA 3 vector) was added to all 
dishes. A very high concentration of G-418 (1 mg/ml) was used initially to select for 
resistant clones, and the medium changed every 2-3 days to maintain a good selection 
environment. After 7 to 10 days, when the untransfected cells (control dish) in the 
medium containing geneticin sulphate were dead and another transfected cells 
confluent, isolated clones of cells in the transfected dishes were picked. The picked 
clones (about 24 for each type of DNA transfected) were detached from the dish by 
scraping with sterile blue tips and at the same time transferring into 24 well plate with 
0.5 ml of medium. The clones were grown in 24 well plate in 1 ml of G-418 (800 
pg/ml) per well and medium changed every 4-5 days until the confluent.
After 7-10 days, each confluent clone was split 1:2 into 25 cm^ flasks and grown 
until about 80 % of confluency. When individual clones in one of the 25 cm^ flask 
were confluent, cells were harvested for assaying their receptor levels. Once the best 
clones were obtained for both fusion proteins, cells growing in the another 25 cm^ 
flask were expanded to 75 cm^ flask in medium containing G-418 (800 pg/ml). The 
rest of clones were harvested and preserved at -200 ° C in liquid nitrogen tanks. 
Routine cultures of stable cell lines were in DMEM medium containing 700 pg/ml of 
G-418.
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2.4.4. P reservation  of cell lines; s to rage  and recovery
Stable cell lines were preserved in the earliest passage possible (passage 1-5). 
Both best clones for the fusion proteins in 75 cm^ flasks were grown to confluency 
before trypsinisation. After centrifugation, the cell pellet was suspended in 1 ml of 
NBCS with 10 % DMSO (as a cryo-protectant). The cell suspension was transformed 
into sterile 1,5ml cryovials, and labelled clearly according to the early passages. These 
followed to a slow freezing process; the first 3 to 6  h in a -20 ° C freezer, then 
overnight in a -80 ° C freezer, and finally long term storage in -200 ° C liquid 
nitrogen tanks. Also the rest of clones were preserved in the same way into 1.5ml 
cryovials and kept in liquid nitrogen tanks.
Preserved cell line can be rescued by thawing the cryovial in 37 ° C water bath 
and resuspended in 10 ml of pre-warmed medium. Then the cell suspension was 
centrifuged at 1000 rpm for about 5 min at R. T. to remove all traces of DMSO. 
Finally the cell pellet was resuspended in about 10-15 ml of normal medium or 
medium containing G-418 (700 pg/ml) and grown in 75 cm^ flask.
2.4.5. T reatm ent of ceiis with P ertu ssis  toxins
Pertussis toxin (PTx), Islet activating protein; lAP from Bordetella pertussis : 
sterile filtered solution of 50 pg/ml in 50 % (v/v) glycerol containing 50 mM Tris, pH
7.5. 10 mM glycine, and 0.5 M sodium chloride (Sigma). PTx was kept in -20 ° C. A 
buffer containing 25 mM sodium phosphate, pH 9.0, 0.5 M sodium chloride and 4 %
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(Vv) glycerol is recommended for dilution. Preincubate the PTx in the presence of 1-5 
mM adenosine triphosphate (ATP) and 1-5 mM dithiothreitol (DTT) for in vitro use 
with cell membranes. Preincubation with ATP and DTT is not recommended for use 
with intact cells or in-vivo use (Moss et al., 1983).
Stable or transiently expressing cells were treated with PTx in vivo. PTx stock 
was diluted to a final concentration of 200 pg/ml. It was added directly into the dishes 
or the flasks under aseptic environment, followed by incubation for the appropriate 
amount of time. PTx was added to a final concentration of 25 ng/ml to the medium 
before 16h harvesting the transfected cells.
2.4.6. Labelling of cells with [^H] adenine for AC a ssa y s
One day before the assay, cells stably expressing hDOR-Giia (Ile^^^)/-Goia 
(Ile^^^) fusion proteins were labelled and incubated with [^H] adenine (Amersham 
Pharmacia biotech, 1.0 pCi/ml per well in 12 well plates, 0.5 pCi/ml per well in 24 
well plates) in DMEM containing 700 pg/ml of G-418 overnight.
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2.5. Other protocols
2.5.1. P reparation of p lasm a m em brane fractions
Membranes were prepared according to the method of Koski and Klee, (1981). 
Frozen cell pastes were thawed on ice and resuspended in 2 ml of ice-cold T/E buffer 
(10 mM Tris-HCl, 0.1 mM EDTA, pH 7.5) and transferred to a pre-chilled glass 
homogenizer. Then the harvested cells were homogenized, on ice, with 40-50 strokes 
of a hand-held teflon-on-glass homogenizer. Again the resulting homogenates were 
passed through orange needles with 8 - 1 0  strokes, transferred to the eppendorf tubes 
and spinned down at 1000 rpm for 10 min at 4 ° C. The supernant (0.5-1 ml) was 
taken and transferred to ultracentrifuge tubes (Beckman Instruments, Inc). Centrifuge 
tubes were placed in a type TLA-100.2 (Beckman Instruments, Inc) and centrifuged at 
very high speed 50,000-75,000 rpm for 30 min at 4 ° C. Before the centrifugation, all 
the tubes were balanced and rotor was pre-chilled at 4 ° C. The supernant was 
discarded and pellet resuspended in 2-5 ml of T/E buffer, to make the aliquots of 
small volume and to give an approximate protein concentration of 1-3 ng/|al. The 
samples were then frozen at -80 ° C in 100-200 pi fractions until required.
2.6.2. Determ ination of protein concentration
Protein concentrations were determined by the method of Lowry et a/ (1951), 
using Bovine Serum Albumin (BSA, 0-2.0 mg/ml) as standard. The samples were 
read at 492 nM on SLT. SPECTRA.
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2.6.3. Deglycosylation of glycosylated form s of hDOR-Goia 
(lle^ ®^ ) fusion protein
For the deglycosylation reaction, membranes from HEK293 cells stably 
expressing hDOR-Goia (Ile^^^) fusion protein containing N-Glycosidase F (Roche 
Molecular Biochemicals) (membranes 5 pi, dénaturation buffer 5 pi, reaction buffer 10 
pi, NGF 2.4 units/10pi) were incubated overnight at R.T. Both samples of untreated 
and N-Glycosidase F-treated resolved in 10% SDS-PAGE at the same time. Following 
transfer to nitrocellulose, both samples were immunoblotted with antiserum ONI 
(specific for the N-terminal hexapeptide of Goia).
Reaction principle:
Protein—asn—GlcNAc—GIvcan Protein—asp + + GlcNAc—GIvcan
2.6.4. W estern blotting
A) Preparation of SDS-PAGE gel
SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) 
was normally performed with 10% acrylamide resolving gels. It was prepared as 
follows:
100
10% R esolvina Gel
Water (deionised) 8.3 ml (2)
Acrylamide (30 % ^/y), bis-acrylamide (0.8 % ^/y) 6  ml (1)
Tris/HCl (1.5M, pH 8 .8 ), SDS (0.4% % ) 8  ml (3)
Glycerol (50 % % ) 1 . 6  ml
Ammonium persulphate (AmpS0 4 ) (10% ^/y) 90 pi (5)
TEMED 8  pi (4)
Total volume 23.9 ml
30 % acrylamide/0.8 % bis-acrylamide solution was made up of H2 O and kept in 4°C 
freeze (light-sensitive). AmpSO^was diluted in water.
The above resolving gel is sufficient for a single gel cast in a Hoefer Gel Caster 
with two 180 X 160 mm glass plates and 1.5 mm spacers. After setting up the gel 
following the numbering of the right side, the gel was layered with 0.1 % %  SDS and 
polymerised at R.T for about 60-90 min.
After the gel had polymerised, the layer was washed off and the stacking gel 
prepared:
Stackina Gel
Water (deionised) 9.75 ml (2)
Acrylamide (30 % Vv), bis-acrylamide (0.8 % "'/v) 1.5 ml (1)
Tris/HCl (0.5M, pH 6 .8 ), SDS (0.4% % ) 3.75 ml (3)
Ammonium persulphate (APS) (10% ^/y) 150 pi (5)
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TEMED 8 pi (4)
Total volume 15.1ml
The gel was set up according to the numbering of the right side, a 15 well teflon 
comb was layered on top of the stacking gel, polymerised for about 60 min. Made up 
gels can be kept at 4 ° C for 2-3 days until required.
B) Electrophoresis of SDS-PAGE
Gel running buffer was made upto 2.5 litre for electrophoresis tank. Protein 
samples (30-50 pg per lane) were diluted 1:1 ratio in Laemli buffer (2X), heated for 5 
min at 95 ° C on a heating block. A Hamilton syringe was used to load samples into 
the wells of the gel. Prestained protein markers was also loaded into the front line of 
gel. Then, electrophoresis of 10 % SDS-PAGE gel was usually at 30 mA constant 
current overnight (about 14-16 h) and the voltage set at least 90 V, and the power at 
least l o w .
C) Protein transfer onto nitrocellulose membranes (Western blotting)
After electrophoresis, the glass plates with the gel were taken out from the kit. 5 
litre of western transfer buffer was prepared, nitrocellulose membranes and Whatman 
filter papers cut to the right size of the gel and pre-wetted in buffer. The nitrocellulose 
membranes and gel combined together, then sandwiched between two pieces of 
Whatman filter paper and assembled into a LKB Transphor apparatus. The
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nitrocellulose membrane was positioned nearer to the positive end, which protein 
transfer on the gel could be performed to the nitrocellulose membranes from the 
negative to the positive at 1.5 mA for 90 to 120 min. After that, the protein transferred 
to the nitrocellulose membranes can be detected by temporarily staining with a 
solution consisting of 0.1 % %  Ponceau S and 3 % %  TCA, followed by wash buffer.
D) Incubation with antibodies
Protein transferred to the nitrocellulose membranes were covered with 5 % non­
fat milk (Marvel) in PBS or TBS overnight at 4 ° C or 2-3 h at R.T with shaking at 
slow speed. All antibodies were diluted in 1-3 % Marvel in PBS or TBS. Membranes 
containing antibodies were incubated for 1-2 h at R.T. with shaking. After primary 
antibody treatment, the membranes were washed at least 3-4 times with PB ST or 
TBST before the secondary antibody was added. Used antibodies can be stored with a 
trace of thimerosal for no more than 5 times or 3 months.
Dilutions of the used antibodies as follows:
Primary antibody 
I1C 
ON1
Dilution
1:1000
1:6000
Secondary antibody
Anti-rabbit IgG 
Anti-rabbit IgG
Dilution
1:2000
1:10000
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E) Enhanced chemiluminescence
Visualisation and detection of horse-radish-peroxidase conjugated antibodies on 
the nitrocellulose membrane was performed by enhanced chemiluminescence (ECL) 
(Amersham, U.K) or SuperSignal® enhanced chemiluminescence reagent (Pierce, 
U.S.A) according to the manufacturer's instructions. Membranes were washed with 
wash buffer several times before incubation with the ECL reagent (1:1 ratio of 
solution A and B). After 2-3 min incubation, the membranes were covered by tow 
pieces of clear plastic sheet and removed air bubbles carefully. Finally, the 
nitrocellulose membranes were put into a film cassette, carried to the darkroom and a 
light sensitive X-ray film (Fuji photo film Ltd) put on top of the membranes. The film 
was developed in an automatic film developer (Kodak Xomat) after an exposure time 
(10 sec-5 min).
f) Staining of gels with Coomassie Blue
Following electrophoresis, gels were soaked, with gentle shaking on a rotary 
shaker, for 1 h in 45 % (%) methanol, 10 % (%) acetic acid containing 0.25 % (% ) 
Coomassie Blue R-250. Destaining was achieved by washing gels in several changes 
of 45 % (7v) methanol, 10 % (7y) acetic acid.
104
2.6. Data analysis and statistical method
All the data were analysed using GraphPad Prism (3.0) version. All the 
statistics (P values) were compared with ttest (unpaired).
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CHAPTER III
Comparisons of the activation of G^a and Goia using 
fusion proteins between the human 5-opioid receptor
and these G proteins
INTRODUCTION (Chapter 3)
The superfamily of regulatory GTP hydrolases (G proteins) includes Ras and its 
close homologues, translation elongation factor, and heterotrimeric G proteins. Here, 
the heterotrimeric G proteins will be discussed. GPCRs transduce a large variety of 
signals across the cell membrane via heterotrimeric G proteins. G proteins transduce 
ligand binding to these receptors into intracellular responses which underlie 
physiological responses of tissues and organisms. G protein heterotrimers consist of 
three subunits named a, p and y. So far some 20a, 6 p and 12y polypeptides have been 
identified. Four main classes of G proteins are known: Gs, which stimulates adenylyl 
cyclases; Gi, which inhibits adenylyl cyclases; Gq, which activates phospholipase C; 
and Gi2 which regulate cytoskeletal structure. G proteins are inactive with GDP 
tightly bound to the a-subunit. When the activated receptor interacts with a 
heterotrimeric G protein it induces GDP release and this is followed by association of 
GTP with the empty nucleotide-binding site (Birnbaumer et al., 1990; Hamm, 1998). 
GTP binding induces a conformational change that results in dissociation of the 
heterotrimer into a  and Py subunits and activation of downstream effectors by both 
Ga-GTP and free Gpy subunits. G protein deactivation is required to turn-off the 
cellular response and occurs when the G a subunit hydrolyses GTP to GDP and 
inorganic phosphate. The a  subunit/ GDP complex can then reassociate with the Py 
subunits to form the heterotrimeric G protein. The Ga subunit contains two domains; 
a domain involved in binding and hydrolysing GTP (the G domain) that is structurally 
similar to the superfamily of GTPases and a unique helical domain that buries the 
GTP in the core of the protein. The p subunit has a 7-membered p-propeller structure
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based on 7 WD-40 repeats (Lambright et aL, 1996) and y subunits interact with P 
through a N-terminal coiled-coil and via extensive contacts all along the base of p.
The py subunits themselves can play active roles in signal transduction, for example, 
through regulation of K+ channels, PLC p and certain isoforms of AC in animal cells, 
and activation of the pheromone response pathway in budding yeast, py subunits 
inhibit GDP release from Ga in Ga-catalysed GTP hydrolysis thus rendering 
reactivation dependent upon the interaction of G a with ligand-activated receptors 
(Sprang, 1997). Clearly, Py subunits enhance receptor interaction with a  subunits. 
Single Ala mutations in residues of the p subunit that contact the a  subunit block 
receptor-mediated GTP/GDP exchange. A number of effector enzymes have been 
shown to display GTPase activating protein (GAP) activity towards their partner G 
proteins and Regulators of G protein Signalling (RGS) proteins play key roles in 
accelerating the GTP hydrolysis rates of at least the Gi and Gq families of G proteins 
(Koelle, 1997).
The relatively recent cloning of opioid receptors has established that the products 
of three distinct genes form the known subtypes, namely, the ô (DOR), p (MGR), and 
K (KOR)- opioid receptors. These are highly homologous with overlapping 
distributions but these opioid receptors have distinct pharmacological profiles. The 
endogenous opioid peptide-receptor systems mediate important physiologic functions 
related to pain perception, locomotion, motivation, reward, autonomic function, 
immunomodulation and hormone secretion. The DOR has been associated with 
several physiological functions, including analgesia (Heyman et aL, 1988), tolerance 
(Abdelhamid et aL, 1991; Kest et aL, 1996) and reproduction (Zhu and Pintar, 1998).
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The DOR is expressed in multiple regions of the adult nervous system, with high 
levels in the olfactory bulb, striatum, cortex, hippocampal formation, pons, spinal cord 
and dorsal root ganglion (Zhu et aL, 1998). DOR selective drugs may have potential 
clinical benefits which include greater relief of neuropathic pain (Dickenson, 1997), 
reduced respiratory depression (Cheng et aL, 1993) and constipation (Sheldon et aL, 
1990), as well as a minimal potential for the development of physical dependence 
(Cowan et aL, 1998). A major signalling mechanism of the DOR is to inhibit cAMP 
production through Gi/Go family G proteins, an effect which is blocked by treatment 
with pertussis toxin (Law et aL, 1985b). The DOR also stimulates potassium channel 
conductance through Gi/Go proteins and inhibits calcium channel conductance 
through Go proteins. The expression of Go proteins is restricted to neuronal and 
endocrine systems and the heart and it is highly abundant in mammalian brain. Three 
distinct subforms, i.e., Goia, Go2 a  and Gqs a  have been identified, with Goi and Go2 , 
representing splice variants whereas Gqs represents a recently characterised post- 
translational modification of Goi a  and represents about 30% of the total Go in brain 
(Exner et aL, 1999). The cDNA for DOR was first cloned using hybridization 
screening methods (Knapp et aL, 1994; Simonin et aL, 1994). Pharmacological 
studies have suggested at least two DOR subtypes. In general, the b\ receptor subtype 
is preferentially activated by the agonists [D-Pen^, D-Pen^]-enkephalin/[D-Ala^, D- 
Leu^]-enkephalin and antagonised by 7-benzylidenenaltrexone/[D-Ala^, Leu^, Cys^]- 
enkephalin while the Ô2 receptor is activated by [D-Ala^, D-Glu" ]^ deltorphin (Mattia et 
aL, 1991, 1992; Hiller et al., 1996) /[D-Ser^, Leu^]-enkephalyl-Thr and antagonised 
by naltriben/ naltrindole-5 ’-isothiocyanate. A transgenic p,-opioid knockout mouse has 
been used to study possible interactions between DOR and MOR in the central
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nervous system (Sora et aL, 1997 a,b). They found that the antinociceptive effect of 
DPDPE, a classic ô-selective receptor agonist, appeared to be dependent on intact 
MOR. Wang et a l, (1994) constructed chimeric receptors from the second 
extracellular loop sequences of hMOR which was replaced with that of KOR. This 
result suggests that this region contributes substantially to the KOR’s selectivity in 
dynorphin ligand recognition. Meng et aL, (1995) also constructed four different 
chimeric receptors from KOR and DOR. The results show that the DOR and KOR 
bind the same opioid core differently and achieve their selectivity through different 
mechanisms. These chimeric receptors were capable of binding opioid ligands and 
following introduction of a number of point mutations into the second extracellular 
loop and the top half of TM domain IV of the DOR helix. It was concluded that a 
region composed of the second extracellular loop and the top half of TM domain IV of 
the DOR helix was particularly important in the binding of prodynorphin products.
GPCRs interact with G proteins to regulate the downstream activity of effector
systems. To understand these signalling pathways, transient transfection has provided
a convenient method of overexpressing the components. The efficiency of GPCR and
G protein coupling depends on the ratio and the absolute concentrations of each
(Kenakin, 1997). However, in co-transfection studies with GPCRs and G proteins, it
has been an unresolved pharmacological problem to achieve precisely defined GPCR;
G protein ratios. Also, the efficacy and potency of agonist ligands depends on which
specific G protein activation-deactivation cycle step is assessed (Seifert et aL, 1999).
For some G proteins (Gs and Gq), it is difficult to analysis GPCR-Ga coupling at the
G protein level by measuring GTPyS binding and GTP hydrolysis. A method to
control ratio of the receptor and G proteins has been to employ purified G protein a
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subunits in reconstitution assays (Hartman et ah, 1996; Hellmich et aL, 1997; Glass et 
aL, 1999; Jian et aL, 1999). This has been a useful methodology for precise kinetic 
analysis of receptor-G protein coupling and allowed definition of the identity and 
concentration of each component.
In 1994, Bertin et ah introduced a new and rather unusual strategy, the 
construction of a fusion protein between the human (^ 2 -adrenoceptor and the a  subunit 
of its cognate G protein Gs. This construct was shown to be more efficient than non­
fused P2AR at stabilising high affinity agonist binding and resulted in agonist 
activation of AC when expressed in Gsa-deficient 849 eye ~ lymphoma cells. In 1997, 
Bertin et al reported that use of the (3 2AR-Gsa fusion protein in tumour cells 
prevented tumour proliferation in cell culture and in syngeneic mice. Subsequently 
several groups have concluded that the basic properties of fusion proteins, including 
the defined 1 : 1  stoichiometry of the signalling partners and the close physical 
proximity of the signalling partners following expression are attractive for analysis. 
The fusion protein strategy has now been applied successfully to a number of GPCRs 
and G proteins. Fusions are produced by linking the ORF of the two proteins using 
DNA restriction enzyme, PCR - based techniques, or both. Expression levels of fusion 
proteins can be determined by [^H] antagonist saturation binding and these provide 
direct measures of expression level of the associated G proteins (Wise et aL, 1997). 
Furthermore, they can be detected with antibodies if the receptor is epitope-tagged 
(Seifert et aL, 1998; Fong et aL, 1999). Moreover, the unique properties of fusion 
proteins have allowed measurements of GPCR-regulated GTP turnover number and 
Km values for GTP hydrolysis by the fused G protein (Wise et aL, 1997; Seifert et aL,
1998; Carr et aL, 1998; Kellet et aL, 1999; Fong et aL, 1999). Kobilka and co-workers
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studied the P2 AR/Gsa interaction using variant receptor and G protein fusion proteins 
expressed in insect Sf9 cells using baculovirus expression systems (Seifert et aL, 
1998; Wenzel-Seifert et al, 1998; Seifert et a l, 1999), which allow effective 
measurement of the effects of ligands due to low basal high-affinity GTPase activity. 
For example, it has been shown that marked coupling differences exist between p 
2AR-GsaS (the short splice variant of the a-subunit of the stimulatory G protein of 
AC) and P2AR-GsaL (the long splice variant). Specifically, the P2AR in P2AR-GsaL 
showed hallmarks of constitutive activity, whereas P2AR in p2AR-GsaS did not. This 
difference may be due to the lower GDP affinity of GsaL than GsaS (Seifert et aL,
1998). To overcome the difficulty in measuring agonist stimulation of high-affinity 
GTPase activity following co-transfection of the human IP protanoid receptor and Gs 
a , Fong and colleagues constructed a human IP prostanoid receptor-Gsa fusion 
protein to allow significant agonist output (Fong et aL, 1998; Fong and Milligan,
1999). Comparisons between co-transfection of receptor and non-fused G protein and 
the receptor-G protein fusion protein have been demonstrated, P2 AR-Gsa fusion 
proteins reconstituted greater high-affinity agonist binding and induced significantly 
higher AC activation than P2AR expressed in combination with the a-subunit of Gs 
(Seifert et aL, 1998). Importantly however, a comparative analysis of ligand efficacy 
at fusion proteins between the human adenosine Ai receptor and PTx-resistant forms 
of the a-subunits of each Gu, Gj2 , Gis and Gqi indicated the difference between fused 
and non-fused systems was much less than for p2AR-Gsa coupling (Wise et aL, 
1999).
I l l
It has been reported that the extreme C-terminal region of G protein a-subunits is 
a key element for GPCR activation (Conklin et aL, 1993; Liu et aL, 1995; Bourne et 
al, 1997; Medici et a l, 1997) and modification of three amino acids from the C- 
terminus of a  subunits of the PLC-linked G protein Gq has been shown to cause 
alteration in the GPCRs which can activate the G protein (Conklin et aL, 1993). 
Following co-expression of the IP prostanoid receptor with a chimeric G protein, 
Gii/Gs(6 ) which had the backbone of Giia with only the six amino acids of the C- 
terminus derived from Gsa, agonist stimulation of GTPase activity was more 
effective, thus indicating a key role of the extreme C-terminal region of G-protein a- 
subunits (Fong et al, 1998; Fong and Milligan, 1999).
Modulation by pertussis toxin has been used as a useful tool to characterise 
certain G protein-dependent signalling pathways. Pertussis toxin is also called Islet 
activating protein (lAP). It is produced by Bordetella pertussis and causes ADP- 
ribosylation of a cysteine side chain four amino acids from the C-terminus of the a- 
subunits of Gi, Go, and Gt. This prevents activation of the G protein trimer by its 
receptor (Katada and Ui, 1982;West, 1985). Efficient ADP-ribosylation by PTX 
requires the apy trimer and isolated a-subunits aie reported to be poor substrates 
(Casey et aL, 1989). The py-subunits may act by promoting favorable contacts of the 
a-subunits with PTx or by relieving unfavorable contacts between the G protein and 
the toxin (Scheuring et aL, 1998).
To understand the signalling pathways of G ^a following activation by a 2AAR, 
A iR  and 5 H T iaA R , fused PTx-resistant mutants of G n have been expressed in
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mammalian cell lines (COS-7, Rati fibroblast, HEK293). This has allowed the 
interactions of GPCRs with the endogenous Gi proteins to be abolished by PTx 
treatment with the interactions between GPCRs and the fixed and mutated G proteins 
being preserved. The Œ2AAR- Gna(Gly fusion protein has been shown to have the 
capacity to activate both endogenously expressed Gi and PTx-resistant fused Gi 
protein in Rati-fibroblasts stably expressing this construct (Burt et a l,  1998). 
Agonist-regulated GTPase activity between fused and endogenous G proteins was 
measured in membranes of PTx-untreated and treated cells. The azAAR-G^a (Gly^^^) 
fusion protein was able to inhibit forskolin-amplified AC activity. However, following 
PTx treatments, Œ2aAR agonists could no longer regulate this activity. The same was 
true for p44 MAP kinase and p70 S6 kinase. These observations demonstrate the 
effects to be due to activation of the endogenous Gna proteins, not the fused Gi 
protein. Other, unexpected differences between the isolated receptor and fusion 
proteins have been observed (Sautel and Milligan, 1998). The a 2AAR-Gna (Gly ^^ )^ 
fusion protein coupled to endogenous Gi proteins to inhibit AC activity with a lower 
effectiveness than the isolated receptor. However, unlike non-fused Œ2aAR, the fused 
receptor was unable to couple to endogenous Gs proteins. Two possibilities, which 
could explain these observations, can be considered. First, this fusion protein attached 
some physical constraint to the receptor such that its interaction with endogenous Ggtt 
was covered whereas interactions with endogenous Gia may be less effected.
Secondly, differences in the distribution of the isolated receptor and the fusion 
proteins in the plasma membrane may limit availability and access to the endogenous 
G proteins. Unlike the above, high affinity GTPase activity and AC regulation by 
5HTiAR“Giia (He ^^ *) and 5 H T iaR - Giia (Gly ^^ )^ fusion protein stably expressed in
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HEK293 cells is unaffected by PTx treatment, indicating both the functionality of the 
agonist-activated fusion protein and a lack of interaction with endogenously expressed 
Gia proteins (Kellet et al., 1999). Moreover, spiperone functioned as an inverse 
agonist in membranes expressing 5HTiAR-Giia (wild type) and 5HTiAR-Gjia (Ile^^*) 
fusion proteins but not the 5HTiAR-Giia (Gly ^^ )^ fusion protein. This demonstrates 
that alteration of a single amino acid in the C-terminal region of Gjia can regulate 
agonist-independent constitutive activity of GPCRs. Dupuis et al, (1999) have also 
used PTx-resistant 5HTiaR- Goia fusion proteins to measure agonist efficacy and 
Wenzel-Seifert et a l, (1999) have demonstrated highly efficient coupling of the 
human formyl peptide receptor to fused Giia Giza and Gisa.
GPCR-Gi/Go fusion proteins have provided useful tools to determine the kinetics 
of GTP hydrolysis, the efficacies of agonists and measurement of downstream effector 
signalling (Kellet et al., 1999; Burt et a l, 1998). The aim of this present study was to 
understand the signalling of the hDOR coupling to the closely related Gn and 
Goi proteins using the fusion protein strategy.
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RESULTS (Chapter 3) 
Construction of the PTx-resistant hDOR-Giia(Xaa®®^)/ 
Goi<x(Xaa^ ^^ ) fusion protein mutants
The hDOR-Giia(wild type) and the hDOR-Gua (Xaa^^^) mutants 
(Ile/Leu/PheWal/Ser/Ala/Gly/Arg) were constructed inpcDNA3.1 (Invitrogen, The 
Netherlands). The cDNA encoding the hDOR, originally cloned in pCDNA4, was 
obtained from Dr. C. Scorer (Glaxo Wellcome R. and D, Stevenage, U.K.). The last 
157 bps of the hDOR was amplified by PGR in which the stop codon was deleted and 
Si 3'BamHl site added. The open reading frame (ORF) of wild type rat Giia was used 
as a template in order to synthesise a PGR fragment, characterised by the deletion of 
the ATG start codon and by the addition of 5'BamHI and 3 'Ecoi?/restriction sites.
The hDOR cDNA was digested with BamHI and N o tlto generate a 5'-1012bp 
fragment. The PGR amplified fragments (157bps Augment of hDOR and Giia) and the 
remaining segment of the hDOR was ligated to pcDNA3.1 through these restriction 
sites (Figures 3.1A, 3.2A). Cys Xaa PTx resistant forms of rat G ^a were generated 
previously (Bahia et a l, 1998). The PTx resistant hDOR-Gna (Xaa^^^) fusion proteins 
were constructed by recovering the unique EcoNI and fragments Aom G ^a 
(Xaa^^^) mutants (Ile/Leu/Phe/Val/Ser/Ala/ Gly/Arg) and replacing the equivalent 
section of the hDOR-Gna (wild type) fusion protein (Figures 3.1B, 3.2B).
Secondly, the 5 '120bps of hDOR cDNA was digested with Kpnl and BssHI and
the remaining 1020bps Aagment Aom the hDOR-Gna (wild type) was digested with
BssHI and BamHL A Aagment of 1065bps from the cDNA encoding Go i a  was
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modified by introducing the flanking restriction sites 5 'Bglll and 3 'Xbal hy PCR 
amplification. Three different fragments were ligated into pcDNA3,l using the 
compatibility of BamHI and 5g///(Figures 3.3A, 3.4A). Using the same approach as 
for the hDOR-Gjia(Xaa^^^) mutants, Cys Xaa PTx resistant forms of Goiahad been 
generated previously (Bahia et al., unpublished). The PTx resistant hDOR-Goia 
(Xaa^^^) fusion proteins were constructed by recovering the C/a/and fragment 
from Go I a  (Xaa^^^) mutants (He/Leu/Gly) and replacing the equivalent segment of the 
hDOR-Goia(wild type) fusion protein (Figures 3.3B, 3.4B). All fusion proteins were 
fully sequenced prior to use (Figures 3.1C, 3.3C).
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Characterisation of the hDOR-Gn/Goi fusion proteins 
following transient expression in HEK293T cells
I. Analysis of expression using [^H] naitrindoie binding studies
All of the constructs could be transiently expressed in HEK293T cells. Transient
transfection of these constructs (8, 10, 12, 15, 18)ug of DNA) into HEK293T cells was
optimised in lOcm^ dishes using Lipofectamine'^^ as transfection reagent- (data not
shown). This gave a reasonable expression level (1-6 pmol/mg of protein), monitored
by the appearance of specific binding sites for [^H] naitrindoie, which is a neutral
antagonist for the hDOR (Figures 3.5A, 3.5B). Although levels of expression of the
constructs varied between individual transfections, there was no specific pattern of
expression associated with the identity of the G protein mutant. Saturation binding
studies using [^H] naitrindoie indicated this ligand was bound with high affinity (Kj:
0.1-0.8 nM) by all the constructs. This is similar to the results obtained by Meng et al,
(2000) for the isolated receptor Kd= 0.3 ±0.1 nM. Figure 3.6A and Figure 3.7A are
representative [^H] naitrindoie saturation binding experiments for the hDOR-Gua
(He ^^ )^ and -Giia (Gly ^^ )^ fusion proteins respectively. Membranes expressing these
fusion proteins were prepared and their level of expression (B^ax) and dissociation
constant (Kd) for [^H] naitrindoie measured. Scatchard plots (bound/free versus
bound) were produced (Figures 3.6B, 3.7B). The Kd for [^H] naitrindoie at hDOR-
Giia (He ^^ )^ after PTx treatment (25ng/ml, 16h) of cells was 0.77 ±0.12 nM (mean ±
S.E.M, n=3) and that of hDOR-Gna (Gly ^^ )^ was 0.13 ± 0.02 nM (mean ± S.E.M,
n=3). Surprisingly, the Kd of [^H] naitrindoie for the hDOR-Gna (He^^*) was about 6
times higher than that of the hDOR-Gna (Gly^^^) (P < 0.001). Chapter 4 will examine
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this in greater detail.
Table 3.1. Comparison of the Kd for [^H] naitrindoie to bind transiently 
expressed hDOR-Giia (Ile^ ^^ ) and hDOR-Gna (Gly^ ^^ ) fusion proteins.
Constructs Kd for [^H] naitrindoie (nM )
hDOR-Giia (Ile^^^) 0.77 ± 0.12
hDOR-Giia (Gly^^‘) 0.13 ± 0.02***
This data represent means ± S.E.M  from three independent experiments.
Significantly different from hDOR-Giia (Ile^^^), P < 0.001.
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II. Immunological detection
All the fusion proteins were transiently transfected into HEK293T cells and cell 
membranes were prepared and loaded in 10% SDS-PAGE followed by 
immunoblotting. Antiserum IIC, specific for an internal domain (159-168 aa) of G^a 
(Green et al., 1990), was used to detect the expression of the hDOR-Gji fusion 
proteins (Figures 3.8A, 3.8B). In Figure 3.8A, western blotting was performed in four 
different conditions -  boiling/reducing, 2" ;^ boiling/non-reducing, 3*^ ;^ non­
boiling/reducing, 4^ '^ ; non-boiling/non-reducing -. The conditions of (lanes 2, 3) and 
2"  ^(lanes 5, 6) seemed to be successful in detecting strong bands corresponding to 
hDOR-Gii fusion proteins, but not in mock (pcDNA 3.1) loaded lanes (lanes 1, 4, 7, 
10) as a negative control. All the hDOR-Gn fusion proteins were detected with 
antiserum 11C, as shown in Figure 3.8B, The fusion proteins were detected as multiple 
bands which may reflect differential glycosylation A deglycosylation experiment using 
N-glycosidase F was successful in reducing the mobility and complexity of bands 
corresponding to the stably expressed hDOR-Goia (Ile^^ )^ fusion protein (Figure 
3.17B). There are a range of examples of detecting the expression of fusion proteins, 
including
5-HTiA-Giia fusion protein with antiserum IlC  (Kellet et al., 1999),
FPR-Gja fusion protein (Wenzel-Seifert et al., 1999),
(32AR-Gsa fusion protein (Seifert et al., 1999).
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III. Agonist-regulated high affinity GTPase activity
G proteins are enzymes which function to bind and hydrolysis GTP, producing 
GDP and inorganic phosphate. To monitor G protein mediated enzymatic activity 
(GTP hydrolysis), breakdovm of y[^^P] GTP with the production of [^^Pi] can be 
measured and [^^Pi] is then separated from remaining y[^^P] GTP and the rate of GTP 
hydrolysis measured (Gierschik et ah, 1994). Each assay tube contained 50pmol of 
GTP (0.5 p-M) in addition to approximately 50000cpm. The specific activity of the 
GTP is thus approx. 1000 cpm per pmol.
The rate of hydrolysis of GTP is calculated as
C 1000 1
---------------  X 2 X ---------------  X —
S.A.
Where: C = the counts in a SOOqi sample
S.A = the specific activity of the GTP 
P = the amount of protein present (jug) 
T = the time of assay (min)
This gives the rate of hydrolysis of GTP in pmol/min/mg of membrane protein.
The GTPase assay is suitable for determination of ligand efficacies and potencies 
because it monitors receptor-G protein coupling at steady state.
Following transient expression and prior PTx treatment (25ng/ml, 16h) of cells
expressing the hDOR-Gua (Ile^^^) fusion protein, membranes were prepared and PTx-
insensitive high affinity GTPase activity and the effect of varying concentrations of
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DADLE was monitored using 0.5 \iM GTP as substrate. Stimulation of GTPase 
activity was produced in a concentration-dependent manner with pEC5o= 7.1 ±0.1 
(mean ± S.E.M, n=3) for DADLE (Figure 3.9A). Equivalent experiments on 
membranes expressing the hDOR-Giia (Gly^^*) showed a significantly lower potency 
for DADLE with pECso = 6.2 ± 0.1 (mean ± S.E.M, n=3) (Figure 3.9B). This value 
was significantly different from hDOR-Gua (Ile^^^) (P < 0.005). Equivalent 
experiments on membranes expressing the hDOR-Goia (Ile^^ )^ fusion protein 
demonstrated a similar potency for DADLE of for the hDOR-Gua (Ile^^*) with pECgo 
= 7.2 ± 0.3 (mean ± S.E.M, n=3) (Figure 3.9C), This value was not significantly 
different (P = 0.61). As expected, naitrindoie was not able to stimulate the GTPase 
activity of these fusion proteins (data not shown).
Table 3.2. Comparison of the potency of DADLE to stimulate high affinity 
GTPase activity of the hDOR-fusion proteins
Constructs pECso
hDOR-Giia (Ile^ ^^ ) 7.1 ±0.1
hDOR-Giia (Gly^ ^^ ) 6.2 ±0.1**
hDOR-Goia (Ile^ ^^ ) 7.2 ± 0.3
The data represent means ± S.E.M from three independent experiments.
** Significantly different from hDOR-Gua (Ile^^*), P < 0.005.
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IV. Kinetics of agonist-stimulated GTP hydrolysis and measurement of 
GTP turnover number
As GTP hydrolysis is an enzymatic reaction it is possible to determine the 
velocity of a maximally effective concentration of agonist and thus measure Vmax and 
K,n of this process by using a wide range of substrate (GTP) concentrations. The 
defined 1:1 stoichiometry of GPCR and G a in the fusion proteins allows 
determination of ligand-regulated GTP turnover number in a membrane system (i.e. 
mol GTP hydrolysed per unit time per mol fusion protein) (Seifert et al., 1998; Wise 
et al., 1997). Membranes prepared from cells expressing the hDOR fusion proteins 
[hDOR-Giia (Ile^^^), -G^a (Gly^^^), -Goia(Ile^^^)] and pretreated with PTx (25ng/ml, 
16h) were assayed for basal and 100 pM DADLE-stimulated GTPase activity at GTP 
concentrations from 20 nM to 2 pM. The effect of the agonist was predominantly to 
increase Vmax of the GTPase activity with only a minor effect on the estimated Km. 
Direct plots of the GTPase activity versus GTP concentrations were obtained for cells 
expressing hDOR-Gua (Ile^^^), -G^a (Gly^^*), -Goia (Ile^^^) (Figures 3.10A, 3.11A, 
3.12A). Eadie-Hofstee plots (velocity versus velocity/substrate) are commonly used to 
estimate Vmax and Km for substrate. Bmax values of receptor antagonist, ([^H] 
naitrindoie) saturation binding was assessed on the same membranes and thus the 
GTPase activities (Vmax for DADLE -Vmax for basal) were divided by expression level 
( B m a x )  to calculate DADLE-induced turnover number for GTP. Eadie-Hofstee plots of 
cells expressing hDOR-Gua (Ile^^*), -G^a (Gly^^^), -Goia (Ile^^^) are shown. (Figures 
3.10B, 3.11B, 3.12B), Km, V m a x  and turnover number were obtained and shown in 
Table 3.3.
1 2 2
Table 3.3. DADLE (100 pM) -stimulated GTP hydrolysis is greatest for hDOR 
when activating Giia(Ile^^^).
hDOR-Gua (Ile '^ )^ hDOR-Gua (Gly^'‘) hDOR-G,ia (Ile^ ^^ )
GTP turnover
number 9.5 ± 0.1 4.9 ± 1.1* 3.0 ± 0.1***
(+DADLE) (m in ')
Km GTP 0.41 ± 0.05 0.70 ± 0.11 0.68 ±0.09
(basal) (pM)
Km GTP 0.54 ± 0.06 0.73 ± 0.07 0.62 ±0.10
(+DADLE) (pM)
The data represent means ± S.E.M from three independent experiments.
* Significantly different from hDOR-Gua (Ile^^^), P < 0.05.
*** Significantly different from hDOR-Gua (Ile^^^), P < 0.0001.
The turnover number for DADLE-stimulated GTP hydrolysis and Km for GTP of 
basal and maximal DADLE (100 pM) stimulation are compared for the hDOR-Gua 
(Ile^^^), -Gua (Gly^^^) and -Goia (Ile^^') fusion proteins in Table 3.3. The ranlc order 
of GTP hydrolysis is the highest in the hDOR-Gua (Ile^^ )^ and the lowest in -Goia 
(Ile^^*) fusion proteins, which demonstrates that GTP hydrolysis for G ua by hDOR is 
faster than that for Goia. The Km for GTP of basal and DADLE-stimulation was not 
different but minor differences were seen with the different fusion protein mutants. As 
previously noted for the a^A-adrenoceptor substitution of Ile^^  ^by Gly substantially 
reduced the agonist-induced turnover number (Jackson et al, 1999).
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Characterisation of the hDOR-Gi/Go fusion proteins 
stably expressed in HEK293 ceiis
I. Setting up of stable cell lines
Stable cell lines of hDOR-Gua (Ile^^^) and hDOR-Goia (Ile^^*) fusion proteins 
were set up using antibiotic (geneticin sulphate, 1 mg/ml) as selection. A number of 
the selected clones expressing hDOR-Gua (Ile^^^) and -G^a (Ile^^^) fusion proteins 
are shown in Figures 3.13 A and 3.13B. The specific binding of a single, near 
saturating, concentration of [^H] naitrindoie and the DADLE stimulated high affinity 
GTPase activity of the same membranes of a number of clones of these stable cell 
lines were correlated. (Figures 3.14A, 3.14B). In general, clones expressing higher 
levels of hDOR-Goia (Ile^^^) were identified but these gave lower DADLE stimulated 
GTPase activity per mol of fusion protein that those expressing hDOR-Giia (Ile^^*).
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II. Analysis using [^ H] naitrindoie binding studies
Similar experiments to these reported earlier on transient transfections were 
repeated on cell lines stably expressing the fusion proteins. Clone no.6 of the hDOR- 
Gua (Ile^^^) fusion protein and no.9 of the hDOR-Goia (Ile^^^) fusion protein were 
selected and expanded with maintenance of antibiotic selection (geneticin sulphate, 
700 pg/ral). The Kd and Bmax of both clones were assessed by [^H] naitrindoie binding 
experiments with nonspecific binding defined in the presence of 100 pM naloxone. 
The level of expression in clones no.6 and no.9 slightly increased with passage. It was 
thus difficult to estimate the exact Bmax of the clones. The Bmax of clone no.6 was 
between 3-6 pmol/mg of protein and that of clone no.9 between 5-10 pmol/mg of 
protein. The Kd of clone no.6 for [^H] naitrindoie was 0.47 ± 0.04 nM (mean ± S.E.M, 
n=3) and that of clone no.9 was 0.89 ± 0.35 nM (mean ± S.E.M, n=3, P = 0.11). These 
values were not significantly different. Figures 3.15A and 3.16A are typical examples 
of saturation experiments for the clones. Scatchard plots were generated (Figures 
3.15B, 3.16B) to estimate Kd and Bmax*
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III. Glycosylation and deglycosylation of the hDOR-Goia (lle^ ®^ ) fusion 
protein
Glycosylation of plasma membrane proteins is a common post-translational 
modification that is thought to be important for protein folding in internal organelles 
and in some cases for membrane targeting and function. The two common classes of 
glycosylation are those containing N-glycosidically linked oligosaccharide chains 
attached to asparagine residues and 0-glycosidically linlced oligosaccharide chains 
linked to serine or threonine residues in the polypeptide (Lennarz, 1983). Cell 
membranes from stable cell lines expressing the hDOR-Goia (Ile^^^) fusion protein (5- 
10 pmol/mg of protein) were prepaied and their protein resolved by SDS-PAGE 
followed by immunoblotting. Antiserum ONI, specific for the N-terminal 
hexadecapeptide of isoforms of Goia and Goza was used. It detected three strong 
bands but not in mock (pcDNA3.1) transfected cells (Lanel) (Figure 3.17A), which 
may represent differential glycosylation (Mr 75-95 kDa). During optimisation of this 
reaction, rat brain cortex Go, (a 39kDa polypeptide) was used as a positive control 
(data not shown). NGF (N-Glycosidase F) was used for structural analysis of the 
presence of N-linked carbohydrate. After the deglycosylation reaction, the protein was 
analysed on 10% SDS-PAGE, where a shift to a lower apparent molecular mass 
(~75kDa) was observed, consistant with the removal of aspargine-linked glycan 
chains (Figure 3.17B).
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IV. Functional analysis of agonist regulated high affinity GTPase activity
Prior PTx treated (25ng/ml, 16h) cell membranes were prepared and the potency 
for DADLE to activate the fusion proteins was monitored in high affinity GTPase 
activity assays with a range of concentrations of DADLE, The comparison of pEC^o 
values between hDOR-Gua (Ile^^^) and -Goia (Ile^^^) fusion proteins is shown 
(Figures 3.18A, 3.18B). The pECgo for clone no.6 was 7.50 ±0.18 (mean ± S.E.M, 
n=3) and that of clone no.9 was 7.32 ± 0,23 (mean ± S.E.M, n=3). These values were 
not significantly different (P= 0.35). Previously, the pECso values following transient 
expression of both constructs were shown to be similar (Table 3.1).
Table 3.4. Comparison of high affinity GTPase activity by the hDOR-Gua (Ile^ ^^ )
and hDOR-Goia (Ile^ ^^ ) fusion proteins.
High affinity GTPase activity hDOR-Gua (Ile“ ‘) hDOR-Goia (Ile^")
(pmoEmg/min)
Basal (+PTx) 20.34 ± 1.05 16.24 ±2.67
DADLE (10 "M)(+PTx) 62.10 ±6.12 28.99 ±3.92
All the data represent means ± S.E.M from three independent experiments.
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V. Kinetics of DADLE-stimuiated high affinity GTPase activities and 
measurement of GTP turnover number
When DADLE (100 |j,M)-stimulated GTPase activity was monitored at a wide 
range of GTP concentrations on membranes prepared from prior PTx treated clones 
(no.6 and no.9), the effect of the agonist was predominantly to increase Vmax of the 
GTPase activity with only a minor effect on the estimated Km for GTP (Figures 
3.19A, 3.20A). Eadie-Hofstee plots were generated to measure Vmax, Km and turnover 
number (min'^) from direct GTP saturation graphs (Figures 3.19B, 3.2GB). The Km 
values of basal and DADLE (100 pM)-stimulated GTPase for the hDOR-Gua (Ile^^ )^ 
fusion protein were 0.53 ± 0.07 |liM  (mean ± S.E.M, n=3) and 0.50 ± 0.07 pM (mean 
± S.E.M, n=3) respectively. In comparison, the Km values of basal and DADLE (100 p 
M)-stimulated GTPase for the hDOR-Goia (Ile^^^) fusion protein were 0.66 ± 0.09 
pM (mean ± S.E.M, n=3) and 0.47 ± 0.12 pM (mean ± S.E.M, n=3) respectively. 
Parallel saturation binding experiments with [^H] naitrindoie on the same membranes 
measured expression levels of the fusion proteins in both clones and thus allowed 
calculation of the DADLE-induced turnover number for GTP by the hDOR-Gua 
(Ile^^*) construct as 8.07 ± 0.35 min'^ (mean ± S.E.M, n=3). In comparison, the 
hDOR-Goia (Ile^^ )^ fusion protein produced a DADLE-stimulated GTPase turnover 
number of only 2.07 ± 0.72 min'^ (mean ± S.E.M, n=3). These values were 
significantly different (P < 0.01).
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V. Sensitivity to pertussis toxin
In cells stably expressing the hDOR-Gua (Ile^^^) fusion protein (clone no.6), PTx 
treatment (25ng/ml, 16h) was performed to see if PTx affected the signalling of 
DADLE (Figure 3,21). The calculated pECso values for untreated and treated 
membranes were similar, which demonstrated that PTx treatment does not affect the 
signalling of the hDOR-Gua (Ile^^^) fusion protein. In other words, the GTPase 
activity following PTx treatment of these membranes is due entirely to activation of 
the linked Gua and there appears to be little or no activation of endogenous Gi-like 
proteins.
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VI. Measuring downstream effects: adenylyl cyclase activity
To compare the regulation of a downstream effect of receptor occupancy on both 
stably expressed hDOR-Gua (Ile^^^) (clone no.6) and -Goia (Ile^^*) (clone no.9) 
fusion proteins, AC activity and its regulation by DADLE was measm'ed. Intact cell 
AC assays were performed essentially as described by Wong, (1994) and Merkouris et 
al., (1997). This whole cell AC assay is based on the use of [^H] adenine which labels 
the intracellular adenine nucleotide pool and measurement of subsequent conversion 
of [^H] ATP to [^H] cAMP on AC stimulation. The [^H] cAMP thus produced is 
separated from [^H] adenine and [^H] ATP by a two-step column method (Salomon et 
al, 1979). Cells of the two clones were split into 12 well plates and grow in geneticin 
containing medium until about 80% confluence. One day before the assay, plates were 
incubated overnight with [^H] adenine at 1 pCi per well and PTx (25ng/ml) was added 
at the same time. HEPES buffered DMEM medium containing increasing 
concentrations of DADLE was then added and the cells incubated for 30 min at 37 °C. 
The reaction was terminated on ice by addition of 1ml of stop solution to extract [^H] 
adenine nucleotides. Harvested cell extract was loaded to separate cAMP from other 
radiolabelled nucleotides (adenosine, AMP, ADP etc) by Dowex and then Alumina 
chromatography. Finally, [^H] cAMP was eluted from the alumina with O.IM 
imidazole (pH 7.3) and quantified.
Initially, forskolin (50 pM) - stimulated AC activity of cells stably expressing the
isolated hDOR was assessed to pre-check the inhibition of AC activity upon addition
of increasing concentrations of DADLE. With PTx treatment, the effect of DADLE on
AC activity was fully attenuated. This confirms that the hDOR signals inhibition of
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AC via Gi-like G proteins (data not shown). Using the two fusion protein expressing 
clones, the pECso value for DADLE to inhibit forskolin stimulated AC activity was 
10.06 ± 0.38 in untreated cells (mean ± S.E.M, n=3) and 9.58 ± 0.14 (mean ± S.E.M, 
n=3) in PTx treated cells of the hDOR-Giia (Ile^^ )^ fusion protein (clone no.6). The 
maximal inhibition of forskolin stimulation was 75-85%. These values were not 
significantly different (P = 0.11). By comparison, the pEC$o for DADLE inhibition of 
forskolin stimulated AC activity for the hDOR-Goia (Ile^^ )^ fusion protein -  9.84 ± 
0.36 in untreated (mean ± S.E.M, n=3) and = 9.32 ± 0.08 for PTx treated cells (mean 
± S.E.M, n=3) was monitored for -G ^a (Ile^^^) 65-75% of inhibition was obtained. 
These values were not significantly different (P = 0.08). Figures 3.22A and 3.22B are 
typical examples of experiments on each clone. First of all, these results demonstrate 
that forskolin stimulated AC activity could be inhibited through both G ^a and Goia 
linlced to the agonist-occupied hDOR. Secondly, PTx treatment did not affect the 
regulation of AC by either of the two constructs. In other words, this is due to 
activation of the linked Gna/Goia rather than via activation of endogenous Gi-like 
proteins.
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Table 3.5. Comparison of signalling by the hDOR-Gjia (Ile^  ^ ) and hDOR-Goia 
(Ile^ ^^ ) fusion proteins.
hDOR-Giia (lie^ *^) hDOR-Goia (He""*)
Kd for [^H] naitrindoie (nM) 0.47 ± 0.04 0.88 ±0.35
pECso for DADLE 7.50 ±0.18 7.32 ± 0.23
(high affinity GTPase activity)
GTP turnover number (min'*) 8.07 ±0.35 2.07 ± 0.72**
(+DADLE)
Km GTP 0.53 ±0.07 0.66 ±0.09
(basal) (pM)
Km GTP 0.50 ±0.08 0.47 ±0.12
(+DADLE) (pM)
pECso for DADLE (nM) 10.06 ±0.38 9.84 ±0.36
(-PTx: AC activity)
pECso for DADLE (nM) 9.58 ±0.14 9.32 ±0.08
(+PTx; AC activity)
All the data represent means ± S.E.M from three independent experiments.
** Significantly different from hDOR-Giia (Ile^^^), P< 0.01.
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VII. Characterisation of transiently expressed hMOR-Gna (lle^ ®^ ) fusion 
protein
To compare the signalling of the hDOR and hMOR, which are highly 
homologous (Knapp et al., 1995: Law et al., 2000), a similar strategy as for hDOR 
was used to a generate hMOR-1-Gua (Ile^^^) fusion protein. This was used to explore 
the relative capacity of hMOR-1 and hDOR to activate Gua. I was given the hMOR- 
1-Giia (Ile^^^) fusion protein which was constructed by Dr. Dominique Massotte, 
(Département des récepteurs et protéines membranaires, (CNRS UPR 9050), Ecole 
Supérieure de Biotechnologie de Strasbourg, Illkirch-Graffenstaden, France). The 
hMOR-1 isoform (Pan et al., 1999) of the hMOR (Wang et al., 1994) was used in 
these studies. The cDNA of hMOR-1 was amplified by PCR in order to shorten the 5' 
end by introducing a Kpnl site. At the same time, the stop codon was removed and 
another Kpnl site was introduced. The sequence amplified by PCR was digested with 
Kpnl and purified on an agarose gel. This was ligated into the Kpnl site of pcDNA3 
containing G ^a (Ile^^^) (Figure 3.23). This fusion protein was fully sequenced prior to 
use.
Transient transfection of the construct into HEK293T cells was carried using 
Lipofectamine™ as transfection reagent for the hDOR fusion proteins. This gave a 
reasonable expression level (0.8-2 pmol/mg of protein), monitored by the appearance 
of specific binding sites for [^H] diprenorphine, which is a general antagonist for all 
the opioid receptors. Saturation binding studies using [^H] diprenorphine indicated 
this ligand was bound with high affinity. Membranes expressing this fusion protein
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were prepared and its level of expression ( B m a x )  and K d  for [ ^ H ]  diprenorphine 
measured. (Figures 3.24A, 3.24B). The Kdfor [^ H] diprenorphine at tiMOR-Gjia (He 
after PTx treatment (25ng/ml, 16h) of cells was 0.44 ±0.18 nM (mean ± S.E.M, 
n=3).
Following transient expression and prior PTx treatment (25ng/ml, 16h) of cells 
expressing the hMOR-Gjia (He^^ )^ fusion protein, membranes were prepared and the 
effect of varying concentrations of DADLE was monitored. Stimulation of GTPase 
activity was produced in a concentration-dependent manner with pECso = 6.6 ± 0.2 
(mean ± S.E.M, n=3) (Figure 3.25). This value was significantly different (P < 0.05) 
from these of hDOR-Giia (He^^ )^ and hDOR-Goia (He^^') (Table 3.2).
Basal and 100 |iM DADLE-stimulated GTPase activity was then measured at 
various GTP concentrations. The effect of the agonist was predominantly to increase 
Vmax of the GTPase activity with only a minor effect on the estimated Km (Figures 
3.26A, 3.26B). B m a x  values for receptor was assessed on the same membranes and 
thus the GTPase activities were divided by expression level to calculate DADLE- 
induced turnover number for GTP as 10.1 ± 1.0 min’  ^ (Table 3.5), equivalent to that 
produced by the hDOR-Gua (He^^*) fusion protein. Therefore, these two opioid 
receptor subtypes were equally effective in activating G^a.
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Table 3.6. Characterisation of the hMOR-Gna (Ile^ ^^ ) fusion protein
hMOR-Giia (He""*)
Kd for [^H] diprenorphine (nM) 0.44 ±0.18
pECso for DADLE 6.6 ±0.2*
(high affinity GTPase activity)
GTP turnover number (min"^) 10.1 ± 1.0
(+DADLE)
Km GTP 0.69 ±0.08
(basal) (pM)
Km GTP 0.75 ±0.08
(+DADLE) (pM)
All the data represent means ± S.E.M from three independent experiments. 
* Significantly different from hDOR-Gjia (Ile^ ®^ ) and hDOR-Goia (Ile^ ‘^),
P < 0.05.
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Discussion (Chapters)
I. Using the fusion protein strategy to understand the 
regulation of G protein activation by the human 5-opioid 
receptor
In this current study I have examined the regulation of activation of the G proteins 
Giia and Goia by the hDOR using a fusion protein strategy. Since the cloning of opioid 
receptors, the individual pharmacological and biochemical profiles of the p, 6 and k- 
opioid receptors have been better defined. However, there are many aspects of opioid 
receptor biology that still remain poorly understood. A major signalling pathway of the 
hDOR is to inhibit cAMP production. This is transduced by Gi-Go family G proteins as 
PTx blocks opioid effects (Law et al., 1985b) The specific G proteins that mediate Ô- 
selective effects on cAMP production have been characterised through the use of IgG 
fractions specific for individual G protein a  subunits (McKenzie and Milligan, 1990). It 
was found that DADLE-mediated inhibition of forskolin-stimulated cAMP production 
was Giia-dependent in NG-108-15 cells. Using a similar approach, antipeptide anti-G 
protein antisera against Gja and Goa were used to examine the interaction of rat brain 
cortical opioid receptors with the G protein. Go (Georgoussi et al., 1993; Georgoussi et 
al., 1995). Fusion proteins derive from a single open reading frame (ORF), which allow 
expression of a single polypeptide containing the sequences of both a GPCR and G 
protein. The benefits of these strategies have recently been extensively reviewed (Seifert 
et al., 1999; Milligan, 2000). However, because the fusion of a receptor C-terminus to
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the G a N-terminus is artificial, it may be a concern that the fusion substantially alters 
the properties of receptor and G protein coupling. For example, in Rati fibroblasts, an 
a 2A-adrenoreceptor-Giia fusion protein does not only activate the fused G ^a partner but 
also endogenous G proteins (Burt et al., 1998) and this also results in loss of Gs 
coupling of the a 2A-adrenoreceptor (Sautel and Milligan, 1998). However, comparison 
of the coupling of human formyl peptide receptor to Gi2 a  in the fused and non-fused 
state by visualising activated G proteins by photoaffinity labelling showed that there 
were only minor differences in FPR-Gj2 a  coupling between the fused and non-fused 
states (Wenzel-Seifert et al., 1999). The strongest properties of these fusion proteins are 
first to have defined 1:1 stoichiometry of the partners, which can provide highly 
efficient receptor-G protein coupling (Wenzel-Seifert et al., 1999). Secondly, it has been 
shown that this strategy provides a useful tool for pharmacological examination of the 
mechanism of activation of G proteins by an agonist-occupied receptor, particularly, 
agonist-receptor efficacy. This can be quantified with high affinity GTPase studies and 
[^^S] GTPyS binding studies. In addition, investigation of receptor-PTx-resistant Gia 
and Goa fusion proteins has shown agonist-stimulated GTP hydrolysis, which was 
unaffected by prior PTx treatment; thus demonstrating the effect to occur via the G 
protein linked to the receptor (Wise et al., 1997b; Jackson et al., 1999). The extreme C- 
terminus of G protein a  subunits is known to be an important contact site for GPCRs 
and ADP-ribosylation by PTx of the Cys (C^^*) located four amino acids from the C- 
terminus abolishes interaction with GPCRs. In early studies, a single alteration 
introduced by mutating this PTx-sensitive Cys of Gn resulted in a method to measure 
interaction efficiency between GPCRs and G proteins in terms of GTP hydrolysis (Bahia
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et al., 1998). Based on the above previous studies, the construction of cDNAs encoding 
fusion proteins between the hDOR and its cognate G proteins, Giia/Goia was performed 
and successfully used in the current study. This construction provided problems. Thus, 
the subcloning strategy was approached in a stepwise fashion. The last 157bps of a 
hDOR cDNA was first amplified by PCR to generate a 5'NotI and a new 3'BamHl 
restriction site by removing the stop codon. The remaining segment of hDORs was 
digested with 5 'BamHI and 3 ^ NotL 5 'BamHI and 3 'EcoRI restriction site were added to 
Giia (wild type) by PCR followed removing of the ATG start codon. Finally, the three 
different fragments were ligated into pcDNA3.1 in a single four-fragment ligation 
reaction (Figures 3.1A, 3.2A). However, because the hDOR now had BamHI sites at 
both 5' and 3' ends, the orientation for ligation is unsure. Figure 3.2A (first clone) 
shows an example of a product ligated incorrectly. Initially a combination of Sac/I and 
jEcoi?/was tried to recover Giia. This caused a problem because of the new generation 
of a Bac/I site in the region joining the C-terminal of the receptor and N-terminal of the 
Gi protein. Another unique restriction pairing - EcoNI and EcoRI - allowed recovery of 
a segment of G ^a (Xaa^^^) mutants (Ile/Leu/Phe/Val/Ser/Ala/Arg/Gly) and their 
replacement for the equivalent section of the hDOR-Giia (wild type) fusion protein 
(Figures 3.1B, 3.2B). A PTx-resistant hDOR-Gua (Pro^^*) was also constructed in the 
same manner, but it was not used further because of the unique aliphatic-like structure 
of the cyclic imino amino acid. A proline residue at this position in Gji might be 
expected to disrupt interaction with the hDOR. The une mutation of Gsa, which results 
from an Arg-Pro alteration 6 amino acid from the C-terminus, is known to prevent 
productive interactions with GPCRs (Sullivan et al., 1987). In a similar way, a hDOR-
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Goia (wild type) fusion protein was also constructed. Here the initial 120bps from the 
original hDOR in pcDNA4 was digested with Kpnl and BssHII and the remaining 
segment of 1020bps from hDOR-Giia (wild type) was digested with BssHII and BamHI 
separately. The ORF of Goia (1065bps) had 5'BglII and 3'XbaI sites introduced by 
PCR. The three different fragments were then ligated into pcDNA3.1 by using the 
compatibility of BamHI and Bglll (Figures 3.3A, 3.4A). PTx-resistant hDOR-Goia 
(Xaa^^^) mutants (Ile/Leu/Gly) were generated by using the unique restriction sites- Clal 
and the second last polylinker in pcDNA3.1, Apal (due to several Xbal sites in Goia) 
from previously constructed Goia (Xaa^^^) mutants (Ile/Leu/Gly) and replacing the 
equivalent segment of hDOR-Goia (wild type) (Figures 3.3B, 3.4B).
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II. Successful transient and stable transfections
All the fusion proteins could be expressed successfully in transient transfection 
using HEK293 cells and Lipofectamine™ transfection reagent as assessed by [^H] 
naltrindole binding studies (Figures 3.5A, 3.5B). Also, immunological detection 
demonstrated the expression of all the fusion proteins, which showed bands of 
appropriate size, which were not in mock (pcDNA 3.1) transfected cells (Figures 3.6A, 
3.6B). One of the benefits of fusion proteins, is they have a 1:1 stoichiometry of 
expression of GPCR and G protein. For this reason direct saturation ligand binding 
studies using [^H] antagonist allowed measurement of the level of expression of the G 
protein as well as the GPCR. This is difficult to quantify with independently co­
expressed GPCRs and G proteins. Initially, all the fusion proteins (hDOR-Gi/Go fusion 
proteins) were transiently transfected and receptor expression measured by single­
concentration [^H] naltrindole-binding assay. With the same membranes, high affinity 
GTPase activity was measured in response to a maximal concentration (100 qM) of 
DADLE. Three different fusion protein mutants -hDOR-Giia (Ile^^^), -Gna (Gly^^^), 
-Goia (Ile^^^) were selected to compare the effect of point mutation and G protein 
identification on signal initiation. It was previously demonstrated that the 
hydrophobicity of re s id u e ^ o f  the G protein determines the extent of activation by the 
a 2A-adrenoceptor (Bahia et al., 1998). Conversion of binding data to Scatchard plots 
showed the ligand affinity for [^H] naltrindole for the transiently expressed hDOR-Gua 
(Ile^^^) and -Gna (Gly^^^) fusion proteins (Figures 3.7A, 3.7B, 3.8A, 3.8B). According 
to my results, the Kd for [^H] naltrindole for the hDOR-Gua (Ile^^^) fusion protein (0.77
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± 0.12 nM, mean ± S.E.M, n=3) was about 6 times higher than for the hDOR- 
Giia (Gly^^^) fusion protein (0.13 ± 0.02 nM, mean ± S.E.M, n=3) (P< 0.001). It has 
been considered that naltrindole is a neutral ô-antagonist and it can prevent the activity 
of an inverse agonist (Neilan et al., 1999). One possibility to explain these different Kd 
values for the same receptor is that naltrindole behaves as an inverse agonist on the 
hDOR-Giia (Ile^^ )^ fusion protein, which may have greater constitutive activity due to 
the mutation to the strong hydrophobic, aliphatic amino acid, He, but not on the Gly^^  ^
residue containing fusion protein. Previously spiperone was shown to act as an inverse 
agonist for 5HTiA-Gua (Ile^^^) but not for 5HTiA-Gna (Gly^^^) (Kellet et al., 1999). In 
other experiments which chapter 4 will introduce the effect of GDP on the binding of 
the agonist [^H] DADLE was dependent upon the identity of r e s id u e ^ o f  the G protein 
and GDP increased the binding of [^H] naltrindole to hDOR-Gna (Ile^^*). In chapter 4, 
more explanation will introduce the stability of ternary complexes of two different 
mutant fusion proteins regarding association and dissociation kinetics of agonist 
binding. Following stable transfection, comparisons of the Kd for [^H] naltrindole 
between hDOR-Gua (Ile^^ )^ and -Goia (Ile^^*) was obtained (Table 3.4, Figures 3.ISA, 
3.15B, 3.16A, 3.16B). The Kd was not different by 0.47 ± 0.04 nM (mean ± S.E.M, n=3) 
for the hDOR-Giia (Ile^^ )^ and by 0.88 ± 0.35 nM (mean ± S.E.M, n=3) for -Goia 
(Ile^^^) fusion proteins after PTx treatment (P = 0.11).
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III. Comparison of agonist potency to activate Gna and
G o ld
GPCR-G protein fusion proteins have been useful tools for pharmacological 
analysis of agonist efficacy (Wise et al, 1997). Because they have a clear 1:1 
stoichiometry of expression of the two protein partners, these fusion proteins have 
overcome the problem of how estimates of ligand efficacy alter with varying ratios of 
co-expression of GPCRs and G proteins. Ligand regulation of guanine nucleotide 
exchange on the fused G protein provides the most appropriate means to utilise the 
unique features of GPCR-G protein fusion proteins (Milligan et ah, 2000). ‘Agonist 
efficacy’ is defined as a measure of the ability of an agonist bound receptor to stimulate 
a measurable response in a cell or tissue (Quock et al., 1999). Previously, PTx-resistant 
fusion protein mutants have been constructed with the Gi-family of PTx sensitive G 
proteins containing mutation of the cysteine side chain four amino acids (Cys^^^) from 
the C-terminus of the a-subunits of Gi and Go (Jackson et al., 1999; Wise et ah, 1999; 
Dupuis et al, 1999). With the same approach, PTx-resistant hDOR-Gua (Xaa^^^Goia 
(Xaa^^^) fusion proteins mutants were constructed to monitor the differential capacities 
of ligands to activate Gi and Go. The agonist DADLE was used to compare potency for 
two selective hDOR-fusion proteins -hDOR-Gua (Ile^^^) and -Goia (Ile^^^)- following 
transient expression. DADLE had pECso = 7.1 ± 0.1 for -G^a (Ile^^*) and pECgo = 7.2 ± 
0.3 for -Goia (Ile^^^) respectively (means ± S.E.M, n=3). Equivalent experiments were 
performed on two stably expressing clones of hDOR-Gua (Ile^^^) and -Goia (Ile^^ )^ with 
pEC5o= 7.5 ±0.18 for -Gua (Ile^^^) and pECgo = 7.32 ± 0.23 for -Goia (Ile^^^) (means ±
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S.E.M, n=3). Summarising the above results, the potency for DADLE was similar for 
both transient and stable expression and for -Gu and -Goi as well (Figures 3.9A, 3.9C, 
3.18A, 3.18B). The maximum level of DADLE-stimulation of the GTPase activity, 
Emax, varied with levels of fusion protein expression. It was calculated that stimulation 
of Gi is much higher than that for Go of the hDOR. This will be further explained later 
related to the rate of GTP hydrolysis (Kcat). It is clear that GPCR-Ga fusion proteins 
can interact with (3y-subunits (Seifert et al., 1998; Wise et al., 1997). Regarding this, 
there still remains question about the role of Py-subunits. In the earliest studies on the P 
2AR-Gsa fusion protein constructed by Bertin et al, (1994) ADP-ribosylation of Gsa by 
cholera toxin (CTx) was dependent on the presence of Py-subunits. However, in Sf9 
insect membranes expressing p2AR-GsaL, mammalian Piy2 -complex was without effect 
(Seifert et al., 1998), whereas in COS cell membranes expressing a 2AAR-Gna (Gly ^^ )^, 
the GTPase activity was increased by co-expression of the piy2 complex (Wise et al.,
1997). For this reason, the effect of Py-complex remains to be further investigated for 
the hDOR fusion proteins. Secondly, only DADLE was used to examine the possible 
differential agonist activation of Gi and Go of the hDOR. Thus the effects of other 
ligands requires to be analysed.
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IV. Comparison GTP turnover of G^a and Goia by the 
human 5-opioid receptor
One attraction of the fusion protein strategy which encodes the functions of both 
proteins in the same polypeptide has been the ability to activate guanine nucleotide 
exchange (i.e. GTPyS binding) and hydrolysis (GTPase activity) by the G protein 
element of the fusion (Wise et al., 1997; Carr et al., 1998; Kellet et al., 1999). For 
example, at a maximally effective concentration of 5-HT, each of the 5-HTia receptor 
Giia fusion proteins studied caused a large stimulation of membrane GTPase activity 
(Kellet et al., 1999). In studies of a a 2AAR-Gua (Gly ^^ )^ fusion protein transiently 
expressed in COS cells, the agonist UK14304 increased Vmax of the fusion protein as a 
GTPase with a GTP turnover number of 3 min'^ (Wise et al., 1997). Although Gs- 
coupled GPCRs often have been mentioned as being difficult to record agonist- 
stimulated GTPase activity, a FLAG-tagged human IP prostanoid (FhIPR)-Gsa fusion 
protein, stably expressed in HEK293 cells could produce a robust iloprost-mediated 
GTPase activity. Cell membranes expressing the hDOR fusion proteins [hDOR-Gua 
(Ile^^^) and -Goia (Ile^^^)] both transiently and stably were assayed for basal and 100 qM 
DADLE-stimulated GTPase activity with increasing concentrations of GTP. The effect 
of DADLE was to significantly increase Vmax of GTPase activity with only a minor 
effect on the estimated Km for GTP. The direct plots of Michaelis Menten kinetics and 
Eadie-Hofstee transformation were produced to obtain Vmax for basal and agonist 
stimulation, Km for GTP and turnover number for cells expressing hDOR-Gua (Ile^^ )^ 
and -Goia (Ile^^^) (Figures 3.10A, 3.10B, 3.12A, 3.12B, 3.19A, 3.19B, 3.20A, 3.20B,
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Tables 3.3, 3.4). Summarising the two different expression systems and constructs, it 
was shown that Km for hDOR-Gua (Ile^^^) was lower than that for -Goia (Ile^^^) and the 
turnover number for DADLE of the hDOR-Gua (Ile^^ )^ was 3-4 times higher than that 
of -Goia (Ile^^^). As GDP release is the rate limiting step of agonist-induced G protein 
activation and deactivation (Gilman, 1987), the greater hydrolysis rate shows that the 
receptor was more efficient at activating Gu than Goi.
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V. Comparison of agonist potency to regulate AC 
activity via the hDOR fusion proteins
Fusion proteins have been shown to activate AC more efficiently than the isolated 
GPCR and G protein expressed as separate proteins. The PiAR-Gsa fusion protein 
constructed by Bertin et al, (1994) demonstrated the importance of physical proximity 
of GPCR and G a for their efficient coupling compared with the non-fused state (Bertin 
et al., 1994). The hDOR inhibits intracellular cAMP levels via Gi-Go proteins. In cells 
expressing the isolated hDOR, DADLE mediated inhibition of forskolin-amplified AC 
activity, which was obliterated after PTx treatment of the cells (data not shown).
AC inhibition by two stable expressed fusion constructs (clone no.6 and 9 of each) 
was shown to give a robust inhibition of forskolin stimulated cAMP production, in 
presence of DADLE (80-85% for -Gua: 65-75% for -Goia), which was stronger than 
for the isolated receptor. The pECso values for DADLE on both stably expressing the 
hDOR-Giia (Ile^^^) and -Goia (Ile^^ )^ fusion proteins were measured and PTx treatment 
did not affect the potency of DADLE or level of inhibition of AC activity (Tables 3.4, 
Figures 3.22A, 3.22B). Moreover, the level of inhibition for hDOR-Giia (Ile^^ )^ fusion 
proteins was much stronger than that for -Goia (Ile^^^), even though the expression level 
of hDOR-Giia (Ile^^ )^ was always lower than that of -Goia (Ile^^*). This demonstrated 
that hDOR-Giia (Ile^^^) and -Goia (Ile^^^) fusion proteins could directly regulate AC 
activity and fused Goia was able to inhibit AC activity as the same way as fused Giia.
146
The a 2AAR-Giia (Gly^^^) fusion protein has the capacity to activate both 
endogenously expressed Gi and PTx-resistant fused Gi protein in stably expressing 
Rati-fibroblasts (Burt et al, 1998). However the a 2AAR-Giia (Gly^^^) fusion protein 
was unable to regulate secondary messengers. A possible reason is that the C-tail of 
Œ2aAR (20 a.a) is significantly shorter than that of the (32AR(84 a.a): the difference in 
function between the two fusions could be due to the differential length of the C- 
terminal tail. In cells expressing 5-HTlA-Gua fusion proteins, 5-HT is able to produce 
robust AC inhibition (Kellet et a l, 1999). Wenzel-Seifert et al, (1998) reported how 
deletions of the C-terminal tail of the P2AR in P2 AR-Gsa fusion proteins [P2 ARGSOCL, p 
2AR(A26) GsotL, P2AR(A70) G saJ  affected the coupling of the P2AR to Gsa by 
studying GTPyS binding, GTPase activity and AC activity. Restricting the mobility of 
Gsa relative to the P2AR results in a decrease of GTP hydrolysis, prolonged G protein 
activation and thus enhanced AC stimulation.
Opioid receptor is known to mediate MAP kinase phosphorylation. It could be very 
interesting to investigate and compare the regulation of MAP kinase pathways by 
hDOR-Gi and hDOR-Go fusion proteins. In fact, it was shown that DOR expressed in 
Rati fibroblasts was able to initiate activation of the MAP kinase cascade in a Gi- 
dependent manner (Burt et a l,  1996). Mi muscarinic acetylcholine receptor is able to 
couple to Go to activate a novel PKC-dependent mitogenic signalling pathway 
independent activation (Biesen et al, 1996). The regulation of MAP kinase by Go 
activated opioid receptors still remains to be investigated.
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VI. Alteration of a single amino acid (Cys®®h in Gua 
modulates the stimulation by DADLE
It has been shown that the physiochemical properties of residue 351 in the C-tail of 
G protein modulate the agonist efficacy of PTx-resistant GPCR-G proteins. PTx- 
treatment in cells expressing these constructs prevents the cross-talk of GPCRs to 
endogenous Gi-proteins and made possible measurements of the comparative activity of 
fused C^ ^^  modified G proteins. The hDOR-Gua (Ile^^ )^ and -G^a (Gly^^‘) fusion 
proteins transiently expressed have different activation of GTPase activity by agonist. 
The potency for DADLE at hDOR-Gua (Ile^^^) (pECso = 7.1 ± 0.1, ihean ± S.E.M, n=3) 
was shown to be a significantly higher than for -G u a  (Gly^^') (pECso = 6.2 ± 0.1, mean 
± S.E.M, n=3) (P<0.005) (Figures 3.9A, 3.9B, Table 3.2). DADLE-stimulated GTPase 
activity with increasing concentration of GTP allowed me to calculate the rate of GTP 
hydrolysis between different DOR constructs; the turnover number for DADLE- 
stimulated GTP hydrolysis on hDOR-Gua (Ile^^^) was 9.5 ±0.1 min  ^ (mean ± S.E.M, 
n=3) and -G u a  (Gly^^^) was 4.9 ± 1.1 min'^ (mean ± S.E.M, n=3). The K,n (qM) for 
GTP respectively for basal and DADLE-stimulated GTPase activity was 0.41 ± 0.05 and 
0.54 ± 0.06 respectively for hDOR-Gua (Ile^^^) and 0.70 ±0.11 and 0.73 ± 0.07 
respectively for -G u a  (Gly^^^). (Figures 3.10A, 3.10B, 3.11A, and 3.11B, Table 3.3). 
Jackson et al,, (1999) demonstrated the relative intrinsic activity of agonists for PTx- 
resistant aiA AR-Giia (Ile^^^)/wild type/(Gly^^^) fusion proteins could be regulated by 
structural alteration in fused G proteins by mutating r e s i d u e ^ T h i s  was the first 
demonstration that the relative intrinsic activity of a range of agonists can be modified
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by a point mutation on the G protein rather than on the receptor.
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VII. Pertussis toxin treatment did not affect the 
signalling of the hDOR fusion proteins.
In my current studies, I have examined the cross-talk of GPCR-Gia/Goa fusion 
proteins with endogenous G proteins by treatment with or without PTx. On cells stably 
expressing the hDOR-Gua (Ile^^^) fusion protein, DADLE stimulated high affinity 
GTPase activity was monitored in presence or absence of PTx, and no difference was 
observed: calculated pECso value were identical (Figure 3.21). Again, in cell lines 
stably expressing hDOR-Gua (Ile^^^) and -Goia (Ile^^^) fusion proteins, DADLE 
regulated AC activity in a concentration dependent manner. PTx treatment did not affect 
this either (Table 3.4) The same results were shown in cells stably expressing PTx- 
resistant 5-HTiA-Giia fusion proteins, essentially no effect on agonist stimulated 
GTPase activity or AC activity was observed after PTx (Kellet et aL, 1999). Lack of 
functional access to the endogenous Gi for the receptor moiety could explain the 
preferential coupling with fused G protein versus endogenous. In marked contrast, the 
a 2AAR-Gua (Gly ^^ *) fusion protein expressed in Rati-fibroblasts interacted very 
efficiently with endogenous Gi-proteins as monitored by high affinity GTPase activity 
and by AC activity (Burt et aL, 1998). In conclusion, the hDOR fusion proteins signal 
through the G protein moiety and all measurements reflect the activation of the 
engineered G protein mutants.
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VIII. The hMOR-1 activates Giia as efficiently as the 
hDOR
The hMOR is also coupled to its effectors predominantly via members of the Gi- 
family of PTx sensitive G proteins (Connor and Christie, 1999: Law et aL, 2000). To 
assess the relative capacity of the hMOR-1 and hDOR to activate Gua, the hMOR-1 
-Gua (Ile^^^) fusion protein was constructed and expressed transiently in HEK293T 
cells (Figure 3.23). This construct was compared with the hDOR-Gua (Ile^^^). This 
bound [^H] diprenorphine with high affinity (Kd = 0.44 ±0.18 nM, mean ± S.E.M, n=3) 
(Figures 3.24A, 3.24B) and high affinity GTPase activity was stimulated in the presence 
of varying concentrations of DADLE. The pECso value was 6.6 ± 0.2 (mean ± S.E.M, 
n=3) (Figure 3.25). However, a maximally effective concentration of DADLE 
stimulated hydrolysis of GTP with a turnover number as 10.1 ± 1.0 min (mean ± 
S.E.M, n-3) (Figures 3.26A, 3.26B, Table 3.5). The results were clear-cut in that the 
GTP turnover number of G ua (Ile^^^) following maximal occupation of the hMOR-1 by 
DADLE was not different from that produced by the hDOR. These results indicate that 
the liMOR-1 activates Gua as efficiently as the hDOR, at least when DADLE is 
employed as the common agonist ligand.
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Figure 3.1. Graphie representation of construction of hDOR-Giia fusion 
proteins
A. Construction of a hDOR-Gua (wild type) fusion protein
A cDNA encoding hDOR and the ORF of rat Gua (wild type) was constructed into 
pcDNA (3.1), by digesting BamHI and Notl from hDOR and by removing the stop 
codon from hDOR and the start codon of Gua and adding BamHI sites to both to 
allow ligation.
B. Construction of PTx-resistant hDOR-Gua (Xaa^^ )^ fusion proteins mutants
cDNAs encoding PTx-resistant hDOR-Gua (Xaa^^^) fusion protein 
(I/L/F/V/S/R/A/G) mutants were constructed by recovering unique restriction 
fragments (EcoNI and EcoRI fragment) from modified forms of G ua (Bahia et a l,
1998), These were used to replace the equivalent fragment from hDOR-Gua (wild 
type).
C. Genetic code for mutations
All of the (Xaa^^^) residues in hDOR-Gua fusion proteins were sequenced prior to
use.
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BamHI
63
Giia(wt|
63 ( 1) Stop f3)
Giia (Xaa^") 
(l/UF/V/S/A/G/R) pcDNA 3.1
BamHI EcoNI EcoNI EcoRI
(2) (1) (3)
hDOR Giia (Xaa“ )^ 
(l/UF/V/S/A/G/R)
pcDNA 3.1
A.A. Genetic code A.A. Genetic code
lie ATC Ser AGO
Leu CTC Ala GOG
Phe TTC Arg CGG
Val GTG Gly GGT

Figure 3.2. DNA agarose gel analysis of hDOR-Gua fusion proteins
A. DNA agarose gel analysis of hDOR-Giia (wild type) fusion protein
DNAs from E.coli clones (selected clones of transformed ligated hDOR/ 
Giia mix) were digested with Bglll and resolved in a 1% agarose gel. Clones in lane 
2,3 and 4 contain digested fragments close to the approximate length of 4.6kb, 1.6kb 
and 1.1 kb expected for the liDOR-Gna (wild type) fusion protein. The clone in 
lanel contains a digested fragment of the wrong orientation.
B. DNA agarose gel analysis of PTx-resistant hDOR-Gua (Xaa^^ )^ fusion protein 
mutants
DNAs from E.coli clones (selected clones of transformed ligated hDOR/
Giia (Xaa^^^) fusion protein mix) were digested with Bglll mid resolved in a 1% 
agarose gel. This is a typical example of digested hDOR-Gua (Val^^ )^ (lanes 1, 2, 3, 
4) and -Gua (Ala^^') (lanes 5, 6, 7) fusion proteins. All the clones contain digested 
fragments close to the approximate lengths of 4.6 kb, 1.6 kb and 1.1 kb expected for 
hDOR-Giia (Xaa^^*) fusion proteins.
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Figure 3.3. Graphic representation of construction of hDOR-Goia fusion 
proteins
A. Construction of a hDOR-Goia (wild type) fusion protein
A cDNA encoding hDOR and the ORF of Goia (wild type) was constructed into 
pcDNA (3.1), by digesting with Kpnl and BssHII sites from hDOR in pcDNA4 and 
by digesting with BssHII and BamHI sites from the hDOR-Giia (wild type) and 
adding a Bglll sites for the N-terminus of Goia to ligate both ends using 
compatibility.
B. Construction of PTx-resistant hDOR-Goia (Xaa^^ )^ fusion protein mutants
PTx-resistant liDOR-Goia (Xaa^^^) fusion protein mutants were constructed by 
recovering the unique C/a/and restriction fragment for mutant Cys^^^Xaa 
forms of Goia. These were used to replace the equivalent fragment from hDOR- 
Goia (wild type).
C Genetic code for mutations
All of the (Xaa^^^) residues in hDOR-Goia fusion proteins were sequenced prior to
use.
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Figure 3.4. DNA agarose gel analysis of hDOR-Goia fusion proteins
A. DNA agarose gel analysis of hDOR-Goia (wild type) fusion protein
DNAs fi'om E.coli clones (selected clones of transformed ligated hDOR/ 
Goia mix) were digested with Bglll and resolved in a 1% agarose gel. Clones in 
lanes 2, 3 and 6 contain digested fragments close to the approximate length of 6.0 kb 
and 1.6 kb expected for the hDOR-Goia (wild type) fusion protein. The clones in 
lanes 1, 4, 5, 7 contain a digested fragment of the wrong ligation products.
B. DNA agarose gel analysis of PTx resistant hDOR-Goia (Xaa^^ )^ fusion protein 
mutants
DNAs from E.coli clones (selected clones of transformed ligated hDOR/ 
Goia (Xaa^^*) fusion protein mutants) were digested with BgUI and resolved in a 
1% agarose gel. Clones in lanes 1, 2 [-Goia (Ile^^^)], 3, 4 [-Goia (Leu^^^)] and 5, 6 
[-Goia (Gly^^*)], contain digested fragments close to the approximate lengths of 6.0 
kb, 1.6 kb expected for the hDOR-Goia (Xaa^^^) fusion protein mutants.
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Figure 3.5. [^H] naltrindole binding studies on transiently expressed
hDOR-Giia/Goia fusion proteins
A. [^H] naltrindole-binding assay on transiently expressed hDOR-Gna (wild 
type) and liDOR-Gua (Xaa^^ )^ fusion protein mutants
Following transient transfection of hDOR-Giia (wild type) and hDOR-Giia 
(Xaa^^^) fusion protein mutants into HEK293T cells using Lipofectamine™ 
membranes were prepared and expression assessed by [^H] naltrindole binding 
(~5 iiM). Non specific binding was assessed in parallel in the presence of 
100 p,M unlabelled naloxone. Specific binding of [^H] naltrindole was obtained by 
substrating non-specific binding counts from total binding counts. This is a 
representative example of one experiment performed in triplicate (mean ± S.D). 
Xaa^^* amino acids are represented by the standard one-letter code.
B. [^H] naltrindole-binding assay on transiently expressed hDOR-Goia (wild 
type) and hDOR-Goicx (Xaa^^ )^ fusion protein mutants
Following transient transfection of hDOR-Goia (wild type) and hDOR-Goia 
(Xaa^^^) fusion protein mutants into HER293T cells using Lipofectamine'^^, a 
binding experiment with prepared membranes was performed as in Figure 3.5A. 
This is a representative example of one experiment performed in triplicate (mean ± 
S.D).
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Figure 3.6. Analysis of [^ H] naltrindole saturation binding to transiently
expressed hDOR-Gna (lle^ ®^ ) fusion proteins
A. [^H] naltrindole saturation-binding studies to membranes of cells transiently 
expressing the hDOR-Giia (Ile^ *^) fusion protein
Following transient expression of the hDOR-Gna (Ile^^^) fusion protein and prior 
PTx treatment (25ng/ml, 16h), saturation binding studies using [^H] naltrindole were 
performed on membranes of HEK293T cells. Bmax of hDOR-Gna (Ile^^^) varied 
in individual experiments (1-6 pmol/mg). The Kd of [^H] naltrindole for hDOR-Gjia 
(Ile^^ )^ was estimated as 0.77 ±0.12 nM (means ± S.E.M, n=3). This is a 
representative example of thi'ee experiments performed.
B. Scatchard analysis
Scatchard plot was generated from the data of Figure 3.6A. The slope of the graph 
provides the negative inverse of K j ( -1/Kd), while the X-intercept is the B^ax- This 
is a typical example of tliree experiments performed.
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Figure 3.7. Analysis of [^H] naitrindoie saturation binding to transiently
expressed hDOR-Gna (Gly^ ®^ ) fusion proteins
A. [^H] naltrindole saturation-binding studies to membranes transiently 
expressing hDOR-Gna (Gly^^ )^ fusion protein
Following transient expression of the hDOR-Giia (Gly^^^) fusion protein and prior 
PTx treatment (25ng/ml, 16h), saturation binding studies using [^H] naltrindole were 
performed on membranes of HEK293T cells. B^axof the hDOR-Giia (Gly^^^) varied 
in individual experiments (1-6 pmol/mg). The Kd of [^H] naltrindole for hDOR-Giia 
(Gly^^*) was estimated as 0.13 ± 0.02 nM (means ± S.E.M, n=3). This is a 
representative example of three experiments performed.
B. Scatchard analysis
Scatchai’d plot was generated from the data of the Figure 3.7A. The slope of the 
graph provides the negative inverse of Kd ( -1/Kd), while the X-intercept is the 
Bmax- This is a typical example of three experiments performed in triplicate.
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Figure 3.8. Immunodetection of hDOR-Giia fusion proteins
A. Optimisation of immunological detection of hDOR-Gna (Xaa^^ )^ fusion protein 
mutants
Immimoblotting with antisermn IlC  to detect hDOR-Giia fusion protein mutants 
was optimised under four different conditions - boiling/reducing, 2" ;^ 
boiling/non-reducing, 3^ ;^ non-boiling/reducing, 4*'^ ; non-boiling/non-reducing 
Two fusion proteins hDOR-Gua (Ile^^^) (lanes 2, 5, 8, 11) and -Gua (Ser^^^) (lanes 
3, 6, 9, 12) were used as were mock-transfected cells (lanes 1, 4, 7, 10), The 
conditions of (lanes 2, 3) and 2"  ^(lanes 5, 6) seemed to be successful in detecting 
strong signals in the positive but not in mock (pcDNA3.1) loaded lanes. Possible 
degradation products from the fusion proteins (lanes 3, 4, 6, 7, 10) were detected 
around ~27kDa, but not in mock loaded lane (lanes 1, 4, 7, 10).
B. Immunological detection of hDOR-Giia (Xaa^^ )^ fusion protein mutants
Immunoblotting with IlC  antiserum, which is specific against an internal domain 
(159-168 aa) of Gil a  indicated multiple immunoreactive proteins corresponding to 
the fusion protein (Green et al, 1990).
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Figure 3.9. Comparison of the potency of DADLE to stimulate the high 
affinity GTPase activity of transiently expressed hDOR-Gna/Goia fusion 
proteins
A. DADLE stimulation of the high affinity GTPase activity of transiently 
expressed hDOR-Gua (Ile^ ^^ ).
Following transient expression of the hDOR-Giia (Ile^^^) fusion protein and prior 
PTx treatment (25ng/ml, 16h), high affinity GTPase activity was measured in the 
presence of varying concentrations of DADLE. The pECso value was 7.1 ±0.1 
(mean ± S.E.M, n=3).
B. DADLE stimulation of the high affinity GTPase activity of transiently 
expressed hDOR-Gua (Gly^^ )^.
Following transient expression of hDOR-Gua (Gly^^^) and prior PTx treatment 
(25ng/ml, 16h), high affinity GTPase activity was measured in the presence of 
vaiying concentrations of DADLE. The pECgo value was 6.2 ±0.1 (mean ± S.E.M, 
11= 3 ).
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c .  DADLE stimulation of the high affinity GTPase activity of transiently 
expressed hDOR-Goia (Ile^ ^^ ).
Following transient expression of hDOR-Goia (Ile^^^) and prior PTx treatment 
(25ng/ml, 16h), high affinity GTPase activity was measured in the presence of 
varying concentrations of DADLE. The pECso value was 7.2 ± 0.3 (mean ± S.E.M, 
n=3).
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Figure 3.10. The kinetics of DADLE-stimulated GTP hydrolysis of
transiently expressed hDOR-Gua (lle^ ®^ ).
A. DADLE-stimulated high affinity GTP activity at various GTP concentrations
Following transient expression of liDOR-Gjia (Ile^^^) and prior PTx treatment 
(25ng/ml, 16h), basal ( ^  ) and DADLE (lOOpM)-stimulated (□ )  high affinity 
GTPase activity was measured at increasing concentrations of GTP. This is a 
representative example of three experiments performed.
B, Eadie-Hofstee analysis
An Eadie-Hofstee plot was produced from the data of Figure 3.10A. The maximum 
velocity (Vmax) was obtained by the difference in y-intercept between the basal ( ^  ) 
and DADLE-stimulated (□ )  activity and the Michaelis-Menten constant (Km) for 
GTP was determined by the negative value of the slope of the graph. K,„ GTP (basal) 
was 0.41 ± 0.05 nM and Km GTP (DADLE) was 0.54 ± 0.06 nM (means ± S.E.M, 
n=3). GTP turnover number was calculated as 9.5 ±0.1 min'^ (mean ± S.E.M, n=3); 
Vmax (DADLE)-Vmax (basal)/Bmax of exprcsslon level in the same membrane 
preparation. This is typical of thi*ee experiments performed.
162
o» 40-
30-
Q. 20-
10-
0 400 800 1200 1600 2000
[GTP] (nM)
B
70-1
C 60-
E 50-D)
1 40-o
E 30-a. 20-
> 10-
0-
0.00 0.02 0.04 0.06 0.08 0.10 0.12
V (pmol/mg/min) / S (nM GTP)

Figure 3.11. The kinetics of DADLE-stimulated GTP hydrolysis of
transiently expressed hDOR-Gna (Gly^ ^^ ).
A. DADLE-stimulated high affinity GTP activity at various GTP concentrations
Following transient expression of hDOR-Giia (Gly^^^) and prior PTx treatment 
(25ng/ml, 16h), basal ( ^  ) and DADLE (100 pM)-stimulated (□ )  high affinity 
GTPase activity was measured at increasing concentrations of GTP. This is a 
representative example of three experiments performed.
B. Eadie-Hofstee analysis
An Eadie-Hofstee plot was produced Rom the data of Figure 3.11 A. K,n GTP (basal) 
was 0.70 ± 0.11 nM and Km GTP (DADLE) was 0.73 ± 0.07 nM (means ± S.E.M, 
n=3). GTP turnover number was calculated as 4.9 ±1.1 min‘  ^ (mean ± S.E.M, n=3). 
This is typical of thiee experiments performed.
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Figure 3.12 The kinetics of DADLE-stimulated G IF  hydrolysis of
transiently expressed hDOR-Goia (lle^ ®^ ).
A. DADLE-stimulated high affinity GTP activity at various GTP concentrations
Following transient expression of hDOR-Goia (Ile^^*) and prior PTx treatment 
(25ng/ml, 16h), basal ( ^  ) and DADLE (100 pM)-stimulated (□ )  high affinity 
GTPase activity was measured at increasing concentrations of GTP. This is a 
representative example of three experiments performed.
B. Eadie-Hofstee analysis
An Eadie-Hofstee plot was produced from the data of Figure 3.12A. Km GTP (basal) 
was 0.68 ± 0.09 nM and Km GTP (DADLE) was 0.62 ±0.10 nM (means ± S.E.M, 
n=3). GTP turnover number was calculated as 3.0 ± 0.1 min"  ^ (mean ± S.E.M, n=3). 
This is typical of thi’ee experiments performed.
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Figure 3.13. Stable cell lines expressing hDOR-Giia (lle^ ®^ ) and hDOR-Goiot
(lle^ ®^ ) fusion proteins
A. Selected clones stably expressing hDOR-Giia (Ile^ ^^ ).
Following stable expression of the hDOR-Giia (Ile^^^) fusion protein in HEK293 
cells in an antibiotic selective manner (0418-sulphate, 1 mg/ml), clones expressing 
liDOR-Ojia (Ile^^*) were expanded. Expression of the fusion protein was assessed 
using ~ 5 nM [^H] naltrindole binding with 100 pM naloxone used to define non­
specific binding. This is a representative example of one experiment performed in 
triplicate (mean ± S.D.).
B. Selected clones stably expressing hDOR-Goia (Ile^ ^^ ).
Following stable expression of the hDOR-Goia (Ile^^^) fusion protein in HEK293 
cells in an antibiotic selective manner (G418-sulphate, Img/ml), clones expressing 
hDOR-Goia (Ile^^^) were expanded. Expression of the fusion protein was assessed 
using ~ 5 nM [^H] naltrindole binding with 100 pM naloxone used to define non­
specific binding. This is a representative example of one experiment performed in 
triplicate (mean ± S.D.).
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Figure 3.14. Correlation between specific [^H] naltrindole binding and
DADLE-stimulated GTPase activity of clones stably expressing hDOR-
Giia/ Goia fusion proteins
Correlation between single concentration [^H] naltrindole binding (Figure 3.13A) 
and maximal concentration DADLE-stimulated GTPase activity of selected clones 
stably expressing hDOR-Giia (Ile^^^) (□ )  and between single concentration [^H] 
naltrindole binding (Figure 3.13B) and maximal concentration DADLE-stimulated 
GTPase activity of selected clones stably expressing hDOR-Goia (Ile^^^) (^  ).
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Figure 3.15. Analysis of [^H] naltrindole binding to stably expressed
hDOR-Giia (lle^ ®^ ).
A. [^ HJ naltrindole binding studies on membranes stably expressing bDOR- 
Giia (He""').
Following stable expression of the hDOR-Gjia (He""') fusion protein and prior PTx 
treatment (25ng/ml, 16h), saturation binding studies using ["H] naltrindole were 
performed on membranes of HEK293T cells at various range of ["H] naltrindole.
Non specific binding was assessed in parallel in the presence of 100 pM unlabelled 
naloxone. Bmax of hDOR-Giia (He""') varied with passage (3-6 pmol/mg). The 
Kd of ["H] naltrindole for hDOR-Giia (He""') was estimated as 0.47 ±  0.04 nM.
(mean ± S.E.M, n=3). This is a representative example of three experiments 
performed.
B. Scatchard analysis
Scatchard plot was generated from the data of Figure 3.15 A. The slope of the graph 
provides the negative inverse of Kd (-1/Kd), while the X-intercept is the Bmax- This 
is a typical example of thi'ee experiments performed.
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Figure 3.16 Analysis of [^ H] naltrindole binding on stably expressing
hDOR-Goia (lle^ ®^ ).
A. [^H] naltrindole binding studies on membranes stably expressing hDOR- 
Goia (Ile^ ^^ ).
Following stable expression of hDOR-Goia (Ile^^^) and prior PTx treatment 
(25ng/ml, 16h), saturation binding studies using [^H] naltrindole were performed on 
membranes of HEK293T cells at various concentrations of [^H] naltrindole. Non 
specific binding was assessed in parallel in the presence of 100 pM unlabelled 
naloxone. Bmax of hDOR-Goia (Ile^^^) varied with passage (5-10 pmol/mg). The 
Kd of [^H] naltrindole for hDOR-Goia (Ile^^‘) was estimated as 0.88 ± 0.35 nM 
(mean ± S.E.M, n=3). This is a representative example of three experiments 
performed.
B. Scatchard analysis
Scatchard plot was analysed fiom the Figure 3.16A. The slope of the graph gave 
the negative inverse of Kj (-1/Kd), while the X-intercept is the Bmax- This is a 
typical representative of three experiments performed.
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Figure 3.17. Deglycosylation of glycosylated forms of hDOR-Goia (lle^ ®^ ).
A. Glycosylation
Membranes from HEK293 cells stably expressing hDOR-Goia (Ile^^^) were 
prepared and their protein resolved in 10% SDS-PAGE. Following transfer to 
nitrocellulose, samples were immunoblotted with antiserum ONI (specific for the 
N-terminal hexadecapeptide of Goia ). Three bands were detected at increasing 
concentration of membrane protein (lOpl, 7pl, 3pl / lanes 2, 3, 4), but not in mock 
transfected cells (Lanel), which were glycosylated (Mr 75-95 kDa).
B. Deglycosylation
NGF (N-Glycosidase F, Roche Molecular Biochemicals) was used for structural 
analysis of N (aspai'agine)-linked carbohydrate chains of glycoproteins. After the 
deglycosylation reaction, the protein was analysed on 10% SDS-PAGE, where a shift 
to a lower appaient molecular mass indicates the removal of aspargine-linked glycan 
chains. Successful deglycosylated of this fusion protein (Mr 75 kDa, lane2) was 
obtained. Lane 1, untreated, lane 2, NGF-treated.
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Figure 3.18. DADLE-stimulated high affinity GTPase activities of stably
expressed hDOR-Gna/Goia.
A. DADLE-stimulated high affinity GTPase activity of stably expressed hDOR-
G iia
Cells stably expressing liDOR-Gjia (Ile^®’) were PTx treated (25ng/ml, 16h) and 
DADLE-stimulated high affinity GTPase activity was measured in membrane 
preparations. The pECso value was 7.5 ±0.18 (mean ± S.E.M, n=3).
B. DADLE-stimulated high affinity GTPase activity of stably expressed hDOR- 
G„ia (IIe^ ®‘).
Cells stably expressing hDOR-Goia (Ile^^’) were PTx treated (25ng/ml, 16h) and 
DADLE-stimulated high affinity GTPase activity was measured in membrane 
preparations. The pECgo value was 7.32 ± 0.23 (mean ± S.E.M, n=3).
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Figure 3.19. The kinetics of DADLE-stimulated GTP hydrolysis of stably
expressed hDOR-Gna (lle^ ®^ ).
A. DADLE-stimulated high affinity GTP activity at various GTP concentrations
Cells stably expressing hDOR-Gna (Ile^^^) were PTx treated (25ng/ml, 16h) and 
basal ( ^  ) and DADLE (lOOpM)-stimulated (□ )  high affinity GTPase activity 
was measured at increasing concentrations of GTP. This is typical of three 
experiments performed.
B. Eadie-Hofstee analysis
An Eadie-Hofstee plot was produced from the data of Figure 3.19A. Vmax was 
obtained by the difference in y-intercept between the basal and DADLE- 
stimulated (□ )  activity and Km for GTP was determined by the negative value of the 
slope of the graph. Km GTP (basal) was 0.53 ± 0.07 nM and Km GTP (DADLE) was 
0.50 ± 0.08 nM (means ± S.E.M, n=3). GTP turnover number was calculated as 8.07 
± 0.35 min^ (mean ± S.E.M, n=3). This is a typical of three experiments performed.
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Figure 3.20. The kinetics of DADLE-stimulated GTP hydrolysis of stably
expressed hDOR-Goia (lle^ ®^ ).
A. DADLE-stimulated high affinity GTP activity at various GTP concentrations
Cells stably expressing hDOR-Goia (Ile^^^) were PTx treated (25ng/ml, 16h) and 
basal ( ^  ) and DADLE (100 pM)-stimulated (□ ) high affinity GTPase activity was 
measured at increasing concentrations of GTP. This is a typical of three experiments 
performed.
B. Eadie-Hofstee analysis
An Eadie-Hofstee plot was produced from the data of Figure 3.20A. The Km GTP 
(basal) was 0.66 ± 0.09 nM and Km GTP (DADLE) was 0.47 ± 0.12 nM (means ± 
S.E.M, n=3). GTP turnover number was calculated as 2.07 ± 0.72 min'^ (mean ± 
S.E.M, n=3). This is a typical of thi’ee experiments performed.
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Figure 3.21. Effect of PTx treatment on the high affinity GTPase activity of 
hDOR-Gna (lle^®').
Membranes were prepared from a clone stably expressing hDOR-Gna (Ile^^') which 
was untreated (□ )  or treated ( ^  ) with PTx (25ng/ml, 16h). DADLE-stimulated 
GTPase was measured. This is a representative experiment performed in triplicate 
(mean ± S.D.)
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Figure 3.22 Comparison of DADLE regulation of adenylyl cyclase activity
in cells stably expressing hDOR-Gna (lle^ ®^ ) and hDOR-Goia (lle^ ®^ ) fusion
proteins.
A. Effect of liDOR-Giia on AC activity
Forskolin (50pM) stimulated AC activity was measured in untreated ) and PTx 
(25ng/mlj 16h) treated (□ )  cells stably expressing hDOR-Gna (Ile^^^) as was the 
effects of increasing concentration of DADLE. The pECgo value for hDOR-Gna 
(Ile^^^) was 10.06 ± 0.38 (mean ± S.E.M, n=3) for untreated and 9.58 ± 0.14 (mean 
± S.E.M, 11=3) for PTx-treated. This is a typical example of three experiments 
performed.
B. Effect of hDOR-Goia on AC activity
Forskolin (50pM) stimulated AC activity was measured in untreated ( ^  ) and PTx 
(25ng/ml, 16h) treated (□ )  cells stably expressing hDOR-Goia (Ile^^^) as was the 
effects of increasing concentrations of DADLE. The pECso value for hDOR-Goia 
(Ile^^^) was 9.84 ± 0.36 (mean ± S.E.M, n=3) for untreated and as 9.32 ± 0.08 
(mean ± S.E.M, n=3) for PTx-treated. This is a typical example of three experiments 
performed.
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Figure 3.23. Graphie representation of the construction of the hWlOR-
Giia fusion protein
The cDNA of hMOR-1 was amplified by PCR in order to shorten the 5 ' terminal 
by introducing a Kpnl site and to remove the stop codon by introducing another 
Kpnl site. The sequence amplified by PCR was digested with Kpnl, purified and 
ligated into the KpnIsitQ of pcDNA3 containing Giia (Ile^^^). This fusion protein 
was fully sequenced prior to use.
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Figure 3.24. Analysis of [^ H] diprenorphine binding to transiently
expressed hW10R-Giia (lle^ ®^ ).
A. [ H] diprenorphine saturation-binding studies to membranes transiently 
expressing the hMOR-Giia (Ile^ ^^ ) fusion protein
Following transient expression of the hMOR-Gna (Ile^^^) fusion protein and prior 
PTx treatment (25ng/ml, 16h), [^H] diprenorphine saturation binding studies 
were performed on membranes of HEK293T cells. This is a representative 
example of tliree experiments performed.
B. Scatchard analysis
A Scatchard plot was generated from the data of Figure 3.24A. This is a typical 
example of three experiments performed in triplicate.
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Figure 3.25. DADLE stimulates the high affinity GTPase activity of
transiently expressed hMOR-Gna (lle^ ®^ ).
Following transient expression of liMOR-Giia (Ile^^^) and prior PTx treatment 
(25ng/ml, 16h), high affinity GTPase activity was measured in the presence of 
vaiying concentrations of DADLE. Data represent the mean ± S.E.M from three 
independent experiments.
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Figure 3.26. DADLE-stimulated GTP hydrolysis of transiently expressed
hMOR-Giia (lle^ ®^ ).
A. DADLE-stimulates high affinity GTP activity at various GTP concentrations
Following transient expression of hMOR-Gna (Ile^^*) and prior PTx treatment 
(25ng/ml, 16h), basal and DADLE (lOOpM)-stimulated (□ )  high affinity 
GTPase activity was measured at increasing concentrations of GTP. This is a 
representative example of three experiments performed.
B. Eadie-Hofstee analysis
An Eadie-Hofstee plot was produced from the data of Figure 3.26A. This is typical 
of tlii'ce experiments perfoimed.
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CHAPTER IV
Control of the efficiency of agonist-indnced 
information transfer and stability of the ternary 
complexes containing the 5-opioid receptor and the a- 
subunits of and Goi by mutation of a receptor/G 
protein contact interface.
INTRODUCTION (Chapter 4)
The 5, n and k opioid receptors are highly homologous, all members of the 
GPCR superfamily (Knapp et ah, 1995: Connor and Christie, 1999: Law et aL, 2000). 
Each mediates the bulk of its effects via activation of members of the Gi family of 
heterotrimeric G proteins (Connor and Christie, 1999: Law et ah, 2000). These opioid 
receptors can activate both Goia and Giia, which are closely related, and highly 
expressed in the central nervous system. Since the initial pharmacological 
identification of the DOR, considerable effort has been directed toward understanding 
the signal transduction pathways that couple this receptor to analgesia and other 
functional responses. It is well established that most DOR-mediated events are 
dependent on the activity of PTx-sensitive G proteins. It is also well established that 
DOR-selective ligands inhibit intracellular cAMP levels and modulate the activity of 
voltage-gated calcium and potassium channels.
Evidence from a wide range of experimental approaches has indicated that the C- 
terminal region of G protein a  subunits plays a key role in the selectivity of 
interactions with members of the family of GPCRs (Hamm, 1998: Schonerberg et ah, 
1999: Wess, 1998: Gether and Kobilka, 1998). These include that the une mutation of 
Gsa, which results from an Arg-Pro alteration 6  amino acids from the C-terminus, 
prevents productive interactions with GPCRs (Sullivan et aL, 1987) and that 
chimaeric G proteins, in which the extreme C-terminal region is exchanged, alter 
GPCR coupling specificity (Milligan and Rees, 1999). Through alanine scan
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mutagenesis, Osawa and Weiss (1995) identified several residues in the C-terminus of 
G ta which affect coupling of the G protein with its cognate receptor. One of the 
residues identified by Osawa and Weiss (1995) was a cysteine residue, located four 
amino acids from the C-terminus. Substitution of this residue for tyrosine (C347Y) 
was seen to result in a loss of G protein/receptor coupling. Similarly, ADP- 
ribosylation of this residue by PTx has been shown to prevent the coupling of receptor 
and G protein. Moreover, substitution of the equivalent cysteine residue by glycine in 
Giia (Senogles, 1994) or serine in Gisa (Hunt et al., 1994) has been shown to result in 
a less marked decrease in G protein/receptor coupling.
The importance of C-terminal residues of G a proteins in receptor coupling was 
further demonstrated by Conklin et al (1993a) when they generated Gqa/Giza 
chimeric proteins by replacing 1 to 23 amino acids of the C-terminal region of Gqa 
with those of Gi2a. When these chimeric G proteins were co-expressed with A% 
adenosine or D2 dopamine receptors, which are G ia coupled receptors, functional 
coupling in HEK293 cells was shown by elevation of agonist stimulated PLC activity. 
The critical C-terminal residues involved in receptor coupling were further defined to 
be at the -3 and -4  position from the C-terminus of Ga, using mutation studies of a 
Gqa/Gza chimera (Conklin et al., 1996). However, in a study of other chimeric G 
proteins with substitutions of their extreme C-terminus, it was apparent that not all 
GPCRs were able to couple as efficiently. For example, replacement of C-terminal 
amino acids of Gqa with the equivalent Gsa sequence permitted V2  vasopressin 
receptor but not p2 -adrenergic receptor (both are Gs coupled GPCRs) to stimulate 
PLC. Similar replacement of Gsa amino acids with those from Gqa permitted
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bombesin and V ia  vasopressin receptors but not the oxytocin receptor (all are Gq 
coupled GPCRs) to stimulate AC (Conklin et aL, 1996).
In 1997, Medici et aL, expressed a fusion protein between the a-factor receptor 
(Ste2) and the yeast G a subunit (Gpal) into Saccharomyces cerevisiae devoid of 
endogenous STE2 and GPAÎ genes. In GPAÎ gene deleted yeast cells, the free Gpy 
complex constitutively activates the pheromone response pathway, which leads to 
growth inhibition, and finally lethality in haploid cells. The fusion protein Ste2-Gpal 
was transformed into Gpal deficient yeast cells and was able to function as normal 
Gpal by binding GPy complex, and hence allowed normal growth. In another fusion 
protein, the C-terminal portion of Gpal was replaced by the corresponding domain of 
mammalian Gsa. This chimeric protein consists of the N-terminal 362 a.a of yeast 
Gpal and C-terminal 128 a.a of rat Gsa. This chimeric Gpal-Gsa restored signal 
transduction in Gpal-deficient cells only when fused to Ste2. Thus, the function of the 
G protein C-terminus was mainly to bring Gpal in close vicinity to Ste2. It was 
concluded that the C-terminus of G a may not have a particular role in transmitting 
signal from the receptor, but it mainly responsible for ensuring close contact between 
the receptor and G protein.
In 1999, Fong and Milligan constructed a fusion protein between a FLAG- 
epitope-tagged human IP prostanoid receptor (FhlPR) and the chimaeric G a subunit, 
Gii/Gs6 a  in which the last 6  a.a of G ^a were replaced with those of Gsa. In this 
study, functional activities were compared between the freely interacting components 
and three FhlPR-Ga fusion proteins (FhlPR-Gsa, FhlPR-Gjia, FliIPR-Gii/Gs6 a) 
using both [^^S] GTPyS binding assays and high affinity GTPase assays. The 
importance of the C-terminus of Gsa was demonstrated in restoring the coupling
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between FhlPR and G a subunit. Furthermore, unlike the work of Medici et al, 1997, 
these studies support a maintained central role for the G protein C-terminus in GPCR 
interactions within the fusion protein context.
In fusion proteins, the GPCR C-terminus serves as a tether between the GPCR 
core and Ga. The length of the C-terminus of different GPCRs is extremely variable 
(Reneke et aL, 1988). The C-termini of the a%AAR and P2AR comprise 25 and 72 
amino acids respectively. This large difference in the length of the C-terminus could 
significantly impact on receptor-G protein and G protein-effector coupling in fusion 
proteins. For example, the properties of fusion proteins in which 26 [p2AR(A26)- 
G sa J  or 70 [P2AR(A70)-GsaL] residues of the P2AR C-terminus were deleted were 
examined and compared with the previously described P2ARGsa (Wenzel-Seifert et 
aL, 1998). Deletions in the P2AR C-terminus strongly reduced steady-state GTP 
hydrolysis, GTPy[^^S] binding activity and AC activity. They concluded that deletion 
of the receptor C-terminus in P2ARGsa fusion proteins decreased the mobility of Gsa 
relative to receptor and thus enhanced basal and agonist-regulated AC activity by 
slowing down G protein inactivation. In other words, restricting the mobility of G 
proteins relative to receptors represents a potential mechanism by which signalling 
efficiency can be modulated.
Conformational changes in this region are associated with G protein activation 
(Yang et aL, 1999). The Gi-family G proteins share a common cysteine residue 4 
amino acids from the C-terminus which is the site of action of the ADP-
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ribosyltransferase activity of PTx (Milligan, 1998). This modification prevents 
effective interactions between GPCRs and these G proteins. However, as it is routine 
for cells to express multiple Gi-family G proteins the molecular identity of the G 
protein(s) responsible cannot be determined from this alone (Milligan, 1988). In 
general, treatment of cells expressing an opioid receptor with PTx frequently prevents 
downstream signalling by opioid agonists (Connor and Christie, 1999).
Many studies have employed mutants of these proteins in which the PTx- 
sensitive Cys has been altered (Senogles et al., 1994; Chuprun et al., 1997:
Yamaguchi et al., 1997: Wise et al., 1997b). This has allowed the elimination of 
potential interactions of GPCRs with endogenously expressed forms of Gi by prior 
PTx treatment and analysis of interactions by reconstitution of function provided by 
the mutated G protein. In studies with the a 2A-adrenoceptor Bahia et ah, (1998) co­
expressed this GPCR along with forms of Giia in which the PTx-sensitive Cys was 
replaced by all of the other natumlly occurring amino acids. They observed a wide 
range of capacity of the agonist-occupied receptor to activate the modified forms of 
the G protein.
Over the years a range of approaches have been taken to explore potential
selectivity of different Gi-family G proteins to both interact with opioid receptors and
to regulate signal transduction cascades. These include the use of G protein subtype
selective antisera (Mckenzie and Milligan, 1990: Georgoussi et al., 1995: Murphy and
Makhlouf, 1996: Chalecka-Franaszek et al., 2000), reconstitution studies with purified
G proteins (Chan et al., 1995) and strategies which incorporate a covalent label only
into G proteins which have become activated by a receptor (Milligan and Mckenzie,
1988: Roerig et al., 1992: Laugwitz et al, 1993: Prather et al., 1994: Chakrabarti et
al., 1995). However, it is difficult to explore quantitative aspects of possible
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differences in receptor activation of related G proteins using any of these methods. 
Despite this a range of studies have suggested differential effects of either opioid 
receptor subtypes to activate the same G protein (Laugwitz et al, 1993: Lee et al.,
1998) or of a single receptor subtype to activate closely related G proteins (Laugwitz 
et al, 1993: Kohno et al., 2000), alteration in the identity of the G proteins associated 
with opioid receptors when they become activated (Law and Reisine, 1997) or 
different coupling efficiencies of an opioid receptor to G proteins in different brain 
regions (Maher et a l, 2000). In contrast to this literature, a recent review (Connor and 
Christie, 1999) concluded that “ notions that different types of opioid receptors 
intrinsically couple preferentially to one type of effector rather than another should be 
discarded” .
For the above reasons, both we and a number of other groups have generated 
fusion proteins between GPCRs and G protein a  subunits in which single ORF 
containing both GPCR and G protein function are produced (Seifert et al., 1999; 
Milligan, 2000). These comprise a single ORF such that following removal of the stop 
codon from a DNA encoding a GPCR the G protein a  subunit is attached in-frame 
and thus a single polypeptide encoding both functionalities can be expressed and 
analysed. The use of such fusion proteins has recently been extensively reviewed 
(Seifert et ah, 1999: Milligan, 2000).
Some benefits and successful examples of this strategy have already been
presented in Chapter III. Several researchers, including Colquhoun, (1998) have
concluded that specific features of the fusion proteins make them unique tools for
investigating a range of pharmacological questions. This has been used for
understanding the basis of ligand efficacy in terms of information transfer between the
proteins (Carr et a l,  1998: Jackson et al., 1999). Secondly, it also has been used to
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examine the quantitative effects of point mutations in GPCR and G proteins on the 
affinity of their interactions (Waldhoer et a i, 1999). Using fused tandems of the Ai- 
adenosine receptor and G protein a-subunits [Ai-Gna (wild type), Ai-Gna (Ile^^*),
A 1-Gila (Gly^^^)], the kinetics of high affinity agonist binding on the ternary complex 
between agonist, receptor and G protein was investigated as was the importance of 
Cys^^  ^of G proteins for regulating the affinity between the receptor and mutated G 
proteins.
Most intercellular signal molecules exert their effects through GPCRs that couple 
to heterotrimeric G proteins, which in turn regulate the activity of effector systems 
(Gilman, 1987). The extended ternary complex model of receptor activation assumes 
that GPCRs exist either in an inactive “ R” state or an active “ R*” state (Lefkowitz 
et al,, 1993: Leff, 1995). GPCRs can isomerise from R to R* spontaneously, and this 
imbues constitutive activity to the system. Receptor agonists stabilise the R* state and 
increase basal G protein activity, whereas inverse agonists stabilise the R state and 
reduce basal G protein activity (Lefkowitz et a l, 1993: Leff, 1995). Neutral 
antagonists bind equally well to both R and R*, and thus do not alter either the 
equilibrium between the two states or effector activity.
The basic principle underlying the use of agonist-binding to detect receptor/G 
protein interactions is that any parameter of the system (for example, agonist affinity) 
which changes with the conformation of the receptor may be used as a monitor of RG 
coupling. It is known that receptors exist in two states, R (receptor alone) and RG 
(receptor coupled to the G protein). The former has a low affinity for agonists, while 
the latter has a high affinity.
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In order to detect high affinity agonist binding in binding assays (either direct or 
competition), it is necessary to eliminate contamination of the membrane preparation 
by endogenous GTP or GDP. High affinity agonist binding is measured in radioligand 
binding assays that employ cell membrane preparations that have been washed to 
remove guanine nucleotide. The G protein in the agonist high-affmity ternary complex 
is in the trimeric form (a-subunit coupled to the Py-dimer). GDP strongly stabilises 
the trimeric form of the G protein. In binding assays, the concentration of free GDP 
could be low enough to limit the association of the G protein a  subunit and Py dimer 
so that only a fraction of the G protein is in a form that can interact with the receptor 
to form the high affinity agonist binding state.
Electrostatic, direct hydrogen-bond and van der Waals interactions between two
molecules in an aqueous environment are not particularly favorable energetically
because there are comparable competing interactions between the molecules in
question and the water surrounding them. Water is a very poor solvent for nonpolar
molecules compared with most organic liquids. Nonpolar molecules cannot participate
in the hydrogen bonding that appears to be so important in liquid water, and aqueous
solutions of such molecules have many anomalous physical properties. This relative
absence of hydrogen bonds between nonpolar molecules and water causes interactions
among the nonpolar molecules: the water causes enhanced interactions among the
nonpolar groups themselves, which are much more favorable than it would be the case
in ordered solvents. In conclusion nonpolar molecules greatly prefer nonpolar
environments. This preference of nonpolar atoms for nonaqueous environments has
come to be known as the hydrophobic interaction. It is a major factor in the
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stabilities of proteins, nucleic acids, and membranes, and it has some unusual 
characteristics. The hydrophobicities of the individual amino acid side chains have 
been measured experimentally in a variety of ways, using the free amino acids and 
amino acids with the amino and carboxyl groups engaged in molecular bonding.
In CO “transfection studies with the porcine a 2A-adrenoceptor and forms of Giia in 
which Cys^^  ^was replaced by all other 19 possible amino acids (Bahia et al., 1998), 
the agonist UK14304 displayed a spectrum of capacity to activate the modified G 
proteins. This capacity correlated highly with the hydrophobicity of the different 
amino acids positioned at residue Furthermore, mutationally modified forms of 
fused Gjtt subunits designed to be resistant to the actions of PTx have been used to 
examine potential selectivity of coupling with a range of other GPCRs. In 1999, 
Jackson et al., examined the relative intrinsic activity of a series of partial agonists at 
three distinct fusion proteins that contained the porcine a 2A-adrenoceptor and forms of 
Giia in which residue was either Gly, Cys or He. Similar studies in which fusion 
proteins were constructed between the human 5-HTia receptor and residue mutants 
of Goia have also demonstrated variation in agonist relative intrinsic activity with 
modification of this residue (Dupuis et ah, 1999). Furthermore, Leaney and Tinker, 
(2000) examined the role of isoforms of PTx-sensitive G protein a  subunits (G^a, 
Gi2a, Gi3 a  and Goia) in mediating coupling between various receptor systems (Ai, 
cc2a,D 2 s, M4 , GABAsla+2, and GABABlb+2) and the cloned neuronal ion channel 
effectors (Kir3.1 +3.2A).
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With the benefits of the fusion protein strategy the characteristics of the ternary 
complex of receptor, agonist and G protein was investigated using high affinity 
agonist binding studies. Herein, fusion proteins between the hDOR and a range of 
modified forms of Giia have been employed to explore the effect of G protein 
mutation on agonist-GPCR-G protein ternary complex formation and dissociation and 
the stability of this ternary complex in GPCR to G protein information transfer.
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RESULTS (Chapter 4)
Structure of amino acids
Every protein can be viewed as a polymer of amino acids. There are 20 common 
amino acids. The central carbon is covalently bonded on one side to an amino group 
(NH2 ) and one the other side to a carboxyl group (COOH). A third bond is always 
hydrogen, and the fourth bond is to a variable side chain ( R ). Figure 4.1 introduces 
the structure of 8  different amino acids that I have used in all my experiments for the 
hDOR-Ga fusion protein mutants.
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[^ H] DADLE binding to hDOR and hDOR-Giia 
Goia (lle^ ®h fusion proteins
I. Analysis of [^H] DADLE binding to stably expressed isolated hDOR
Agonist-induced exchange of GTP for GDP on a G protein is accepted as the rate- 
limiting step of the GTP exchange and hydrolysis cycle and reflects enhanced 
dissociation of GDP from the nucleotide binding site (Gilman et al, 1987). Thus, 
agonist stimulation of subsequent GTPase activity provides a direct monitor of G 
protein activation by the agonist-occupied receptor (Gierschik et ah, 1994). As the 
addition of agonist reduces the affinity of the G protein for GDP, then increasing 
concentrations of GDP would be expected to reduce the binding affinity of [^H] agonist 
for the receptor. In preliminary membrane binding experiments, [^H] naltrindole and 
[^H] DADLE saturation binding studies were performed on stably expressed hDOR 
cell lines (Figures 4.2A, 4.3A). Scatchard conversions were obtained from the direct 
saturation experiments. Kd of [^H] naltrindole was estimated as 0.54 ± 0.36 nM (mean 
± range, n=2) and that of [^H] DADLE was 0.85 ± 0.18 nM (mean ± range, n=2) 
(Figures 4.2B, 4.3B). The effectiveness of PTx treatment was optimised for PTx 
amount (50, 100 ng/ml) and incubation time (12, 24 h) (Figure 4.4). In membrane 
binding experiments which used a single concentration of the agonist [^H] DADLE, 
addition of GDP caused a concentration-dependent reduction in levels of [^H] DADLE 
binding to the stably expressed hDOR in HEK293 cells (Figure 4.5A). PTx treatment 
(100 ng/ml, 24h) of cells expressing the hDOR prior to membrane preparation also 
reduced the level of [^H] DADLE binding. This was to a similar extent as produced by 
maximally effective concentrations of GDP and following PTx treatment GDP
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produced no further reduction in [^H] DADLE (5 nM) binding. In contrast, the binding 
of the hDOR antagonist [^H] naltrindole (4 nM) to membranes was not reduced by the 
presence of GDP (Figure 4.5B). Prior PTx treatment actually increased levels of 
binding of [^H] naltrindole by increasing the total number of binding sites (Figures 
4.5B, 4.5C). Further [^H] naltrindole saturation binding experiments were performed 
on membranes of untreated and of PTx treated (25ng/ml, 16h) cells stably expressed 
either hDOR (data not shown) and hDOR-G^a (Ile^^^) (Figure 4.5C). There was a 
little change for the hDOR but a significant up-regulation for hDOR-Giia (Ile^^*). This 
showed an increase of receptor number (Bmax) without alteration of Kd for [^H] 
naltrindole. In addition, [^H] naltrindole binding at a single concentration of 
radioligand to membranes of stably expressed hDOR (PTx untreated) was displaced 
with unlabelled DADLE in a concentration-dependent fashion (data not shown). 
According to the two-state receptor theory, it could be expected to see the presence of 
two binding affinity sites. However, it was not possible to detect two such sites. 
However, in the presence of the poorly hydrolysed analogue of Gpp[NH]p (100 pM) 
the IC 50 value for DADLE was moved to higher concentration, which indicated a 
reduction of binding affinity of DADLE to the hDOR.
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II. Analysis of [^H] DADLE binding to stably expressed hDOR-Giia(lle^®^)
fusion protein
In preliminary membrane binding experiments, [^H] naltrindole saturation binding 
experiments were performed on the stably expressed hDOR-Gna (Ile^^^) fusion protein 
(clone no.6 ) (Figure 4.6). The Kd of [^H] naltrindole was 0.47 ± 0.04 nM (mean ± 
S.E.M, n=3). In addition, [^H] DADLE saturation binding experiments were performed 
on this stable cell line (Figure 4.7). Unlike the isolated receptor, as was expected from 
the two state receptor theory, both high affinity and low affinity states of [^H] DADLE 
for this fusion protein could be detected. The Kh of [^H] DADLE was 0.60± 0.16 nM 
(mean ± S.E.M, n=3). Furthermore, [^H] DADLE binding to membranes of untreated 
(Figure 4.8A) and PTx treated (Figure 4.8B) (25ng/ml, 16h) of this cell line was 
displaced by GDP in a concentration-dependent fashion. Moreover, like the isolated 
receptor, DADLE had the capacity to compete with [^H] naltrindole to bind to the 
hDOR-Giia (Ile^^^) fusion protein in membranes of PTx treated cells. In the absence of 
guanine nucleotides, two sites with distinct affinities for DADLE were observed (pKi 
high affinity = 9.3 ±0.19, pKi low affinity = 6.5 ± 0.22, means ± S.E.M, n=3), whereas 
in the presence of either GDP (Figure 4.9), or the poorly hydrolysed analogue of GTP, 
Gpp[NH]p (data not shown) (both 100 pM) a monophasic competition curve (pKi =
6.5 ± 0.25, mean ± S.E.M, n=3) was obtained in which only the low affinity site for 
DADLE was observed. In contrast, membranes of untreated (Figure 4. 10A) and PTx 
treated (Figure 4.10B) cells were prepared and the binding of [^H] naltrindole to the 
hDOR-Giia (Ile^^^) was monitored as GDP concentration was increased. Surprisingly, 
an increase in [^H] naltrindole binding was detected in both cases. Further [^H]
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naltrindole saturation binding experiments were performed on membranes in the 
presence and the absence of GDP (Figure 4.10C). An increase of receptor number was 
detected without alteration of for [^H] naltrindole.
Table 4.1. Summary of characterisation of stably expressed hDOR-Gua (Ile^  ^ ) 
fusion protein
hDOR-Giia
Kd for pH] naltrindole (nM) 0.47 ± 0.04
Kh for pH] DADLE (nM) 0.60 ± 0.16
pKi high affinity for DADLE 9.3 ±0.19
pKi low affinity for DADLE 6.5 ±0.22***
Data represent means ± S.E.M from three independent experiments
*** This data is significantly different from pKi high affinity (P < 0.0001).
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III. Analysis of [^ H] DADLE binding to stably expressed hDOR-Goia (lle^ ®^ )
fusion protein
In preliminary membrane binding experiments, [^H] naltrindole saturation binding 
experiments were performed on the stably expressed hDOR-Goia (Ile^^*) fusion protein 
(clone no.9) (Figure 4.11). The Kd of [^H] naltrindole was 0.88 ± 0.35 nM (mean ± 
S.E.M, n=3). In addition, [^H] DADLE saturation binding experiments were performed 
on this stable cell line (Figure 4.12). Like the hDOR-Gna (Ile^^^) fusion protein, two 
distinct binding affinity sites for [^H] DADLE were detected with this construct. The 
K nof [^H] DADLE was 0.75 ± 0.03 nM (mean ± range, n=2). [^H] DADLE binding to 
membranes of untreated (Figure 4.13 A) and PTx treated (Figure 4.13B) (25ng/ml,
16h) cells was displaced by GDP in a concentration-dependent fashion. Moreover, as 
with the isolated receptor and the hDOR-Giia (Ile^^^) fusion protein, DADLE had the 
capacity to compete with [^H] naltrindole to bind to the hDOR-Goia (Ile^^^) fusion 
protein in membranes of PTx treated cells. However, in membranes of untreated 
(Figure 4.14A) and PTx treated (Figure 4.14B) cells binding of [^H] naltrindole to the 
hDOR-Goia (Ile^^^) was not affected by GDP.
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Table 4.2. Summary of characterisation of stably expressed hDOR-Goia (Ile^ ^^ )
fusion protein
hDOR-Goia (Re^ ^^ )
Kd for [^H] naltrindole (nM) 0.88 ±0.35
Kh for [^H] DADLE (nM) 0.75 ±0.03*
Data represent means ± S.E.M from three independent experiments 
* Results are presented as mean ± range from 2 independent experiments.
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[=‘H] DADLE binding to hDOR-Gna {Xaa^^ %Go a^ (Xaa®®h 
fusion proteins
I. Analysis of [^H] DADLE binding to transiently expressed hDOR-Gna 
(Xaa^ ®^ ) fusion proteins
Chimeric cDNAs encoding fusion proteins between the hDOR and the a  subunit 
of Gil were produced using a range of forms of Gna in which the PTx-sensitive Cys^^  ^
was replaced with other amino acids (Figures 3.1A, 3.IB). All of the constructs could 
be transiently expressed in HEK293T cells as monitored by the appearance of specific 
binding sites for [^H] naltrindole (Figure 3.5). Although levels of expression of the 
constructs varied between individual transfections there was no specific pattern of 
expression associated with the identity of the G protein mutant. Saturation binding 
studies using [^H] naltrindole indicated this ligand was bound with high affinity (Kd, 
0.2-0. 8  nM) by all the constructs (Figures 3.6, 3.7). The capacity of GDP to modulate 
[^H] DADLE binding (InM) was then explored in membranes of PTx-treated 
HEK293T cells following transient expression of 8  distinct forms of the hDOR-Gna 
fiision protein in which residue^^^ of the G protein element was He, Leu, Phe, Val, Ala, 
Ser, Gly or Arg. In all cases the binding of [^H] DADLE was reduced in a 
concentration-dependent fashion by GDP. However, the EC50 for GDP varied by more 
than 10 fold between the different constructs (Figure 4.15A) and the pECso for GDP 
was correlated strongly with the n-octanol/HiO partition co-efficient of residue^^’ (a 
measure of their hydrophobicity) (R^ ->0.7421) (Figure 4.15B). This was similar to 
studies with the a 2A-adrenoceptor (Bahia et a l, 1998) which co-expressed this GPCR
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along with forms of G na in which the PTx-sensitive Cys was replaced by all of the 
other naturally occurring 19 amino acids.
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II. Analysis of [^H] DADLE binding to transiently expressed hDOR-Goia
(Xaa^ ®^ ) fusion proteins
Using the same approach as for the fusion protein mutants between the hDOR and 
the forms of the PTx-resistant a  subunit of Gn, chimeric cDNAs of hDOR and PTx- 
resistant G ^ a  also were produced (Figure 3.3). These constructs could be transiently 
expressed in HEK293T cells as monitored by the appearance of specific binding sites 
for [^H] naltrindole (Figure 3.5). Saturation binding studies using [^H] naltrindole 
indicated this ligand was bound with high affinity (Kj, 0.2-0.8 nM) by these constructs 
(Figures 3.6,3.7). The capacity of GDP to modulate [^H] DADLE binding (InM) was 
then explored in membranes of PTx-treated HEK293T cells following transient 
expression of 3 distinct forms of the hDOR-Goia fusion protein in which re s id u e^ o f 
the G protein element was He, Leu or Gly. In all cases the binding of [^H] DADLE was 
reduced in a concentration-dependent fashion by GDP (Figure 4.16A) and the pECso 
for GDP was correlated with the n-octanol/H20 partition co-efficient of residue^ 
(Figure 4.16B) as noted earlier for the hDOR-Gu (Xaa^^^) fusion protein mutants 
(Figure 4.15B).
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Comparison of the kinetics of [^ H] DADLE binding to 
hDOR-Giia (Gly^®h fusion proteins
\. Comparison of potency of GDP and suramin to modulate [^H] DADLE 
binding to hDOR-Gna fusion proteins
From Figures 4.15A, 4.15B, hDOR-Gna fusion proteins containing either He or 
Gly at residue^w ere selected to compare the precise kinetics of [^H] DADLE binding 
to the fusion proteins [hDOR-Gna (He^^ )^, highest potency for GDP: hDOR-Gna 
(Gly^^^), one example of low potency for GDP]. Membranes from cells transiently 
expressed hDOR-Gna (He^^^)/-Gna (Gly^^^) were prepared and [^H] DADLE binding 
experiments were carried at increasing concentrations of GDP, which were able to 
reduce the binding of agonist to both fusion proteins (Figure 4.17A). GDP was more 
potent at the hDOR-Gna (Gly^^^) fusion protein (pIC50 = 6.58 ± 0.16, mean ± S.E.M, 
n=3) than at the hDOR-Gna (He^^ )^ fusion protein (pIC50 -  5.78 ±0.1, mean ± S.E.M, 
n=3). These values are significantly different (** P< 0.005). By contrast, the binding of 
[^H] naltrindole to either transiently expressed fusion protein was not reduced by GDP 
(Figure 4.17B).
Suramin has been described as a G protein antagonist (Beindl et al., 1996: 
Freissmuth et al., 1999) as it is able to interfere with information transfer from GPCR 
to G protein without acting as a competitive antagonist at the GPCR ligand binding site 
(Beindl et al., 1996: Freissmuth et al., 1999). Increasing concentrations of suramin 
were also able to limit the binding of [^H] DADLE (Figure 4.ISA) to the He and Gly 
containing hDOR-G,ia fusion proteins. As with GDP, suramin was more potent at the
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hDOR-Giia (Gly^^^) fusion protein (pIC50 = 5.28 ± 0.15, mean ± S.E.M, n=3) than at 
the hDOR-Gna (Ile^^^) fusion protein (pIC50 = 4.67 ±0.15, mean ± S.E.M, n=3) 
(Figure 4.ISA). These values are significantly different (**P < 0.01). This effect of 
suramin did not reflect direct competition at the ligand binding site as the binding of 
[^H] naltrindole was not reduced by suramin (Figure 4.18B).
Table 4.3. Comparison of the potency of GDP and suramin to inhibit [^ H] DADLE
binding to the hDOR-Gna fusion proteins
Potency hDOR-Giia hDOR-Giia (Gly“ ‘)
(pICso values)
GDP 5.78 ±0.10 6.58 ±0.16**
Suramin 4.67 ±0.15 5.28 ±0.15**
Experiments were performed with 1 nM [^H] DADLE.
Data represent means ± S.E.M from 3 independent experiments
** Significantly different from the hDOR-Gna (Ile^ ^^ ), P < 0.005 for GDP, P < 0.01
for suramin.
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Il Association and dissociation kinetics of [^H] DADLE binding to hDOR-
Gna fusion proteins
To explore the basis for the difference in GDP effects on [^H] DADLE binding 
hDOR-Giia fusion proteins containing He or Gly at re s id u e^ o f the G protein element 
were used. The binding rate of [^H] DADLE (1.2 nM at 25 “ C) to these constructs was 
indistinguishable with Kobserved= 0.27 ± 0.04 min"  ^ for Gly and 0.25 ± 0.06 min'^ for the 
He containing construct (means ± S.E.M, n=3) (Figure 4.19A, Table 4.4).
However, following attainment of steady-state levels of [^H] DADLE binding, 
addition of a marked excess of the opioid antagonist naloxone (lOpM) demonstrated 
the rate of dissociation of [^H] DADLE to be distinct, with the Gly containing construct 
(Koff = 0.183 ± 0.023* min'^) substantially greater than the Ile-containing one (Koff = 
0.072 ± 0.009 min'^) (Figure 4.19B, Table 4.4). These values are significantly 
different (*P < 0.01).
These values produced a kinetically estimated Kd for [^H] DADLE of 0.5 nM for 
the Ile^^^  construct but a 5 fold higher value (2.5 nM) for the Gly^^  ^containing fusion 
protein (Table 4.4).
I would like to describe more precisely how these estimates of Kd were calculated.
• For hDOR-Giia (Ile^^*) (PTx treated, 25ng/ml, 16h)
[^H] DADLE (1.2 nM at 25 ° C)
Koff= 0.072 ±0.009 min'^
Kobserved = 0.25 ± 0.06 min'^
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According to the equation,
Xob “ Koff 
K on = ................................ ..........
[radioligand] (nM)
0.25 -  0.072
-onK  =    =0.144 nM'^ min'^
1.2
Koff 0.072
Kd = -----------  =  = 0.5 nM
Kon 0.144
• hDOR-Giia (Gly^^^) (PTx treated, 25ng/ml, 16h) 
[^H] DADLE (1.2 nM at 25 ° C)
Koff= 0.183 ±0.023 min^ 
K o b s e r v e d  = 0.27 ± 0.038 uiin'^ 
According to the equation,
Kob “ Koff
K on = .......... ................................
[radioligand] (nM)
0.27-0.183
-o nK  = -    = 0.072 nM'^ min'^
1.2
Koff 0.183
Kd = ----------  = ------------= 2.5 nM
K o n  0.072
Equivalent differences between the constructs were obtained whether the kinetic assays 
were performed at 25°C or 37°C or if  dissociation was monitored following addition of 
an excess of antagonist or by limiting dilution of the assay (data not shown).
Very similar values for these two constructs were obtained from direct 
equilibrium [^ H] DADLE saturation binding studies (Figures 4.20A, 4.21A, Table
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4.4). The Kd for direct [^H] DADLE saturation binding for hDOR-Gjia (Ile^^^) was 
0.68 ± 0.05 nM and that for hDOR-Gu a  (Gly was 2.1 ± 0.38* nM (means ± S.E.M, 
n=3) (Figures 4.20B, 4.21B, Table 4.4). These values are significantly different (*P < 
0 .01).
Table. 4.4. Association and dissociation kinetics of the binding of [^H] DADLE to
hDOR-Giia fusion proteins
hDOR-Giia (Ile^ ^^ ) hDOR-Giia (Gly^ ^^ )
Robscrved (m iU  ) 0.245 ± 0.057 0.27 ± 0.038
Kon (nM'Vmin^) 0.150 ± 0.043 0.066 ± 0.019*
Koff (min'^) 0.072 ± 0.009 0.183 ±  0.023*
Dissociation 10.1 ± 1.2 3.9 ± 0.42*
(ti/2) (min)
Kd (nM) kinetic 0.50 2.54
measure
Kd (nM) equilibrium 0.68 ± 0.05 2.1 ± 0.38*
binding
Kinetic experiments were performed with [^ H] DADLE (1.2nM, 25 “C). 
Dissociation experiments were monitored following the addition of naloxone 
(10 pM).
Data represent means ± S.E.M from 3 independent experiments. 
^Significantly different, P < 0.01.
Significantly different, P < 0.05.
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DISCUSSION (Chapter 4)
Addition of agonist reduces the affinity of the G 
protein for GDP and increasing concentrations of GDP 
reduced the binding affinity of [^ H] DADLE for the 
hDOR and hDOR-Gua (lie^®h/-Goia (lle®®h-
I have taken advantage of a fusion protein strategy in which either Goia or G,ia 
were linked directly to the C-terminal tail of the hDOR. In a variety of studies mutated 
forms of G protein a  subunit cDNAs have been produced to allow expression of 
fusion proteins between a GPCR and the G protein. The benefits of this strategy have 
recently been extensively reviewed (Milligan, 2000: Seifert et a i, 1999). This ensures 
that the proximity of the receptor to each G protein is identical, that they are expressed 
in equal ratios and most importantly that the levels of each G protein can be easily 
measured (Seifert et al., 1999: Milligan, 2000). As the fusion proteins have a 1:1 
stoichiometry of receptor to G protein, saturation binding studies with an antagonist 
ligand provide direct measures of G protein, as well as receptor, expression levels.
It is well known that agonists can demonstrate high affinity for receptor states 
due to the promotion of G protein coupling. This leads to differences in the apparent 
amount of total receptor density when measured with antagonist radioligands (where 
the complete receptor population is measured) and agonist radioligands (where only G 
protein complexed receptors are generally measured). For example, in human brain, 
the az-adrenoceptor agonist radioligand [^H] clonidine measures a high-affinity
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binding density of 47 fmol/mg of protein, while a radioligand antagonist [^H] 
RX821002 measures a considerably larger number (95 fmol/mg of protein) (Kenakin, 
1997).
Table 4.5. Properties of antagonist and agonist radioligands
Radioligand Properties Uses
Antagonist (D high-affmity (D determining total receptor
(D low dissociation rate-constant numbers
CD insensitive to conformational (D competition experiments with
state unlabelled compounds
Agonist (D high and low affinity binding 
sensitive to conformational 
state
(D identifying RG coupling
In 1999, Waldhoer et ah, using the fusion protein strategy, examined the kinetics
of ternary complex formation with fusion proteins composed of the Ai-adenosine
receptor and G protein a-subunits. Binding of the agonist to form a ternary complex
with the GPCR and G protein decreased the binding affinity of GDP for the G protein.
The ability of GDP to suppress the formation of the ternary complex was examined.
Because the activated receptor reduces the affinity of the G protein for GDP (by
promoting GDP release), an excess of GDP conversely lowers the affinity of the G
protein for the receptor (Hepler and Gilman, 1992). Seifert et al., (1999), using a
PiAR-Gs fusion protein, examined the effects of different purine nucleotides [GTP,
ITP, and XTP] on receptor/G protein coupling. They demonstrated that these purine
nucleotides were useful tools to detect ligand-specific G protein-coupling states of
receptors. They concluded that the efficacy and potency of a panel of p^AR ligands
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are affected by the nucleotide bound to Gsa and that purine nucleotides differentially 
disrupt the ternary complex stabilised by different ligands, supporting the concept of 
multiple active receptor conformations.
In preliminary binding experiments utilising the stable expressed isolated hDOR,
[^H] naltrindole and [^H] DADLE saturation binding experiments v^ere performed.
Figure 4.2 and Figure 4.3 are representative [^H] naltrindole and [^H] DADLE
saturation binding experiments respectively. Membranes expressing this receptor were
prepared and their Bmax and Kd for ligand measured. The Kd for [^H] naltrindole at
hDOR was 0.54 ± 0.36 nM (mean ± range, n=2) and that for [^H] DADLE was 0.85 ±
0.18 nM (mean ± range, n=2). Figure 4.4 was one independent experiment to show
the effectiveness of PTx treatment on [^H] DADLE binding to the stably expressed
hDOR. Binding affinity of [^H] DADLE was decreased with increasing concentrations
of GDP. However no effect of GDP was observed following PTx treatment, which
caused a decrease of apparent receptor number for [^ H] DADLE (Figure 4.5A). The
effects of pre-treatment of the cells with PTx or addition of GDP (100 pM) to
membranes on the binding of [^ H] DADLE and [^ H] naltrindole was assessed (Figure
4.5B). It was observed that the specific binding of a single concentration of the agonist
[^H] DADLE, but not the antagonist [^H] naltrindole, was reduced substantially by
both treatments. However, these two elements were not additive, as GDP had no
further effect following PTx treatment. There was an increase of specific binding of
[^H] naltrindole after PTx treatment of cells expressing the hDOR. In order to explain
this [^H] naltrindole saturation binding studies to the stably expressed hDOR-Gu a
(Ile^^ )^ was performed on membranes of PTx untreated and pre-treated (25ng/ml, 16h)
cells. These demonstrated up-regulation of receptor with PTx treatment (Figure
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4.5C).
I selected Ile for the replacement for the bulk of the experiments as it had 
previously been demonstrated that positioning of a hydrophobic amino acid at this 
location provides the most effective interface between GPCR and G protein (Bahia et 
a i,  1998). Two stable cell lines of the hDOR-Gu a  (He^^ )^ (Clone no.6) and hDOR- 
Goia (Ile^^^) (clone no.9) were established (Figure 3.13). Figure 4.6 and Figure 4.7 
are representative [^H] naltrindole and [^H] DADLE saturation binding experiments 
for hDOR-Gu a  (Ile^^^). The Kd for [^H] naltrindole at hDOR-Gu a  (He^^ )^ after PTx 
treatment (25ng/ml, 16h) was 0.47 ± 0.04 nM (mean ± S.E.M, n=3). As expected from 
two-state receptor theory, both high affinity and low affinity states were detected from 
direct [^H] DADLE saturation-binding curves. Conversion of binding data to a 
Scatchard plot showed the high affinity site for [^H] DADLE for this construct as 0.60 
±0.16 nM (mean ± S.E.M, n=3). It was surprised to see the clear two site binding 
states with this construct. Classically it has been difficult problem to detect these two 
site states in expressed isolated receptor. I think that it was possible because the 
structure of fusion protein has 1:1 fixed stoichiometry, which provides same ratio 
between receptor and fused G protein, compared to only receptor expression in the 
cell lines. Binding of [^H] DADLE on membranes of this cell line with PTx untreated 
and pre-treated was decreased with increasing concentrations of GDP. However no 
effect of the binding of [^H] DADLE was observed following PTx treatment, which 
showed to be resistant by PTx treatment into this construct (Figures 4.8A, 4.8B).
With the displacement experiment, the above results were confirmed in studies in 
which the binding of [^H] naltrindole to the hDOR-Gu a  (He^^ )^ fusion protein was
207
competed for by increasing concentrations of DADLE (Figure 4.9, Table 4.1). In the 
absence of added guanine nucleotides, two clearly distinct affinity states for DADLE 
(pKi high affinity, 9.3 ± 0.19; pKi low affinity, 6.5 ± 0.22, means ± S.E.M, n=3, P < 
0.0001***) were identified whereas in the presence of either Gpp[NH]p or GDP a 
monophasic displacement curve was obtained (pKi = 6.5 ± 0.25, mean ± S.E.M, n=3) 
corresponding to a low affinity state for DADLE. Although this is a classical 
expectation from two-state receptor theory, the expression of this feature in the fusion 
protein was substantially more pronounced than is often observed in such studies with 
co-expressed but separate receptors and G proteins, with the Ki values for DADLE 
differing by over 200 fold. The estimated % of high affinity agonist binding sites in 
the absence of guanine nucleotides (42-46%) was also substantial, suggesting that the 
proximity of GPCR and G protein within the fusion construct encouraged these 
interactions. When a similar experiment was tried on membranes stably expressing the 
isolated hDOR, two agonist affinity sites were not clearly distinct in the absence of 
guanine nucleotides but the displacement was moved to lower affinity in the presence 
of Gpp[NH]p (data not shown). Distinct agonist affinity states of a PiAR-Gsa fusion 
protein have also recently been monitored in ligand binding studies (Seifert et aL, 
1999: Seifert et aL, 1999: Wenzel-Seifert and Seifert, 2000). The effect of guanine 
nucleotides on such agonist competition curves is to decrease the affinity and increase 
the Hill slope firom the biphasic to the monophasic curves. In a two-site model, 
nucleotides decrease the affinity of the agonist at the high affinity site or decrease the 
proportion of high-affinity sites. This indicates that the agonist ligand can sense the 
difference between two states of the hDOR-Giia fusion proteins even though the 
protein partners cannot formally separate.
Binding of [^H] naltrindole to hDOR-Gna (lle^^^) in PTx untreated and treated
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membranes (25ng/ml, 16h) (Figures 4.10A, 4.10B) was performed at increasing 
concentrations of GDP. Surprisingly two independent experiments showed an increase 
of receptor binding at high concentrations of GDP. However no effect of the binding 
of [^H] naltrindole was observed following PTx treatment. To explain this result, 
further [^H] naltrindole saturation binding studies were performed on membranes of 
stably expressed hDOR-Giia (Ile^^^) in the absence and the presence of 100 pM GDP, 
which also resulted in an increase of receptor binding for [^H] naltrindole with minor 
alteration of the Kd in the presence of GDP (Figure 4.IOC). I would like to give some 
possible reasons. According to my previous result, the Kd for [^H] naltrindole for the 
hDOR-Giia (Ile^^^) fusion protein (0.77 + 0.12 nM, mean ± S.E.M, n=3) was about 6  
times higher than for the hDOR-Giia (Gly^^^) fusion protein (0.13 ± 0.02 nM, mean ± 
S.E.M, n=3) (***p< 0.001) (Table 3.1). It has been considered that naltrindole is a 
neutral 5-antagonist and it can prevent the activity of an inverse agonist (Neilan et aL,
1999). One possibility to explain these different Kd values for the same receptor is that 
naltrindole behaves as an inverse agonist on the hDOR-Giia (Ile^^^) fusion protein, 
which may have greater constitutive activity due to the mutation to the strong 
hydrophobic, aliphatic amino acid. He, but not on the Gly^^  ^ residue containing fusion 
protein. In support of the above explanation, spiperone has been described as an 
inverse agonist at the human 5 - H T ia  receptor, able to reduce basal, agonist- 
independent, signal transduction (Barr and Manning, 1997). Spiperone functioned as 
an inverse agonist in membranes expressing the 5-HTiA-Giia (wild type) fusion 
protein and in those expressing S-HTiA-Gua (Ile^^^) but not a 5-HTiA-Giia (Gly^^^) 
fusion protein (Kellet et aL, 1999). Therefore I think that these increases are because 
of an inverse agonistic property of naltrindole for the stably expressed hDOR-G^a
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However I was unable to observe such an effect following transient 
expression of hDOR-Giia (Ile^^^) (data not shown) or stable expression of hDOR- 
Goia (Ile^ ^^ ) (Figure 4.14).
[^H] naltrindole and [^H] DADLE saturation binding studies were carried for the 
stably expressed hDOR-Goia (Ile^^^) fusion protein. Figure 4.11 and Figure 4.12 are 
representative [^H] naltrindole and [^H] DADLE saturation binding experiments. The 
Kd for [^H] naltrindole at hDOR-Goia (Ile^^^) after PTx treatment (25ng/ml, 16h) was 
0.88 ± 0.35 nM (mean ± S.E.M, n=3). Both high affinity and low affinity sites were 
detected fi'om direct [^H] DADLE saturation-binding studies. Conversion of binding 
data to Scatchard plots showed the high affinity site for [^H] DADLE at hDOR-Goia 
(Ile^^^) as 0.75 ± 0.03 nM (mean ± range, n=2). Binding of [^H] DADLE was 
decreased with increasing concentrations of GDP in both untreated and PTx treated 
membranes. However no effect on the binding of [^H] DADLE was observed 
following PTx treatment (Figures 4.13A, 4.13B). The binding studies of [^H] 
naltrindole to hDOR-Goia (Ile^^^) with PTx untreated (Figure 4.14A) and treatment 
(25ng/ml, 16h) (Figure 4.14B) were performed with increasing concentrations of 
GDP. No GDP effect was observed on the binding of [^H] naltrindole and PTx 
treatment had no effect on the binding of [^H] naltrindole, which was different from 
the observation from the hDOR-Gna (Ile^^^). Binding of [^H] naltrindole to the 
hDOR-Goia (Ile^^^) was competed for by increasing concentrations of DADLE in the 
absence of added guanine nucleotides and the presence of either Gpp[NH]p or GDP 
(data not shown).
2 1 0
The capacity of GDP to modulate [^ H] DADLE binding 
to membranes of PTx-treated HEK293T cells following 
transient expression of hDOR-Gna (Xaa^^^)/-Goia 
(Xaa^^ )^ fusion protein mutants
Agonist-induced information transfer from GPCR to G protein is dependent upon 
the capacity of the ligand to promote the dissociation of GDP from the nucleotide- 
binding pocket of the G protein and thus allow exchange for GTP. As this is the rate 
limiting step of the cycle of G protein activation and deactivation (Gilman, 1987) it 
can be monitored by following the subsequent rate of hydrolysis of GTP.
In the current studies, I demonstrated that the identity of residue^^' of Gjia alters
both the effectiveness of agonist-induced activation of the G protein by the hDOR and
determines the stability of a ternary complex between agonist, hDOR and Gi%a by
altering its rate of dissociation. These two features are likely to be inherently related as
effective maintenance of the ternary complex is required to allow agonist-induced
information transfer between the partner proteins. A recent novel insight derived from
GPCR-G protein fusion proteins containing point mutations in the G protein C-
terminal region is how these alter the affinity of interaction between the GPCR and G
protein (Waldhoer et aL, 1999). In these studies, two approaches were used to
estimate the affinity of the receptor for the mutated G protein moiety in the tandem.
First, the ability of GDP to suppress the formation of the ternary complex was
determined. Because the activated receptor reduces the affinity of the G protein for
GDP (by promoting GDP release), an excess of GDP conversely lowers the affinity of
the G protein for the receptor (Hepler and Gilman, 1992). The inhibition of high
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affinity binding of (~)-A^-3[^^^I](iodo-4-hydroxy phenylisopropyl adenosine, to 
membranes prepared from HEK293 cells expressing Ai-Giia (wild type) as well as 
the Ai-Giia (Ile^^ )^ and Ai-Giia (Gly^^^) fusion proteins by GDP was then observed. 
The second approach relied on the use of suramin, a G protein antagonist, which binds 
directly to G protein a-subunits (Freissmuth et aL, 1996) and competes with the 
activated receptor for binding to the G protein. High affinity agonist binding to Ai- 
Giia fusion proteins mutated at Cys^^  ^of the G ^a moiety was suppressed by suramin 
as well. It was concluded that G na (Gly^^^) exhibited the lowest affinity for the h \  
adenosine receptor. Such results are consistent with the ranlc order of affinity of the Ai 
adenosine receptor for this G protein being greatest for wild type and lowest for G^a 
(Gly^^^). Equivalent experiments on a range of hDOR-Giia fusion containing only a 
variation of the amino acids (He, Ala, Gly, Ser, Arg, Val, Leu, Phe) at this position 
produced a picture in which there was strong correlation between the partition 
coefficient of each amino acids between n-octanol and H2 O (a measure of their 
hydrophobicity) and the pECso for GDP-mediated reduction in [^H] DADLE binding 
(R^ —> 0.7421) (Figures 4.15A, 4.15B). Similar experiments with hDOR-Goia fusion 
proteins containing different amino acids (He, Leu, Gly) were performed. This also 
resulted in a correlation between the partition coefficient of each amino acids between 
n-octanol and H2 O and the pECso for GDP-mediated reduction in [^H] DADLE 
binding (Figures 4.16A, 4.16B), although with only 3 amino acids tested it is not 
possible to argue the importance of these observations.
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Comparison of the kinetics of [^ H] DADLE binding to 
hDOR-Gna (lle^® )^/-Giia (Gly®®^ ) fusion proteins.
I selected the hDOR-Giia (Ile^^*) and hDOR-Gna (Gly^^^) fusion proteins as 
marked examples of the observed differences in GDP regulation of [^H] DADLE 
binding. In 1999, Waldhoer et ah, using the fusion protein strategy, showed that the 
association of receptor and G protein is not rate-limiting; in contrast, the stability of 
the ternary complex is limited by the dissociation rate of the G protein. In other words, 
this suggested that the fidelity of receptor-G protein coupling is achieved by a kinetic 
proof-reading mechanism.
In these studies, I explored the stability of ternary complexes of two different 
mutant fusion proteins by measuring the association and dissociation kinetics of 
agonist binding. Previously PTx treatment had no effect on the binding of [^H] 
DADLE to either the hDOR-Gua (Ile^^^) or hDOR-Gna (Gly^^^) fusion proteins as 
these are resistant to the actions of the toxin. However, in both cases increasing 
concentrations of GDP again reduced [^H] DADLE binding (Figure 4.17A). It was 
obvious that higher concentrations of GDP were required to restrict the binding of 
[^H] DADLE to the hDOR-Gna (Ile^^*) fusion protein than to the one containing Gna 
(Gly^^^) (pICso values for He = 5.78 ± 0.1, for Gly = 6.58 ± 0.16, means ± S.E.M, 
n=3). Again, GDP did not reduce the binding of [^H] naltrindole to these fusion 
proteins (Figure 4.17B). These results provided clear evidence for differences in the 
ternary complex of DADLE-hDOR-Gna due to the single amino acid alteration. 
Similar results in terms of agonist binding have been observed recently for the Aj
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adenosine receptor (Waldhoer et al., 1999) and used as evidence that the stability of 
the ternary complex is determined by the dissociation rate of the G protein. This is 
supported further by the difference in EC50 for the G protein antagonist suramin 
(Beindl et al, 1996: Freissmuth et a l, 1999) to inhibit [^H] DADLE binding to the 
Gly^^  ^and Ile^^  ^hDOR-containing fusion proteins and indicate greater affinity of 
interaction between hDOR and Ile^^  ^ Giia than between hDOR and Gly^^  ^Gua 
(Figure 4.18A). Previous studies with the 5HTia receptor have shovm this receptor to 
display constitutive, agonist-independent, capacity to activate Ile^^  ^Gjia but not 
Gly^^* Gil a  (Kellet et al, 1999) and there is increased relative intrinsic activity of 
partial agonists at the a 2A-adrenoceptor to activate Ile^ ^^  Gna compared to Gly^^  ^G ^a 
(Jackson et a l, 1999). Such observations further demonstrate the importance of the 
nature of this interface for protein-protein interactions between GPCR and G protein 
and that these interactions, which can be monitored by ternary complex stability, 
determine the effectiveness of information transfer from the GPCR to G protein. Also, 
as for GDP, suramin did not reduce the binding of [^H] naltrindole to these fusion 
proteins (Figure 4.18B).
Association (on-rate) binding experiments were used to determine the Kon- Such 
experiments are effected by the concentration of radioligand, dissociation rate 
constant (Koff) and temperature. Kon is usually expressed in units of Molar"^ min"*.
I have used the following equation.
Kob - Koff 
Kon - ............................
[radioligand]
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Association experiments for [^H] DADLE were carried for various times at 25 °C 
with prior PTx treatment of cells transiently expressing two selective mutants. I was 
able to measure the Kob, observed rate constant (min'*) from the direct association 
experiments. Calculated Kob of these two fusion protein mutants was not significantly 
different.
Dissociation binding experiments measured the “off-rate” for radioligand 
dissociation from the receptor. Initially ligand and receptor were allowed to bind to 
equilibrium. At that point, a very high concentration of an unlabeled ligand was added 
or the sample diluted by incubation to a large volume. The Koff is expressed in units of 
inverse time. This also helps to calculate the ti/2 , half-life for dissociation as 0.6931/ 
Koff.
Dissociation experiments for [^H] DADLE were performed for various times at 
25 ° C with prior PTx treatment, by adding an excess of an antagonist (10 pM 
naloxone). The measured Koff and ti /2  were significantly different between these two 
fusion proteins.
These values, Kon and Koff, I was then used to combine them to calculate the Kd 
of receptor binding.
Koff
Kd = ----------
Kon
The units are consistent: Koff is in units of min Kon is in units of M'^min \  so Kd is 
in units of M.
In order to calculate the high affinity K| value for the competition binding of [^H] 
naltrindole for hDOR-Giia (Ile^^^), I have used the following equation.
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IC50
Ki = ------------------
[radioligand]
1 +  - ...........................
Kd
The association kinetics of [^H] DADLE to these two fusion proteins were not 
different but upon reaching [^H] DADLE binding steady-state, addition of an excess 
of an antagonist allowed dissociation kinetics of [^H] DADLE to be monitored. It was 
clear that, under the conditions employed, dissociation of this ligand was substantially 
more rapid from the Gly^^  ^containing fusion protein and this corresponded to a 5-fold 
difference in the dissociation constant for [^H] DADLE (Figures 4.19A, 4.19B, Table 
4.4). Equivalent variation in the measured Kd for [^H] DADLE was obtained in 
equilibrium saturation binding assays (Figures 4.20, 4.21, Table 4.4). Furthermore, 
the measured Kd for [^H] DADLE binding to the hDOR-Gna (Ile^^^) fusion protein 
was very similar to the Ki for binding (0.25-0.91 nM) of this ligand to the agonist high 
affinity state of the fusion protein estimated from competition binding studies with 
[^H] naltrindole.
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Figure 4.1. Structure of amino acids
Group I. Amino acids with apolar R groups
Alanine pi
Ala, A CH3- L c œ -
Val, V
Leucine
lie,
NH
CH3 H
Valine ^ch—c—coo‘
HCÇ3
Leu, L ^cH-cH.-c~coo-
?■Isoleucine cHg—CHa—ch—c—coo‘
CH3 NHa"
Phenylalanine /  \  ?
f  V c H 2 -C — COQ-
Phe, F —  1 ^ 3
Group II. Amino acids with uncharged polar R groups
Glycine 
Gly, G
?H—C—COO' 
NHj
Serine h
Ser, S H0 -CH3-Ç-C 0 0 -
NH
Cysteine
H
Cys, C HS-CH2-Ç-C 0 0 '
NH3
Group III. Amino acids with charged R groups
Arginine ?H2N—C—NH—(CH2)3—C—COO'
Arg, R NH2 NH3
Adapted from Biochemistry, page 62 (Fourth edition) 
(written by Geoffrey L. Zubay)

Figure 4.2. Analysis of [^H] naltrindole binding to stably expressed
hDOR
A. [^H] naltrindole binding studies on membranes stably expressing hDOR
Following stable expression of the hDOR, saturation binding studies using [^H] 
naltrindole were performed on membranes of HEK293 cells. Non specific binding 
was assessed in paiallel in the presence of 100 pM naloxone. Bmax of hDOR 
varied between 1-2 pmol/mg with different passages. The Kd of [^H] naltrindole 
for liDOR was estimated as 0.54 ± 0.36 nM. (mean ± range, n=2). This is a 
representative example of two experiments performed.
B. Scatchard analysis
A Scatchard plot was generated from the data of Figure 4.2A.
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Figure 4.3. Analysis of [^H] DADLE binding to stabiy expressed hDOR
A. [^H] DADLE binding studies on membranes stably expressing hDOR
Following stable expression of the hDOR, saturation binding studies using [^H] 
DADLE were performed on membranes of HEK293 cells. Non specific binding 
was assessed in parallel in the presence of 10 pM DADLE. The Kd of [^H] 
DADLE for hDOR was estimated as 0.85 + 0.18 nM (mean ± range, n=2). This is 
a representative example of two experiments performed.
B. Scatchard analysis
A Scatchard plot was generated from the data of Figure 4.3 A.
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Figure 4.4. Effect of PTx treatment on stably expressed hDOR
A. Effect of PTx treatment on [^H] DADLE binding in membranes stably 
expressing hDOR
Following stable expression of the hDOR and prior PTx treatment with increasing 
incubation time [50ng/12h,100ng/12h, 50ng/24h, 100ng/24h], [^H] DADLE 
binding studies were performed on membranes of hDOR. This is one typical 
experiment performed.
B. Conversion to percentage from Figure 4.4A
The data from Figure 4.4A was converted to percentage (%).
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Figure 4.5. [^ H] DADLE and [^ H] naltrindole binding studies for stably
expressed hDOR at increasing concentrations of GDP
A. Reduction of binding of [^ H] DADLE at increasing concentrations of GDP
Following stable expression of hDOR, PTx untreated (■) or treated (□) 
(lOOng/ml, 24h) membranes were prepared. The specific binding of [^H] DADLE 
(4.5 nM) was assessed at increasing concentrations of GDP. Non specific binding 
was assessed in parallel in the presence of 10 pM unlabelled DADLE. Data are 
shown from a representative experiment.
B. Effects of GDP and PTx treatment on the binding of [ H] DADLE and [ H] 
naltrindole to the hDOR
The effects of pre-treatment (lOOng/ml, 24h) of the cells with PTx or addition of 
GDP (100 pM) to membranes on the binding of [^H] DADLE (5 nM) and [^H] 
naltrindole (4 nM) was assessed. Results are presented as mean ± range from 2 
independent experiments (** P < 0.05, *** P < 0.01).
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c . Effects of PTx treatment on [ H] naltrindole binding to stably expressing
hDOR-Gi,a (Ile^ ®').
Following stable expression of hDOR-Gna (Ile^^*), PTx untreated ("*• ) or treated
(□) (25ng/ml, 16h) membranes were prepared. Saturation binding studies using 
[^H] naltrindole were performed on membranes of HEK293 cells. Non specific 
binding was assessed in parallel in the presence of 100 pM naloxone. Data are 
shown from a representative experiment.
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Figure 4.6. Analysis of [^H] naltrindole binding to stably expressed
hDOR-Giia (lle=*®^ ).
A. [^H] naltrindole binding studies on membranes stably expressing hDOR-Gna
(Ile^ si).
Following stable expression of the hDOR-Gjia (Ile^^^) fusion protein and prior 
PTx treatment (25ng/ml, 16h), saturation binding studies using [^H] naltrindole 
were performed on membranes of HEK293 cells. Non specific binding was 
assessed in parallel in the presence of 100 naloxone. This is a representative 
example of three performed.
B. Scatchard analysis
A Scatchard plot was generated fiom the data of Figure 4.6 A.
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Figure 4.7 Analysis of [^H] DADLE binding to stably expressed hDOR-
Gîi(x (lle^®^).
A, [^H] DADLE binding studies on membranes stably expressing hDOR- 
Giia (Ile^ si).
Following stable expression of the hDOR-Giia (Ile^^^) fusion protein and prior 
PTx treatment (25ng/ml, 16h), saturation binding studies using [^H] DADLE 
were performed on membranes of HEK293 cells. Non specific binding was 
assessed in parallel in the presence of 10 pM DADLE. Both high affinity and low 
affinity binding sites for [^H] DADLE were detected. This is a representative 
example of tlnee experiments performed.
B. Scatchard analysis
A Scatchard plot was generated from the data of Figure 4.7A.
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Figure 4.8. Increasing concentrations of GDP reduce the binding of [^ H] 
DADLE to the hDOR Gna (lierai).
A. [^ H] DADLE binding studies on membranes stably expressing hDOR-Giia 
(Ile^si).
Following stable expression of the hDOR-Gna (Ile^^^) fusion protein membranes 
of HEK293 cells were prepared without PTx treatment. The binding of [^H] 
DADLE (0.5 nM) was performed at various concentrations of GDP. Data are 
shown fi'om a representative experiment.
B. [^H] DADLE binding studies on membranes stably expressing hDOR-Gna 
(Ile^ ^^ ): Effect of PTx treatment.
Following stable expression of the hDOR-Gua (Ile^^^) fusion protein and prior 
PTx treatment (25ng/ml, 16h), membranes were prepared. The binding of [^H] 
DADLE (1.1 nM) was measured at various concentrations of GDP. Data are 
shown fiom a representative experiment.
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Figure 4.9. The ability of DADLE to displace [^H] naltrindole binding in
membranes stably expressed hDOR-Giia (lle^ ®^ ).
The specific binding of [^H] naltrindole (1.2 nM) to the hDOR-Gua (He 
fusion protein in membranes of PTx treated cells was assessed in the presence of 
varying concentrations of DADLE in the absence of added guanine nucleotides 
(□) and in the presence of 100 pM GDP ('*'). In the absence of guanine 
nucleotides, two sites with distinct affinities for DADLE were observed with pKi 
high affinity = 9.3 ±0.19, pKi low affinity = 6.5 ± 0.22, means ± S.E.M, n=3), 
whereas in the presence of GDP (100 pM) a monophasic competition curve (pKi 
low affinity = 6.5 ± 0.25, mean ± S.E.M, n=3) was obtained. Data are from a 
representative experiment.
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Figure 4.10. Increasing concentrations of GDP do not reduce the binding 
of f  H] naltrindole for the hDOR Gna (lle^ ®^ ).
A. [^H] naltrindole binding studies on membranes stably expressing hDOR-Giia 
(Ile^si).
Following stable expression of the hDOR-Gua (Ile^^^) fusion protein membranes 
of HEK293 cells were prepared. The binding of [^H] naltrindole (4 nM) was 
performed at various concentrations of GDP. Data are shown from a 
representative experiment.
B. [^ H] naltrindole binding studies on membranes stably expressing hDOR-Gua 
(Ilef^*): Effect of PTx treatment
Following stable expression of the hDOR-Gua (Ile^^^) fusion protein and prior 
PTx treatment (25ng/ml, 16h), membranes of HEK293 cells were prepared. The 
binding of [^H] naltrindole (4 nM) was performed at various concentrations of 
GDP. Data are shown from a representative experiment.
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c .  Effect of GDP on ( H] naltrindole binding on membranes stably expressing 
hDOR-Giia (Ile^ ^^ ).
Following stable expression of the hDOR-Gua (Ile^^^) fusion protein, saturation 
binding studies using [^H] naltrindole were performed on membranes of HEK293 
cells in the absence of GDP ( ^  ) and in the presence of 100 pM GDP (□). Non 
specific binding was assessed in parallel in the presence of 100 pM naloxone. 
Data are shown from a representative experiment.
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Figure 4.11. Analysis of fH ] naltrindole binding to stably expressed
hDOR-Goia (lle^® )^.
A. [^H] naltrindole binding studies on membranes stably expressing hDOR- 
Goia (Ile^^^
Following stable expression of the hDOR-Goia (Ile^^^) fusion protein and prior 
PTx treatment (25ng/ml, 16h), saturation binding studies using [^H] naltrindole 
were performed on membranes of HEK293 cells. Non specific binding was 
assessed in paiallel in the presence of 100 |aM naloxone. This is a representative 
example of tlnee experiments performed.
B. Scatchard analysis
A Scatchard plot was generated from the data of Figure 4.11 A.
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Figure 4.12. Analysis of [^H] DADLE binding to stably expressed hDOR-
Goia (lle^® )^.
A. [^ H] DADLE binding studies on membranes stably expressing hDOR- 
G o ia  (Ile^^^).
Following stable expression of the hDOR-Goia (Ile^^^) fusion protein and prior 
PTx treatment (25ng/ml, 16h), saturation binding studies using [^H] DADLE 
were performed on membranes of HEK293 cells. Non specific binding was 
assessed in parallel in the presence of 10 pM DADLE. Both high affinity and low 
affinity binding sites for [^H] DADLE were detected. The K r of [^H] DADLE for 
hDOR-Goia (Ile^^') was estimated as 0.75 ± 0.03 nM.(mean ± range, n=2). This is 
a representative example of two experiments performed.
B, Scatchard analysis
A Scatchard plot was generated from the data of Figure 4.12A.
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Figure 4.13. Increasing concentrations of GDP reduce the binding
affinity of fH ] DADLE for hDOR Goia (ile“ )^.
A. [ HI DADLE binding studies on PTx untreated membranes stably expressing 
hDOR-Goia (Ile^ ‘^).
Following stable expression of the hDOR-Goia (Ile^^^) fiision protein membranes 
of HEK293 cells were prepai’ed. The binding of [^H] DADLE (1.2 nM) was 
performed at various concentrations of GDP. Data are shown from a 
representative experiment.
B. [^H] DADLE binding studies on membranes stably expressing hDOR-Goia 
(Ile^ ^^ ); Effect of PTx treatment
Following stable expression of the hDOR-Goia (Ile^^^) fusion protein and prior 
PTx treatment (25ng/ml, 16h), membranes of HEK293 cells were prepared. The 
binding of [^H] DADLE (1.2 nM) was performed at various concentrations of 
GDP. Data are shown h'om a representative experiment.
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Figure 4.14. Increasing concentrations of GDP do not reduce the binding 
of f  H] naltrindoie for the hDOR Goia (lle^ ®^ ).
A. [^H] naltrindoie binding studies on PTx untreated membranes stably 
expressing hDOR-Goia (Ilef^ )^.
Following stable expression of the hDOR-Goia (Ile^^^) fusion protein membranes 
of HEK293 cells were prepared. The binding of [^H] naltrindoie (4.8 nM) was 
performed at various concentrations of GDP. Data are shown from a 
representative experiment.
B. [^ H] naltrindoie binding studies on membranes stably expressing hDOR-Goia 
(Ile^ ^^ ): Effect of PTx treatment
Following stable expression of the hDOR-Goia (Ile^^^) fusion protein and prior 
PTx treatment (25ng/ml, 16h), membranes of HEK293 cells were prepared. The 
binding of [^H] naltrindoie (4.8 nM) was performed at various concentrations of 
GDP. Data are shown from a representative experiment.
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Figure 4.15. Effect of resîdue^ ®^  of Giia on the potency of GDP to 
regulate [^H] DADLE binding to hDOR-Gna (Xaa fusion protein 
mutants.
A. [^ H] DADLE binding studies on membranes transiently expressing hDOR-Gii 
(Xaa fusion protein mutants.
Following transient expression of hDOR-Gjia (Xaa fusion protein mutants in 
which residue^^' of G na was - He, Ala, Giy, Ser, Arg, Val, Leu or Phe -  and prior 
PTx treatment (25ng/ml, 16h), membranes of HEK293T cells were prepared. [^H] 
DADLE binding (1 nM) was measured at increasing concentrations of GDP.
Data are shown from a representative experiment (R^ 0.7421).
B. The pECso values for GDP-mediated reduction in the specific binding of [^ H] 
DADLE to hDOR-Gii (Xaa ^^ )^ fusion protein mutants.
The pECgo values for GDP-mediated reduction in the specific binding of [^H] 
DADLE was coiTelated with the n-octanol/H20 partition co-efficients (Bahia et 
a l, 1998) of residue of Gn a  in the fusion proteins. Amino acids are designated 
by the standard one letter code.
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Figure 4.16. Effect of residue^ ®^  of Goia on the potency of GDP to 
regulate [^H] DADLE binding to hDOR-Goia (Xaa fusion protein 
mutants.
A. [^H] DADLE binding studies on membranes transiently expressing hDOR- 
Goi (Xaa fusion protein mutants.
Following transient expression of hDOR-Goia (Xaa fusion protein mutants in 
which residue^^^ of Goia was - lie, Leu or Gly -  and prior PTx treatment 
(25ng/ml, 16h), membranes of HEK293T cells were prepared. [^H] DADLE 
binding (1 nM) was measured at increasing concentrations of GDP. Data are 
shown from a representative experiment.
B. The pECso values for GDP-mediated reduction in the specific binding of [^ H] 
DADLE on hDOR-Goi (Xaa fusion protein mutants.
The pECso values for GDP-mediated reduction in the specific binding of [^H] 
DADLE was correlated with the n-octanol/HiO partition co-efficients (Bahia et al, 
1998) of residue of Gd a  in the fusion proteins. Amino acids are designated by
the standard one letter code.
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Figure 4.17. Comparison of GDP effects on binding of [^ H] DADLE and
[^ H] naltrindoie to the hDOR-Gna (lie ^® )^/-Giia (Gly fusion proteins.
A. [ H] DADLE binding studies on membranes transiently expressing hDOR- 
Giitt (He ^^')/-Giia (Gly fusion proteins
Following transient expression of hDOR-Gna (lie (□) and hDOR-Gna (Gly 
^^ ‘) ( ^  ) fusion proteins and prior PTx pre-treatment (25ng/ml, 16h), membranes 
of HEK293T cells were prepared. [^H] DADLE binding (1 nM) was measured at 
increasing concentration of GDP. The pICso value was 5.78 ±0.10 for hDOR- 
Gna (lie and 6.58 + 0.16 for hDOR-Gna (Gly^^‘) (means ± S.E.M, n=3). 
These values are significantly different (**P < 0.005).
B. [^ H] naltrindoie binding studies on membranes transiently expressing hDOR- 
Gna (He ^^ )^/-Gna (Gly fusion proteins
Following transient expression of hDOR-Gna (He ^^ )^ (□) and hDOR-Gna (Gly 
^^ )^ ( ^  ) fusion proteins and prior PTx pre-treatment (25ng/ml, 16h), membranes 
of HEK293T cells were prepared. The specific binding of [^H] naltrindoie (2.2 
nM) was measured at increasing concentration of GDP. Data represent the mean 
± S.E.M from three independent experiments.
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Figure 4.18. The G protein antagonist suramin selectively uncouples a 
hDOR-Giia fusion protein containing Gly at G^a residue
A. [^ H] DADLE binding studies on membranes transiently expressing hDOR- 
Gna (lie ^^ )^/-Giia (Gly fusion proteins
Following transient expression of hDOR-Gna (He (□) and hDOR-Gna (Gly 
( ^  ) fusion proteins and prior PTx pre-treatment (25ng/ml, 16h), membranes 
of HEK293T cells were prepared. [^H] DADLE binding (1 nM) was measured at 
increasing concentration of sur amin. The pICso value was 4.67 + 0.15 for hDOR- 
Gna (He and 5.28 ± 0.15 for hDOR-Gna (Gly^^^) (means ± S.E.M, n=3). 
These values are significantly different (**? < 0.01).
B. [^ H] naltrindoie binding studies on membranes transiently expressing hDOR- 
Gna (He ^^*)/-Giia (Gly ^^ *) fusion proteins
Following transient expression of hDOR-Gna (He ^^ )^ (□) and hDOR-Gna (Gly 
^^ )^ ( '‘  ^) fusion proteins and prior PTx pre-treatment (25ng/ml, 16h), membranes 
of HEK293T cells were prepared. The specific binding of [^H] naltrindoie binding 
(2.3 nM) was measured at increasing concentration of suramin. Data represent the 
mean ± S.E.M from tliree independent experiments.
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Figure 4.19. Association and dissociation kinetics of the binding of [^ H]
DADLE to hDOR-Giia (lie ^® )^/-Giia (Gly
A. Association kinetics of the binding of [^H] DADLE to membranes transiently 
expressing hDOR-Gna (lie ^^ )^/-Gna (Gly fusion proteins
Following transient expression of hDOR-Gna (He ^^ )^ (□) and hDOR-Gna (Gly 
331) ^^  ) proteins and prior PTx pre-treatment (25ng/ml, 16h), membranes 
of HEK293T cells was prepared. The kinetics of association of [^H] DADLE 
binding (1.2 nM) to the hDOR-Gna fusion proteins was monitored at 25°C. Data 
represent the mean ± S.E.M Eom three independent experiments.
B. Dissociation kinetics of the binding of [^H] DADLE to membranes transiently 
expressing hDOR-Gn (He ^^ )^/-Gn (Gly fusion proteins
Following transient expression of hDOR-Gn (He ^^ *) (□) and hDOR-Gn (Gly 
('*') fusion proteins and prior PTx pre-treatment (25ng/ml, 16h), membranes of 
HEK293T cells was prepared and following attainment of steady-state binding of 
[^H] DADLE to the two fusion proteins the antagonist naloxone (10 pM) was 
added at 25 ° C. The kinetics of dissociation of [^H] DADLE were monitored. Data 
represent the mean ± S.E.M from three independent experiments.
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Figure 4.20. Analysis of [^ H] DADLE binding to transiently expressed
hDOR-Gna (lle^^^).
A. [^H] DADLE binding studies to membranes transiently expressing hDOR- 
Gna (Ile^ ^^ ).
Following transient expression of the hDOR-Gna (Ile^^^) fusion protein and prior 
PTx treatment (25ng/ml, 16h), saturation binding studies using [^H] DADLE 
were performed on membranes of HEK293T cells. Non specific binding was 
assessed in parallel in the presence of 10 pM DADLE. The Kr of [^H] DADLE 
for hDOR-Gna (Ile^^^) was estimated as 0.68 ± 0.05 nM (mean ± S.E.M, n=3). 
This is a representative experiment.
B. Scatchard analysis
A Scatchard plot was generated from the data of Figure 4.20A.
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Figure 4.21 Analysis of [^ H] DADLE binding to transiently expressed
hDOR-Giia (Gly^ ®^ ).
A. [ H] DADLE binding studies on membranes transiently expressing hDOR- 
Giia (Giy"" )^.
Following transient expression of the hDOR-Gna (Gly^^^) fusion protein and prior 
PTx treatment (25ng/ml, 16h), saturation binding studies using [^H] DADLE 
were performed on membranes of HEK293T cells. Non specific binding was 
assessed in parallel in the presence of 10 pM DADLE. The Kr of [^H] DADLE 
for hDOR-Gna (Gly^^^) was estimated as 2.1 ± 0.38* nM (mean ± S.E.M, n=3). 
This is a representative experiment. This value is significantly different from the 
liDOR-Gna (Ile^^‘) (*P < 0.01).
B. Scatchard analysis
A Scatchard plot was generated fr om the data of Figure 4.21 A.
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CHAPTER V
Final discussion
FINAL DISCUSSION (CHAPTER V)
GPCRs transduce extracellular signals into the cell by activating heterotrimeric G 
proteins. Agonist-induced information transfer from GPCR to G protein is dependent 
upon the capacity of the ligand to promote the dissociation of GDP from the 
nucleotide binding pocket of the G protein and thus allow exchange for GTP, which is 
the rate limiting step in the cycle of G protein activation and deactivation (Gilman, 
1987).
There are many aspects of opioid receptors that still remain poorly understood.
To understand hDOR signalling, I have taken advantage of a fusion protein strategy in 
which either Goia or Giia were linked directly to the C-terminal tail of the hDOR. 
The benefits of this strategy have recently been extensively reviewed and include that 
it ensures the proximity of the receptor to each G protein is identical, that they are 
expressed in equal ratios and, most importantly, that the levels of each G protein can 
be easily measured (Seifert et ah, 1999; Milligan, 2000). As the fusion proteins have a 
1:1 stoichiometry of receptor to G protein, saturation binding studies with an 
antagonist ligand provide direct measures of G protein, as well as receptor, expression 
levels.
In membranes provided from clones of HEK293 cells transiently/ stably 
expressing either hDOR-Gna (Ile^^^) or hDOR-Goia (Ile^^^) the agonist DADLE 
stimulated high affinity GTPase activity with similar potency. Both constructs were 
designed to be resistant to the ADP-ribosyltransferase activity ofPTx as the target
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cysteine of the G protein sequence: (Cys^^^) was replaced by He. It has previously 
been demonstrated that positioning of a hydrophobic amino acid at this location 
provides the most effective interface between GPCR and G protein (Bahia et aL,
1998). Therefore, agonist-stimulated GTPase activity following PTx treatment of cells 
must reflect activation of the G protein within the fusion construct and not stimulation 
of the pool of endogenously expressed Gi-family proteins because these are crippled 
by this treatment.
In the present studies I have utilised an approach in which receptor-mediated 
guanine nucleotide exchange on a G protein can be measured at Vmax- Measures of 
agonist-stimulated GTPase activity at various concentrations of GTP demonstrated the 
effect of agonist to represent an increase in Vmax without altering the apparent affinity 
(Km) of the fusion protein for substrate. There was a marked difference between the 
DADLE-induced GTP turnover number for the two fusion proteins, with the value for 
liDOR-Giia (Ile^^^) being more than 3 times greater than for hDOR-Goia (Ile^^^), 
which was true whether examining transient or stable expression of the constructs. It 
thus appeal's that activation of Giia by the hDOR is more efficient than for Goia. This 
conclusion is further supported by the observation that isolated Goia releases GDP 
more effectively than Giia and thus in the basal state might be expected to produce 
greater rather than lower levels of guanine nucleotide exchange (Remmers et ah,
1999). It must thus be anticipated that given equal access to the hDOR and equal 
expression levels of the two G proteins in a single neuron agonists at this receptor will 
more efficiently regulate downstream targets of Gna.
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Both the hDOR-Giia (Ile^^^) and hDOR-Goia (Ile^^^) fusion proteins were able to 
inhibit forskolin-stimulated adenylyl cyclase activity in a PTx-insensitive and agonist 
concentration-dependent manner. These results indicate a clear capacity of both these 
fusion proteins to regulate downstream effectors. However, I did not address directly 
whether these effects are produced by the hDOR-linked G a subunits or via p/y 
complexes released from the fusion proteins upon agonist activation. Such fusion 
proteins have been shown directly to interact with p/y complexes by a variety of 
approaches (Bertin et al., 1994; Wise et al., 1997b; Small et al., 2000). The potency of 
DADLE to inhibit AC activity was substantially greater than to stimulate GTPase 
activity. It is unclear whether this reflects a need for only a small level of agonist- 
occupancy of the fusion constructs to maximally inhibit AC activity or relates to the 
very different conditions used for the two assays. Moreover, I wished to assess the 
relative capacity of two distinct opioid receptor subtypes to activate the same G 
protein. For this reason, I also generated a hMOR-Giia (Ile^^ )^ fusion protein, 
transiently expressed this in HEK293 cells and compared in parallel its activation by 
DADLE with the hDOR-Gua (Ile^^*). GTP turnover number of G ua (Ile^^^) following 
maximal occupation of the hMOR-1 by DADLE was not different from that produced 
by the hDOR. These results indicate that the hMOR-1 activates G ^a as efficiently as 
the hDOR, at least when DADLE is used as the common agonist ligand.
I was also able to demonstrate that the identity of re s id u e^ o f G ^a alters both 
the effectiveness of agonist-induced activation of the G protein by the hDOR and 
determines the stability of a ternary complex between agonist, hDOR and Giia by 
altering its rate of dissociation. These two features are likely to be inherently related as
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effective maintenance of the ternary complex is required to allow agonist-induced 
information transfer between the partner proteins.
In preliminary binding experiments utilising only the isolated hDOR, I observed 
that the level of binding of a single concentration of the agonist [^H] DADLE, but not 
of the antagonist [^H] naltrindole, was reduced substantially by both PTx pretreatment 
of cells and by addition of increasing concentrations of GDP to cell membranes. 
Furthermore, these two elements were not additive as GDP had no further effect 
following PTx treatment.
I was surprised to detect two binding states for DADLE to the hDOR-Giia 
(Ile^^^) fusion protein. Expression of this feature in the fusion protein was 
substantially more pronounced than is often observed in such studies with co­
expressed but separate receptors and G proteins, with the Kj values for DADLE 
differing by over 200 fold. In the absence of added guanine nucleotides, two clearly 
distinct affinity states for DADLE were identified whereas in the presence of either 
Gpp[NH]p or GDP a monophasic displacement curve was obtained corresponding to a 
low affinity state for DADLE. This indicates that the agonist ligand can sense the 
difference between two states of the hDOR-Giia fusion proteins even though the 
protein partners cannot formally separate.
The effects of point mutations at cysteine^^^ in Gn on the behaviour of fusion 
proteins constructed between the hDOR and G[\ were further investigated. Equivalent 
experiments on a range of hDOR-Giia fusions containing only a variation of the 
amino acid at this position produced a picture in which there was good correlation for
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the partition coefficient of each amino acid between n-octanol and H2O (a measure of 
their hydrophobicity) and the pECso for GDP-mediated reduction in [^H] DADLE 
binding. By contrast, GDP did not reduce the binding of the antagonist [^H] 
naltrindole to these fusion proteins. These results provided clear evidence for 
differences in the ternary complex of DADLE-hDOR-Giia due to a single amino acid 
alteration in the G protein.
I selected the hDOR-Gna (Ile^^^) and hDOR-Giia (Gly^^^) fusion proteins as 
marked examples of the observed differences in GDP regulation of [^H] DADLE 
binding. PTx treatment had no effect on the binding of [^H] DADLE to either the 
hDOR-Giia (Ile^^^) or hOOR-Gna (Gly^^*) fusion proteins as these are resistant to the 
actions of the toxin. However, in both cases increasing concentrations of GDP 
reduced [^H] DADLE binding. It was obvious that higher concentrations of GDP were 
required to restrict the binding of [^H] DADLE to the hDOR-Gua (Ile^^^) fusion 
protein than the one containing G ^a (Gly^^^). The association kinetics of [^H]
DADLE to these two fusion proteins were not different but upon reaching [^H] 
DADLE binding steady-state, addition of an excess of an antagonist allowed the 
dissociation kinetics of [^H] DADLE to be monitored. Under the conditions 
employed, dissociation of this ligand was substantially more rapid from the Gly^^  ^
containing fusion than from the one in which it was replaced by He and that these 
differences corresponded to a 5-fold difference in the dissociation constant for [^H] 
DADLE. Equivalent variation in the measured Kd for [^H] DADLE was obtained in 
equilibrium saturation binding assays. Measured Kd for [^H] DADLE binding to the 
hDOR-Giia (He^^ )^ fusion protein was very similar to the pK| for binding (9.3 ±0.19,
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means ± S.E.M) of this ligand to the agonist high affinity state of the fusion protein 
estimated from competition binding studies with [^H] naltrindole. The G protein 
antagonist suramin displayed higher potency to inhibit [^H] DADLE binding to the 
Gly^^  ^than to the Ile^^^  hDOR-containing fusion protein, which is consistent with 
greater affinity of interactions between hDOR and G^a (Ile^^^) than between hDOR 
and Giia (Gly^^^). Previous studies with the 5HTia receptor have shown this receptor 
to display constitutive, agonist-independent capacity to activate G na (Ile^^^) but not 
Giia (Gly^^*) and there is increased relative intrinsic activity of partial agonists at the 
aiA-adrenoceptor to activate G ^a (Ile^^^) compared to Giia (Gly^^^). Such 
observations demonstrate the importance of the nature of this interface for protein- 
protein interactions between GPCR and G protein and that these interactions, which 
can be monitored by ternary complex stability, determine the effectiveness of 
information transfer from the GPCR to G protein. In other words, cyste ine^is  
critical for stabilising the ternary complex.
246
List of publications
LIST OF PUBLICATIONS
♦ Control of the efficiency of agonist-induced information transfer and stability of 
the ternary complex containing the 5-opioid receptor and the a  subunit of Gü by 
mutation of a receptor/G protein contact interface.
Hyo-Eun Moon, Daljit S. Bahia, Antonella Cavalli, Marcel Hoffmann and 
Graeme Milligan.
{Submiited to Neuropharmacolasv).
♦ The human 5 opioid receptor activates G ^a more efficiently than Goia. 
Hyo-Eun Moon, Daljit S. Bahia, Antonella Cavalli, Marcel Hoffmann, 
Dominigue Massotte and Graeme Milligan. (2001) Journal o f Neurochemistry 
76, 1805-1813.
247
References
REFERENCES
Abdelhamid E.E., Sultana M., Portoghese P.S., and Takemori A.E. (1991) J. 
Pharmacol. Exp. Ther. 258 (1), 299-303.
Angers S., and Bouvier M. (2000) Trends Pharmacol. Soi. 21, 326-327.
Avidor-Reiss T., Bayewitch M., Levy R., Matus-Leibovitch N., Nevo I., and Vogel Z. 
(1995) J. Biol. Chem. 270, 29732-29738.
Avidor-Reiss T., Nevo L, Saya D., Bayewitch M., and Vogel Z. (1997) J. Biol. Chem. 
272, 5040-5047.
Bahia D.S., Wise A., Fanelli F., Lee M., Rees S., and Milligan G. (1998) 
Biochemistry. 37, 11555-11562.
Barr A.J., and Manning D.R. (1997) J. Biol. Chem. 272, 32979-32987.
Befort K., Tabbara L., Bausch S., Chavkin C., Evans C., and Kieffer, B. (1996) Mol. 
Pharmacol. 49, 216-223.
Befort K., Tabbara L., Kling D., Maigret B., and Kieffer B.L. (1996) J. Biol. Chem. 
271, 10161-10168.
Befort K., Zilliox C., Filliol D., Yue S.Y., and Kieffer, B.L. (1999) J. Biol. Chem. 
274, 18574-18581.
Beindl W., Mitterauer T., Hohenegger M., Ijzerman A.P., Nanoff C., and Freissmuth 
M. (1996) Mol. Pharmacol. 50, 415-423.
Benovic J.L., DeBlasi A., Stone W.C., Caron M.G., and Lefkowitz R.J. (1989) 
Science. 246, 235-240.
248
Bertin B., Friessmuth M., Jockers R., Strosberg A.D., and Marullo S. (1994)
Proc. Natî. Acad. Sel USA. 91, 8827-8831.
Bertin B., Strosberg A.D., and Marullo S. (1997) Int. J. Cancer. 71,1029-1034.
Berman D.M., and Gilman A.G. (1998) J. Biol Chem. 273, 1269-1272.
Berman D.M., Wilkie T.M., and Gilman A.G. (1996) Cell. 86, 445-452.
Berstein G., Blank J.L., Jhon D.Y., Exton J.H., Rhee S.G., and Ross E.M. (1992) Cell 
70,411-418.
Biesen T.V., Hawes B.E., Raymon J.R., Luttrell L.M., Koch W.J., and Lefkowitz R.J. 
{\996)J .B io l Chem. 271, 1266-1269.
Birnbaumer L. (1990) FASEB J. 4, 3178-3188.
Bloch B., Dumartin B., and Bernard V. (1999) Trends Pharmacol. Scl 20, 315-319.
Bot G., Blake A.D., Li S., and Reisine T.(1998) J. Pharmacol Exp. Ther. 284, 283- 
290.
Bond C., Laforge K.S., Tian M., Melia D., Zhang S., Borg L., Gong J., Schluger J., 
Strong J.A., Leal S.M., Tischfield J.A., Kreek M.J., and Yu L. (1998) Proc. Natl 
Acad. Scl USA. 95, 9608-9613.
Bond R.A., Leff P., Johnson T.D., Milano C.A., Rockman H.A., McMinn T.R., 
Apparsundaram S., Hyek M.F., Kenakin T.P., Allen L.F, et al (1995) Nature. 374, 
272-276.
Bonatti S., Migliaccio G., and Simons K. (1989) J. Biol. Chem. 264, 12590-12595,
Bourne H.R. (1997) Curr. Opin. Cell biology. 9, 134-142.
249
Bol G.F., Gros C., Hulster A., Bosel A., and Pfeuffer T. (1997) Biochem. Biophys.
Res. Commun. 237(2), 251-256.
Bray P., Carter A., Simons C., Guo V., Puckett C., Kamholz J., Spiegel A., and 
Nirenberg M. (1986) Proc. Natl Acad. Sci. USA. 83, 8893-8897.
Brown G.P., and Pasternak G.W. (1998) J. Pharmacol. Exp. Ther. 286, 376-381.
Bryen A.J., and Devi L.A. (1999) Nature. 399, 697-700.
Burt A.R., Sautel M., Wilson M.A., Rees S., Wise A., and Milligan G, (1998) J. Biol 
Chem. 273, 10367-10375.
Buss J.E., Mumpy S.M., Casey P.J., Gilman A.G., and Sefton B.M. (1987) Proc. Natl. 
Acad. Scl USA. 84, 7493.
Burt A.R., Carr I.C., Mullaney L, Anderson N.G., and Milligan G. (1996) Biochem J. 
320, 227-235.
Cavalli A., Babey A.M., and Loh H.H. (1999) Neuroscience. 93, 1025-1031.
Cavalli A., Druey K.M., and Milligan G. (2000) J. Biol Chem. 275, 23693-23699.
Carr I.C., Burt A.R., Jackson V. N., Wright J., Wise A., Rees S., and Milligan G. 
{ I 9 n )  FEBSLetters. 428, 17-22.
Cantiello H.F., Patenaude C.R., and Ausiello D.A. (1989) J. Biol Chem. 264, 20867- 
20870.
Cantiello H.F., Patenaude C.R., Codina J., Bimbaumer L., and Ausiello D.A. (1990)
J. Biol Chem. 265, 21624-21628.
Casey P.J., Graziano M.P., and Gilman A.G. (1989) Biochemistry. 28, 611-616.
250
Casey P J. (1995) Science. 268, 221-225.
Cassel D., and Selinger Z. (1978) Proc. Natl. Acad. Sci. USA. 75, 2669-2673.
Chupmn J.K., Raymond J.R., and Blackshear P.J. (1997) J. Biol. Chem. 272, 773-781.
Chu P., Murray S., Lissin D., and Von Zastrow M. (1997) J. Biol. Chem. 272, 27124- 
27130.
Chalecka-Franaszek E., Weems H.B., Crowder A.T., Cox B.M., and Cote T.E. (2000) 
J. Neurochem. 74, 1068-1078.
Chakrabarti S., Prather P.L., Yu L., Law P.Y., and Loh H.H. (1995) J. Neurochem. 64, 
2534-2543.
Chan J.S.C., Chiu T.T., and Wong Y.H. (1995) J. Neurochem. 65, 2682-2689.
Chen G., Way J., Armour S., Watson C., Queen K., Jayawickreme C.K., Chen W.J., 
and Kenekin T. (2000) Mo/. Pharmacol. 57, 125-134.
Chen Y., Harry A., Li J., Smit M.J., Bai X., Magnusson R., Pieroni J.P., Weng G., and 
Iyengar R. (1997) Proc. Natl. Acad. Sci. USA. 94, 14100-14104.
Cheng P.Y., Wu D., Decena J., Soong Y., McCabe S., and Szeto H.H. (1993) Eur. J. 
Pharmacol. 230, 85-88.
Christopoulos A. (1998) Trends Pharmacol. Sci. 19, 351-357.
Claude P.A., Wotta D.R., Zhang X.H., Prather P.L., Mcginn T.M., Erickson L.J., Loh 
H.H., and Law P. Y. (1996) Proc. Natl. Acad. Sci. USA. 93, 5715-5719.
Clarke W.P., and Bond R.A. (1998) Trends Pharmacol. Sci. 19, 270-276.
251
Clapham D.E., andN eerE J. {\991) Annu. Rev. Pharmacol. Toxicol. 37, 167-203.
Conklin B.R., Farfel Z., Lustig K.D., Julius D., and Bourne H.R. (1993a) Nature. 
(Lond) 363, 274-276.
Conklin B.R., and Bourne H.R (1993b) Cell. 21(4), 631-641.
Conklin B.R., Herzmark P., Ishida S., Voyno-Yasenetskaya T.A., Sun Y., Farfel Z., 
and Bourne H.R. (1996) Mol. Pharmacol. 50(4), 885-890.
Connor M., and Christie M.D. (1999) Clin. Exp. Pharmacol. Physiol. 26, 493-499.
Colquhoun D. (1998) Br. J. Pharmacol. 125, 924-947.
Cotecchia S., Exum S., Caron M.G., and Lefkowitz R.J. (1990) Proc. Natl. Acad. Sci. 
USA. 87, 2896-2900.
Cowan C.W., Fariss R.N., Sokal L, Palczewski K., and Wensel T.G. (1998) Proc. 
Natl. Acad. Sci. USA. 95, 5351-5356.
Crain S.M., and Shen K.F. (1998) Trends Pharmacol. Sci. 19, 358-365.
Cvejic S., Trapaidze N., Cyr C., and Devi LA. (1996) J. Biol. Chem. 271, 4073-4076.
Cvejic S., and Devi L.A. (1997) J. Biol. Chem. 272, 26959-26964.
Danielson P.B., and Dores R.M. (1999) General and Comparative Endocrinology. 
113, 169-186.
DeBlasi A., O’Reilly K., and Motulsky H.J. (1989) Trends Pharmacol. Sci. 10, 227- 
229.
252
Degtyarev M.Y., Spiegel A.M., and Jones T.L.Z. (1993) J. Biol. Chem. 268, 23769- 
23772.
Devi L.A. (2000) Trends Pharmacol Sci 21, 324-326.
DeVries L., Mousli M., Wurmser A., and Farquhar M.G. (1995) Proc. Natl. Acad. Scl 
USA. 91, 11916-11920.
Dixon R.A., Kobilka B.K., Strader D.J., Benovic J.L., Dohlman H.G., Frielle T., 
Bolanowski M.A., Bennett C.D., Rands E., Diehl R.E., et al. (1986) Nature. 321, 75- 
79.
Dickenson A.H. (1997) Behav. Brain. Sci. 20, 392-404.
Dietzel C., and Kurgan J. (1987) Cell 50, 1001.
Dohlman H.G., and Thorner J. (1997) J. Biol Chem. 272, 3871-3874.
Dupuis D.S., Tardifs., Wurch T., Colpaert F.C., and Pauwels P.J. (1999) 
Neuropharmacology. 38, 1035-1041.
Eason M.G., Jacinto M.T., Theiss C.T., and Liggett S.B. (1994) Proc. Natl Acad. Scl 
USA. 91, 11178-11182.
Evans C.J., Keith D.E.Jr., Monison H., Magendzo K., and Edwards R.H. (1992) 
Science. 258, 1952-1955.
Exner T., Jensen O.N., Malih M., Kleuss C., and Nürnberg B. (1999) Proc. Natl 
Acad. Scl USA. 96, 1327-1332.
Fanelli F., Menzian C., Scheer A., Cotecchia S., and De Benedetti P.G. (1999) 
PROTEINS: Structure, Function, and Genetics. 37, 145-156.
253
Farndale R.W., Allan L.M., and Martin B.R. (1991). In: Signal Transduction A 
Practical Approach, Oxford University Press, U. K., 75-103.
Fong C.W., Bahia D.S., Rees S., and Milligan G. (1998) M ol Pharmacol. 54, 249- 
257.
Fong C.W., and Milligan G. (1999) Biochem J. 342, 457-463.
Freissmuth M., Waldhoer M., Bofill-Cardona E., and Nanoff C. (1999) Trends 
Pharmacol Scl 20, 237-245.
Freissmuth M., Boehm S., Beindl W., Nickel P., Ijzerman A.P., Hohenegger M., and 
Nanoff C. (1996) M ol Pharmacol. 49, 602-611.
Freissmuth M., and Nanoff C. (1999) CMLS, Cellular and Molecular Life Sciences. 
55, 257-270.
Fukuda K., Kato S., Mori K., Nishi M,, and Takeshima H. (1993) FEBSLett. 327(3), 
311-314.
Gao B., and Gilman A.G (1991) Proc. Natl. Acad. Scl USA. 88, 10178.
Georgoussi Z., Milligan G., and Zioudrou C. (1995) Biochem J. 306, 71-75. 
GetherU., and Kobilka B.K. (1998) J: Biol Chem. 273, 17979-17982.
Georgoussi Z., Carr C., and Milligan G. (1993) M ol Pharmacol. 44, 62-69. 
Gierschik P., Bouillon T., and Jakobs K.H. (1994) Methods. Enzymol. 237, 13-26. 
Gilman A.G. {\9%l)Ann. Rev. Biochem. 56, 615-649.
Glass M., and Northup J.K. (1999) M ol Pharmacol. 56, 1362-1369.
254
Goldsmith P., Backlund P.S., Rossiter K., Carter A., Milligan G., Unson C.G., and 
Spiegel A.M. (1988) Biochemistry. 27, 7085-7090.
Grassie M.A., McCallum J.F., Guzzi F., Magee A.I., Milligan G., and Parenti M.
(1994) Biochem J. 302, 913-920.
Green A., Johnson J.L., and Milligan G. (1990) J. Biol. Chem. 265, 5206-5210.
Gurevich V.V., Dion S.B., Onorato J.J., Ptasienski J., Kim C.M., Sterne-Marr R., 
Hosey M.M., and Benovic J.L. (1995) J. Biol. Chem. 270, 720-731.
Hausdorff W.P., Caron M.G., and Lefkowitz R.J. (1990) FASEB J. 4, 2881-2889.
Hart M.J., Jiang X., Kozasa T., Roscoe W., Singer W.D., Gilman A.G., Sternweis P. 
C., and BollagG. { \9 n )  Science. 280,2112-2114.
Hamm H.E. (1998) J. Biol. Chem. 273, 669-672.
Hamm H.E (1991) Cell. Mol. Neurobiol. 11, 563-578.
Hamm H.E., Deretic D., Arendt A., Hargrave P.A., Koenig B., and Hofmann K.P. 
(19S^) Science. 241, 832-835.
Hamm H.E., Deretic D., Mazzoni M.R., Moore C.A., Takahashi J.S., and Rasenick 
M.M. (1989) J; Biol. Chem. 264, 11475-11482.
Hayashi M. K., and Haga T. (1997) Arch. Biochem. Biophys. 340, 376-382.
Haitman IV, J. L., and Northup J. K. (1996) J. Biol. Chem. 271, 22591-22597.
Hellmich M., Battey J.F., and Northup J.K. (1997) Proc. Natl. Acad. Sci. USA. 94, 
751-756.
255
Hepler J., and Gilman A.G. (1992) Trends Biochem. Sci. 17, 383-387.
Hebert T.E., Moffett S., Morello J.P., Loisel T.P., Bichet D.G., Barret C., and Bouvier 
M. (1996) J. Biol. Chem. 271, 16384-16392.
Hescheler J., Rosenthal W., Wulfern M., Tang M., Yajima M., Trautwein W., and 
Schultz G. {\9%^)Adv. Second Messenger Phosphoprotein Res. 21, 165-14.
Heyman J.S., Vaught J.L., Raffa R.B., and Porreca F. (1988) Trends Pharmacol. Sci.. 
9, 134-138.
Hiller J.M., Fan L.Q., and Simon E.J. (1996) Brain Res. 719(1-2), 85-95.
Hohenegger M., Waldhoer M., Beindl W., Boing B., Kreimeyer A., Nickel P., Nanoff 
C., and Freissmuth M. (1998) Proc. Natl. Acad. Sci. USA. 95, 346-351.
Houslay M.D., and Milligan G. (1997) Trends Pharmacol. Sci. 22, 217-224.
Houslay M.D., and Milligan G. (1990) G- proteins as mediators o f  cellular signalling 
processes, WILEY.
Houslay M.D., Gawler D.J., Milligan G., and Wilson A. (1989) Cell. Signalling. 1, 9- 
22 .
Hurley J.H. (\999) J. Biol. Chem. 274, 7599-7602.
Hurley J.H. (1998) Curr. Opin. Struct. Biol. 8, 770-777.
Hunt T.W., Carroll R.C., and Peralta E.G. (1994) J. Biol. Chem. 269, 29565-29570. 
Hunt T. (2000) Cell. 100, 113-127.
lismaa T.P., Kiefer J., Liu M.L., Baker E., Sutherland G.R., and Shine J. (1994)
256
Genomics. 24, 391-394.
liri T., Backlund P.S., Jones T.L.Z., Wedegaertner P.B., and Bourne H.R. (1996)
Proc. Natl. Acad. Sci. USA. 93, 14592-14597.
Ikeda S.R. (1996^ Nature (London). 380, 255-258.
Inoue H., Nojima H., and Okayama H. (1990) Gene. 96,23-28.
Itoh H., Kozasa T., Nagata S., Nakamura S., Katada T., Ui M., Iwai S., Ohtsuka E., K 
awasaki H., Suzuki K., et al (1986) Proc. Natl. Acad. Sci. USA. 83, 3776-3780.
Iyengar R. (1994) Methods in Enzymology. 237.
Jackson V.N., Bahia D.S., and Milligan G. (1999) Mol. Pharmacol. 55, 195-201.
Jensen A.A., Pederson U.B., Kiemer A., Din N., and Anderson P.H. (1995) J. 
Neurochem. 65, 1325-1331.
Jian X., Sainz E., Clark W.A., Jensen R.T., Battey J.F., and Northup J.K. (1999) J. 
Biol. Chem. 274, 11573-11581.
Ji T.H., Murdoch W.J., and Ji I. (1995) Endocrine. 3, 187-194.
Jiang Y., Ma W., Wan Y., Kozasa T., Hattori S., and Huang X.Y. (1998) Nature. 395, 
808-813
Ji T.H., Grossmann M., and Ji I. (1998) J. Biol. Chem. 273,17299-17302.
Johannes Scheming., Paul J. Berti., and Vern L. Schramm. (1998) Biochemistry. 37, 
2748-2758.
257
Jones K.A., Borowsky B., Tamm J.A., Craig D.A., Durkin M.M., Dai M., Yao W.J., 
Johnson M., Gunwaldsen C., Huang L.Y., Tang C., Shen Q., Salon J.A., Morse K., 
Laz T., Smith K.E., Nagarathnam D., Noble S.A., Branchek T.A., and Gerald C.
(1998) Nature. 396(6712), 674-679.
Jordan B.A., and Devi L.A (1999) Nature. 399 (6737), 697-700.
Katada T., and Ui M. (1982) Proc. Natl. Acad. Sci. USA. 79, 3129-3133.
Katada T., Gilman A.G., Watanabe Y., Bauer S., and Jakobs K.H. (1985) Eur. J. 
Biochem. 151,431-437.
Kaupmarm K., Malitschek B., Schuler V., Held J., Froestl W., Beck P., Mosbacher J., 
Bischoff S., Kulik A., Schigemoto R., Karschin A., and Bettler B. (1998) Nature. 396 
(6712), 683-687.
KawateN., and Menon K.M.J. (1994) J! Biol. Chem. 269, 30651-30658.
Kenakin T. (1997) Trends Pharmacol. Sci. 18, 456-464.
Kennedy M.E., and Limbird L.E. (1994) J. Biol. Chem. 269, 31915-31922.
Kest B., Lee C.E., McLemore G.L., and Inturrisi C.E. (1996) Brain Res. Bull. 39, 185- 
188.
Kellet E., Carr I.C., and Milligan G. (1999) Mol. Pharmacol. 56, 684-692.
Kieffer B.L., Befort K., Gaveriaux-Ruff C., and Hirth C.G. (1992) Proc. Natl. Acad. 
Sci. USA. 89, 12048-12052.
Kieffer B.L., Befort K., Gaveriaux-Ruff C., and Hirth C.G. (1994) Proc. Natl, Acad. 
Sci. USA. 91, 1193.
258
Kieffer B.L. (1999) Trends Pharmacol Sci. 20, 19-26.
Kjelsberg M.A., Cotecchia S., Ostrowski J., Caron M.G., and Lefkowitz R.J. (1992) J. 
Biol Chem. 267, 1430-1433.
Knapp R.J., Malatynska E., Collinss N., Fang L., Wang J.Y., Hruby V.J., Roeske 
W.R., and Yamamura H.I. (1995b) FASEB J. 9, 516-525.
Knapp R.J., Malatynska E., Fang L., Li X., Babin E., Nguyen M., Santoro G., Varga 
E. V., Hruby V.J., Roeske W.R., and Yamamura H.I. (1994) Life Scl 54, PL463- 
PL469.
Kohno M., FukushimaN., Yoshida A., and UedaH. (2000) FEBS Lett. 473,101-105.
Kong H., Raynor K., Yasuda K., Moe S.T., Portoghese P.S., Bell G.I., and Reisine T. 
(1993) J. Biol Chem. 268, 23055-23058.
Kong H., Raynor K., Yano H., Takada J., Bell G.I., and Reisine T. (1994) Proc.Natl 
AcadSclUSA. 91, 8042-8046.
Koelle M.R., and Horvitz H.R, (1996) Cell 84, 115-125.
KoelleM.R. (1997) Curr. Opin. Cell Biol 9, 143-147.
Koski G., and Klee W.A. (1981) Proc. Natl Acad. Scl USA. 78, 4185-4189.
Kozasa T., Kaziro Y., Ohtsuka T., Grigg J.J., Nakajima S., and Nakajima Y. (1996) 
Neuroscl Res. 26, 289-297.
Kramer H.K., and Simon E.J. (2000) Neuropharmacology. 39, 1707-1719.
Kramer H.K., Andria M.L., Douglas H.E., and Simon E.J. (2000) Biochem. 
Pharmacol 60, 781-792.
259
Krupinski J., Coussen F., Bakalyar H., Tang W.J., Feinstein P.G., Orth K., Slaughter 
C., Reed R.R., and Gilman A.G. (1989) Science. 244, 1558-1564.
Kuner R., Kohr G., Grünewald S., Eisenhardt G., Bach A., and Kornau H.C. (1999) 
Science. 283(5398), 74-77.
Lambright D., Sondek I., Bohm A., SkibaN., Hamm H., and Sigler P. (1996) Nature. 
379,311-319.
Laugwitz K.L., Offermanns S., Spicher K., and Schultz G. (1993) Neuron. 10, 233- 
242.
Law S.F., and Reisine T. (1997) J. Pharmacol. Exp. Ther. 281, 1476-1486.
Law P.Y., Wong Y.H., and Loh H.H. (2000) Annu. Rev. Pharmacol. Toxicol. 40, 389- 
430.
Law P.Y., Hom D.S., and Loh H.H. (1985b) J. Biol. Chem. 260, 3561-3569.
Leaney J.L., and Tinker A. (2000) Proc. Natl. Acad. Sci USA. 97, 5651-5656.
Leaney J.L., Milligan G., and Tinker A. (2000) J. Biol. Chem. 275, 921-929,
Lee J.W., Joshi S., Chan J.S., and Wong Y.H. (1998) J. Neurochem. 70, 2203-2211. 
Lee T.W., Cotecchia S., and Milligan G. (1997) Biochem. J. 325, 733-739.
Leff P. (1995) Trends Pharmacol. Sci. 16, 89-97.
Leflcowitz R.J., Cottecchia S., Samama P., and Costa T. (1993) Trends Pharmacol. 
Sci. 14, 303-307.
Lefkowitz R.J. (1998) J  Biol. Chem. 273, 18677-18680.
2 6 0
Lefkowitz R.J. (1993) Cell 74, 409-412.
Lefkowitz R.J., Pitcher J., Krueger K., and Daaka Y. (1998) Adv. Pharmacol 42, 416- 
420.
Lennarz W. (1983) Methods. Enzymol 98, 91-97.
Levin L.R., and Reed R.R. (1995) J. Biol Chem. 270, 7573-7579.
Liu J., Conklin B.R., Blin N., Yun J., and Wess J. (1995) Proc. N atl Acad. Sci. USA. 
92, 11642-11646.
Liu F., Wan Q., Pristupa Z.B., Yu X.M., Wang Y.T., and Niznik H.B. (2000) Nature. 
403, 274-280.
Li X,, Varga E.V., Stropova D., Zalewska T., Malatynska E., Knapp R.J., Roeske 
W.R., and Yamamura H.I. (1996) Eur. J. Pharmacol 300; R1-R2.
Loisel T.P., Ansanay H., Adam L., Marullo S., Seifert R., Lagace M., and Bouvier M.
(1999) J. Biol CAgm. 274, 31014-31019.
Loisel T.P., Adam L., Hebert T., and Bouvier M. (1996) Biochemistry. 35, 15923- 
15932.
Lu W.Y., Xiong Z.G., Lei S., Orser B.A., Dudek E., Browning M.D., and MacDonald 
J.F. (1999) Nature. 2, 331-338.
Malatynska E., Wang Y., Knapp R.J., Waite S., Calderon S., Rice K., Hruby V.J., 
Yamamura H.I., and Roeske W.R. (1996) J. Pharmacol Exp. Ther. 278, 1083-1089.
Martens G. (1992) Prog. Brain Res. 92, 201-214.
Martin S.C., Russek S.J., and Farb D.H. (1999) M ol Cell. Neurosci. 13(3), 180-191.
261
Martin E.L., Rens-Domiano S., Schatz P.J., and Hamm H.E. (1996) J. Biol Chem. 
271, 361-366.
MacEwan D.J., and Milligan G. (1996) FEBS Lett. 399(1-2), 108-112.
Matthes H.W.D., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., 
Befort K., Dierich A., Le Meur M., Doile P., et al (1996) Nature. 383, 819-823.
Maher C.E, Selley D.E., and Childers S.R. (2000) Biochem. Pharmacol 59(11), 1395- 
1401.
Mahan L.C., Koachman A.M., and Insel P.A. (1985) Proc. Natl. Acad. Sel USA. 
82(1), 129-133.
Marshall F.H., Jones K.A., Kaupmann K., and Bettler B. (2000) Trends Pharmacol 
Sci. 20, 396-399.
Massotte D., Baroche L., Simonin F., Yu L., Kieffer B., and Pattus F. (1997) J. Biol 
Chem. 272, 19987-19992.
Mattia A., Farmer S.G., Takemori A.E., Sultana M., Portoghese P.S., Mosberg H.I., 
Bowen W.D., and Porreca F. (1992) J. Pharmacol Exp. Ther. 260, 518-525.
Mattia A., Vanderah T., Mosberg H.I., and Porreca F. (1991) J. Pharmacol Exp.
Ther. 258(2), 583-587.
Mao G., Cook W.J., Zhou M., Federov A.A., Almo S.G., and Ealick S.E. (1998) 
Biochemistry. 37(20), 7135-7146.
Mckenzie F.R., and Milligan G. (1990) Biochem J. 267, 391-398.
McGallum J.F., Wise A., Grassie M.A., Magee A.I., Guzzi F., Parenti M., and 
Milligan G. (1995) Biochem J. 310, 1021-1027.
262
Medici R., Bianchi E., Di Segni G., and Tocchini-Valentini G.P (1997) EMBO 
Journal. 16, 7241-7249.
Merkouris M., Mullaney I., Georgoussi Z., and Milligan G. (1997) J. Neurochem. 69, 
2115-2122.
Merkouris M., Dragatsis I., Megaritis G., Konidakis G., Zioudrou C., Milligan G., and 
Georgoussi Z. (1996) Mol. Pharmacol. 50, 985-993.
Meng P., Wei Q., Hoversten M.T., Taylor L.P., and Akil H. (2000) J. Biol. Chem. 
275,21939-21945.
Meng F., Hoversten M.T., Thompson R.C., Taylor L., Watson S.J., and Akil H. 
{\9 9 5 )J B io l. Chem. 270, 12730-12736.
Meng F., Ueda Y., Hoversten M.T., Thompson R.C., Taylor.L., Watson. S.J., and 
Akil H. (1996) Eur. J. Pharmacol. 311, 285-292.
Metzger T.G., and Ferguson D.M. (1995) FEBS Lett. 37 5 ,1-4.
Milligan G., Groarke D.A., Mclean A., Ward R., Fong C.W., Cavalli A., and Drmota 
T. (1998) Biochemical Society Transactions. 27, 149-154.
Milligan G. (1994) Methods Enzymol. 237, 268-283.
Milligan G., Bond R.A., and Lee M. (1995) Trends.Pharmacol. Sci. 16, 10-13. 
Milligan G., Parenti M., and Magee A.I. (1995) Trends.Biochem. Sci. 20, 181-186. 
Milligan G., Marshall F., and Rees S. (1996) Trends.Pharmacol. Sci. 17, 235-237. 
Milligan G., and Bond R.A. (1997) Trends.Pharmacol. Sci. 18, 468-474.
263
Milligan G., and Mckenzie F.R. (1988) Biochem. J. 252, 369-373.
Milligan G. (1988) Biochem. J. 255, 1-13.
Milligan G. (1998) Trends.Endocrinol. Metab. 9,13-19.
Milligan G., and Klee W.A. (1985) J  Biol. Chem. 260, 2057-2063.
Milligan G., MacEwan D.J., Mercouris M., and Mullaney I. (1997) Receptors and 
Channels. 5, 209-213.
Milligan G., and Rees S. (1999) Trends.Pharmacol. Sci. 20, 118-124,
Milligan G. (2000) Trends.Pharmacol. Sci. 21, 24-28.
Milligan G. (2000) Science. 288, 65-67.
Minami T., Okuda-Ashitaka E., Mori H., Ito S., and Hayaishi O. (1996) J. Pharmacol. 
Exp. Ther. 278(3), 1146-1152.
Mixon M.B., Lee E., Coleman D.E., Berghuis A.M., Gilman A.G., and Sprang S.R.
(1995) Science. 270 (5238), 954-960.
Moffect S., Adam L., Bonin H., Loisel T. P., Bouvier M., and Mouillac B. (1996) J. 
Biol. Chem. 271,21490-21497.
Mouillac B., Caron M,, Bonin H., Dennis M., and Bouvier M. (1992) J. Biol. 
Œem.267, 21733-21737.
Morishita R., Nakayama H., Isobe T., Matsuda T., Hashimoto Y., Okano T., Fukada 
Y., Mizuno K., Olino S., Kozawa O., Kata K., and Asano T. (1995) J. Biol. Chem. 
270, 29469-29475.
264
Moss J., Yost D.A., and Stanley SJ. (1983) J. Biol Chem. 258, 6466-6470.
Murphy K.S., and Maliklouf G.M. (1996) M ol Pharmacol 50, 870-877.
Mullaney I., Carr I.C., and Milligan G. (1996) Biochem. 7! 315, 227-234.
Nathans J., and Hogness D.S. (1983) Cell 34, 807-814.
Neer E.J., Lok J.M., and Wolf E.G. (1984) J. Biol Chem. 259, 14222-14229.
Neilan C.L., Akil H., Woods J.H., and Traynor J.R. (1999) Br. J. Pharmacol. 128 (3), 
556-562.
Ng G.Y., Clark J., Coulombe N., Ethier N., Hebert T.E., Sullivan R., Kargman S., 
Chateauneuf A., Tsukamoto N., McDonald T., Whiting P., Mezey E., Jolmson M.P., 
Liu Q., Kolakowski L.F.Jr., Evans J.F., Bonner T.I., and O’Neill G.P. (1999) J. Biol 
Chem. 274, 7607-7610.
Ng G.Y.K., O'Dowd B.F., Caron M., Dennis M., Brann M.R., and George S.R. (1994) 
J. Neurochem. 63, 1589-1595.
Northup J.K., Sternweis P.C., Smigel M.D., Schleifer L.S., Ross E.M., and Gilman A. 
G. (1980) Proc. N atl Acad. Sci.USA. 77, 6516-6520.
Nukada T., Tanabe T., Takahashi H., Noda M., Haga K., Haga T., Ichiyama A., 
Kanagawa K., Hiranaga M., Matsuo, et al (1986) FEBS Lett. 197, 305-310.
Offermanns S., Schultz G., and Rosenthal W. (1991) J. Biol. Chem. 266, 3365-3368.
Offermanns S., Laugwitz K.L., Spicher K., and Schult, G. (1994) Proc. Natl Acad. 
Sci USA. 91(2), 504-508.
Offermanns S., and Simon M.I. (1995) J. Biol Chem. 270, 15175-15180.
265
Okamoto Y., Ninomiya H., Tanioka M., Sakamoto A., Miwa S., and Masaki T. (1997) 
J. B iol Chem. 272, 21589-21596.
Omary M.B., and Trowbridge I.S. (1981) J. Biol Chem. 256, 4715-4718.
Onogi T., Minami M., Katao Y., Nakagawa T., Aoki Y., Toya T., Katsumata S., and 
Satoh M. (1995) FEBS Lett. 357(1), 93-97.
Osawa S., and Weiss E.R. (1995) J. Biol Chem. 270(52), 31052-31058.
Pan Y.X., Xu Bolan J.E., Abbadie C., Chang A., Zuckerman A., Rossi G., and 
Pasternak G.W. (1999) Mo/. Pharmacol 56, 396-403.
Parma J., Duprez L., Van Sande J., Cochaux P., Gervy C., Mockel J., Dumont J., and 
Vassart G. (1993) Nature. 365, 649-651,
Pei G., Kieffer B.L., Lefkowitz R.J., and Freedman N.J. (1995) M ol Pharmacol 48, 
173-177.
Pei G., Tiberti M., Caron M.G., and Lefkowitz R.J. (1994) Proc. Natl Acad. Sci 
USA. 91, 2699-2702.
Prather P.L., McGinn T.M., Erickson L.J., Evans C.J., Loh H.H., and Law P.Y. (1994) 
J. B iol Chem. 269 (33), 21293-21302.
Premont R.T., Inglese J., and Lefkowitz R.J. (1995) FASEB J. 9, 175-182.
Pyne N.J., Murphy G.J., Milligan G., and Houslay M.D. (1989) FEBS Lett. 243, 77- 
82.
Quock R.M., Burkey T.H., Varga E., Hosohata Y., Hosohata K., Cowell S.M., Slate 
C.A., Ehlert F.J., Roeske W.R., and Yamamura H.I. (1999) Pharmacol Reviews. 51, 
503- 532.
266
Reneke J.E., Blumer K.J., Courchesne W.E., and Thorner J. (1988) Cell. 55, 221-234.
Remmers A.E., Engel C., Liu M., and Neubig R.R (1999) Biochemistry. 38 (42), 
13795-13800.
Roerig S.C., Loh H.H., and Law P.Y. (1992) Mol. Pharmacol. 41(5), 822-831.
Ross E.M., and Gilman A.G. (1977) J. Biol. Chem. 252, 6966-6970.
Ross E.M., Howlett A.C., and Gilman A.G (1979) Prog. Clin. Biol. Res. 31, 735-749.
Rocheville M., Lange D.C., Kumar U., Patel S.C., Patel R.C., and Patel Y.C. (2000) 
Science. 288(5463), 154-157.
Rovati G.E. (1998) Trends.Pharmacol. Sci. 19, 365- 369.
Rohi'er D.K., and Kobilka B.K. (1998) Physiological reviews. 78, 35-78.
Sautel M., and Milligan G. (1998) FEBS Letters. 436, 46-50.
Samama P., Cotecchia S., Costa T., and Lefkowitz R.J. (1993) J. Biol. Chem. 268, 
4625-4636.
Salomon Y., Londos C., and Rodbell M. (\919) Anal. Biochem. 58, 541-548.
Schütz W., and Freissmuth M. (1992) Trends Pharmacol. Sci. 13, 376- 380. 
Scheuring J,, Berti P.J., and Schramm V.L. (1998) Biochemistry. 37, 2748-2758.
Schonerberg T., Schultz G., and Gudermann T. (1999) Mol. Cell. Endocrinol. 151,
181-193.
267
Scholich K., Barbier A.J., Mullenix J.B., and Patei T B. (1997) Proc. Natl. Acad. Sci. 
USA. 94, 2915-2920.
Seifert R., Gether U., Wenzel-Seifert K., and Kobilka B.K. (1999) Mol. Pharmacol. 
56, 348-358.
Seifert R., Wenzel-Seifert K., and Kobilka B.K. (1999b) Trends Pharmacol. Sci. 20, 
383- 389.
Seifert R., Wenzel-Seifert K., Lee T.W., Gether U., Sanders-Bush E., and Kobilka B. 
K (1998) y  Biol. Chem, 273,5109-5116.
Seifert R., Lee T.W., Lam V.T., and Kobilka B.K. (1998) Eur. J. Biochem. 255, 369- 
382.
Seifert R., Wenzel-Seifert K., Gether U., Lam V.T., and Kobilka B.K. (1999) Eur. J. 
Biochem. 255, 369-382.
Senogles S.E. (1994) J. Biol. Chem. 269, 23120-23127.
Sharma S.K., Klee W.A., and Nirenberg M. (1977) Proc. Natl. Acad. Sci. USA. 74, 
3365-3369.
Sheldon R.J., Riviere P.J., Malarchik M.E., Moseberg H.I., Burks T.F., Porreca F. 
(1990) J  Pharmacol Exp Ther. 253(1), 1
Simonin F., Befort K., Gaveriaux-ruff C., Matthes H., Nappey V., Larmes B., 
Micheletti G., and Kieffer B. (1994) Mol. Pharmacol. 46, 1015-1021.
Simon M.I., Strathmann M.P., GautamN. (1991) Science. 252(5007), 802-808.
268
Smit M.J., Leurs R., Alewijnse A.E., Blauw J., VanNieuw Amerongen G.P., Van De 
Vrede Y., Roovers E., and Timmerman H. (1996) Proc. Natl. Acad. Sci. USA. 93(13), 
6802-6807.
Small K. M., Forbes S. L., Raliman F. F., and Liggett S. B. (2000) Biochemistry. 39, 
2815-2821.
Sondek J., Bohm A., Lambright D.G., Hamm H.E., and Sigler P.B. (1996) Nature. 
379(6563), 369-374.
Sora L, Takahashi N., Funada M., Ujike H., Revay R.S., Donovan D.M., Miner L.L., 
and Uhl G.R. (1997a) Proc. Natl. Acad. Sci. USA. 94, 1544-1549.
Sora L, Funada M., and Uhl G.R. (1997b) Eur J  Pharmacol. 324(2-3), Rl-2.
Sprang S.R. (1991) Annu. Rev. Biochem. 66, 639-678.
Standifer K.M., and Pasternak G.W. (1997) Cell signal. 9(3-4), 237-248.
Stanasila L., Massotte D., Kieffer B.L., and Pattus F. (1999) Eur. J. Biochem. 260, 
430-438.
Stein W.D., Cardarelli C., Pastan L, Gottesman M.M. (1994) Mol Pharmacol. 45(4), 
763-772.
Sullivan K.A., Miller R.T., Masters S.B., Beiderman B., Heideman W., and Bourne H. 
R. (19^1) Nature. 330, 758-760.
Tang W.J., and Gilman A.G. (1991) Science. 254, 1500,
Taussig R., Tang W.J., and Gilman A.G. (1994) Methods in enzymology. 238, 95-108.
Taylor K.E., and Cahusac P.M. (\99A) Neuropharmacology. 33(1), 103-108.
269
Tesmer JJ.G., Bermann D.M., Gilman A.G., and Sprang S.R. (1997) Cell 89, 251- 
261.
Tesmer J.J.G., Sunahara R.K., Gilman A.G., and Sprang S.R. (1997) Science. 278, 
1907-1916.
Timothy A.F., and Partick J.C. (1997) Biochem J. 321, 561-571.
Valguette M., Vu H.K., Yue S.Y., Wahlestedt C., and Walker P. (1996) J. Biol Chem 
271, 18789-18796.
Van Ree J.M., Gerrits M.A.F.M., and Vanderschuren J.M.J. (1999) Pharmacol Rev. 
51,341-396.
Voogd T.E., Vansterkenburg E.L.M., Wilting J., and Janssen L.H.M. (1993) 
Pharmacol Rev. 45, 177-203.
Wang J.B., Johnson P.S., Wu J.M., Wang W.F., and Uhl G.R. (1994) J. Biol. Chem. 
269, 25966-25969.
Waldhoer M., Wise A., Milligan G., Freissmuth M., and Nanoff C. (1999) J. Biol 
Chem. 274, 30571-30579.
Wayman G.A., Wei J., Wong S., and Storm D.R. (1996) Mol. Cell. B iol 16, 6075- 
6082.
Wedegaertner P.B., and Bourne H.R. (1994) Cell 77, 1063-1070.
Wenzel-Seifeit K., Arthur J.M., Liu H-Y., and Seifert R. (1999) J. Biol. Chem. 274, 
33259-33266.
Wenzel-Seifert K., Lee T.W., Seifert R., and Kobilka B.K. (1998). Biochem J. 334, 
519-524.
270
Wenzel-Seifert K., and Seifert R. (2000) Mol. Pharmacol. 58, 954-966.
West R.E. Jr., Moss J., Vaughan M., Liu T., and Liu T.Y (1985) J. Biol. Chem. 260, 
14428-14430.
Wei J., Wayman G., and Storm D.R. (1996) J. Biol. Chem. 271, 24231-24235,
Wei H., Fiskum G., Rosenthal R.E., and Perry D.C. (1996) Mol. Chem. Neuropathol. 
29 (1), 37-52.
Weiss J.M., Morgan P.H., Lutz M.W., and Kenakin T.P. (1996) J. theor. Biol. 178, 
151-167
Weiss J.M., Morgan P.H., Lutz M.W., and Kenakin T.P. (1996) J. theor. Biol. 178, 
168-182.
Wess J. (1998) Pharmacol. Ther. 80, 231-264.
Whistler J.L., Chuang H.H., Chu P., Jan L.Y., and Zastrow M.V. (1999) Neuron. 23, 
737-746.
White J.H., Wise A., Main M.J., Green A., Fraser N.J., Disney G.H., Barnes A.A., 
Emson P., Foord S.M., and Marshall F.H. (1998) Nature. 396 (6712), 679-682.
Wise A., Watson-Koken M.A., Rees S., Lee M., and Milligan G. (1997a) Biochem. J. 
321, 721-728.
Wise A., Carr I.C., and Milligan G. (1997b) Biochem J. 325, 17-21.
Wise A., Carr I.C., Groarke D.A., and Milligan G. (1997) FEBS Lett. 419,
141-146.
271
Wise A., Sheehan M., Rees S., Lee M., and Milligan G. (1999) Biochemistry. 38, 
2272-2278.
Wise A., and Milligan G. (1997) J. Biol. Chem. 272, 24673-24678.
Wilkie T., Scherle P., Strathmann M., Slepak V., and Simon M.I. (1991) Proc. Natl 
Acad. Sci USA. 88, 10049-10053.
Wong Y.G (1994) Methods Enzymol. 238, 81-94.
Wu Z., Wong S.T., and Storm D.R. (1993) J. Biol Chem. 268, 23766-23768. 
W uD., LaRosa G.J., and Simon M.I. (\99?>) Science. 261, 101-103.
XiaZ.G., and Storm D.R. (1997) Curr. Opin. Neurobiol 7, 391-396.
YakshT.L. (1999) Trends Pharmacol. Sci 20, 329-337.
Yatsunami K., and Khorana H.G. (1985) Proc. Natl. Acad. Sci USA. 82 (13), 4316- 
4320.
Yamaguchi I., Harmon S.K., Todd R.D., and O’ Malley K.L. (1997) J. Biol. Chem. 
272, 16599-16602.
Yan S.Z., Hahn D., Huang Z.H., and Tang W.J. (1996) J. Biol. Chem. 271, 10941- 
10945.
Yan S.Z., Huang Z.H., Andrews R.K., and Tang W.J. (1998) M ol Pharmacol. 53,
182-187.
Yang C.S., SkibaN.P., Mazzoni M.R., and Hamm H.E. (1999) J. Biol. Chem. 274, 
2379-2385.
272
YoshimuraM., and Cooper D.M. (1992) Proc. Natl. Acad. Sci. USA. 89, 6716-6720.
Yung K.K., Bolam J.P., Smith A.D., Hersch S.M., Ciliax B.J., and Levey A.I. (1995) 
Neuroscience. 65 (3), 709-730.
Zhu Y., King M.A., Schuller A.G.P., Nitsche J.F., Reidl M., Elde R.P., Unterwald E., 
Pasternak G.W., and Pintar J.E. (1999) Neuron. 24, 243-252.
Zhu Y., and Pintar J.E. (1998) Biol. Reprod. 59 (4), 925-932.
Zhu Y., Hsu M.S., and Pintar J.E. (1998) J. Neurosci. 18 (7), 2538-2549.
' '■ I ' . v  f
' J
• .<Y Î
273
